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The source and sink of reactive oxygen species are diverse and so are the control 
mechanisms to counteract them. Sources may be exogenous or endogenous from normal 
metabolic pathways. Similarly, the sink could be a simple radical scavenging event by 
small molecule antioxidants and antioxidant enzymes or complex events involving 
cellular signaling processes. The effects of reactive oxygen species may precipitate 
cellular dysfunction from its toxicity, protect from invading microorganisms or perform 
essential functions through regulation of cell signaling pathways. Excessive Reactive 
oxygen species leads to oxidative stress which mediates cellular damage and is 
implicated in several pathological conditions. The current research addresses biological 
systems that may effect redox balance in humans.  
One goal of the current research was to establish structure activity relationship for 
substrate binding to several human drug metabolizing enzymes implicated in reactive 
oxygen species generation, namely CYP2A6 and CYP2E1. The substrate dynamics of 
these two enzymes were studied by probing the active site with a series of small chain 
saturated and 2,3-unsaturated aldehydes using human liver microsomes. The study 
demonstrated that the aldehydes inhibited both the enzymes in competitive manner with 
unsaturated aldehydes being more potent than their saturated counterparts. The potential 
for π-stacking interactions between the phenylalanine rich active site of these enzymes 
and the double bond at 2-position in unsaturated aldehydes conferred high affinity for  
 
 
these aldehydes. It also confirmed an earlier findings that the active site of CYP2A6 is 
rigid where as CYP2E1 is flexible due to the presence of extended π-system allowing the 
expansion of its active site.  
Another goal was to examine the possible interactions between human 
cytochrome P450 enzymes of pharmacological and toxicological importance with a 
natural product called açaí.  Açaí (Euterpe oleracea) is a Brazilian palm tree that has 
emerged from traditional medicinal plant to a recent super-fruit status. The assumption 
that it is safe to consume açaí currently lacks evidence from its interactions with drug 
metabolizing cytochrome P450 enzymes. The interaction between the crude extracts of 
açaí and major cytochrome P450 enzymes involved in drug metabolism and toxicology 
demonstrated the potential for chloroform extract to inhibit the isoforms CYP1A1, 
CYP2B6 and CYP2C8. The Michaelis-Menten Kinetics studies indicated mixed mode of 
inhibition of these enzymes by crude chloroform extract of açaí with low KI and KI’ 
values for CYP2C8 followed by CYP2B6 and CYP1A1. In addition, the study was 
extended to identification of inhibitors for toxicologically important CYP2A6 and 
CYP2E1 using a collaborative bioassay-guided fractionation approach. Although the 
crude chloroform extract of açaí showed considerable inhibition of these enzymes, 
specific inhibitors were not identified.  
Finally, the regulation of a signal transduction pathway namely Nrf2/ARE 
signaling pathway by açaí constituents was also studied as a potential strategy to prevent 
oxidative damage.  The nuclear factor erythoid 2-related factor 2 (Nrf2)-antioxidant 
 
 
response element (ARE) pathway is a cellular defense to counteract oxidative stress. 
Activation of this pathway increases the expression of a battery of antioxidant genes. This 
was achieved by monitoring the activation of a cis-acting DNA sequence referred to as 
Antioxidant Response Element (ARE) contained in a luciferase-containing promoter 
vector in cultured HepG2 cells. A high-throughput analysis of fractions generated using 
bioassay-guided fractionation of açaí has resulted in the identification of a class of 
compounds known as Pheophorbides as the inducers of ARE-luciferase. Dose response 
analysis using pure compounds demonstrated significant induction of ARE-luciferase at 
concentrations as low as 8.2 µM and 16.9µM  for Pheophorbide a methyl ester and 
Pheophorbide a, respectively.  
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CHAPTER I 
INTRODUCTION TO ANTIOXIDANT RESEARCH, HUMAN ANTIOXIDANT 
SYSTEMS AND DRUG METABOLISM 
 
1.1. Introduction 
1.1.1. Oxygen Evolution and Emergence of Life 
Life on Earth can be distinguished into three distinct landmarks in time based on 
the emergence of various life forms1, 2. Early life began with the evolution of organisms 
such as bacteria capable of performing anoxygenic photosynthesis. These organisms 
developed systems that use hydrogen and sulfur for energy metabolism. The ensuing 
years saw the advent of oxygenic photosynthesis utilizing carbon dioxide and water, and 
the evolution of oxygen as a by-product of the reaction. Light from solar energy served as 
a driving force of oxygenic photosynthesis and is efficiently transformed into chemical 
energy of carbon bonds in glucose. The prosperity of oxygenic photosynthesis resulted in 
the accumulation of atmospheric oxygen. The increase of atmospheric oxygen led to the 
third landmark, the appearance of aerobic life on Earth, beginning with the appearance of 
the eukaryotic organisms and subsequent evolution of metazoan organisms. These 
organisms completed the energy cycle by oxidizing glucose to carbon dioxide and water. 
Just as the prior establishment of photosynthesis is responsible for the emergence of   
eukaryotes, the evolution of metazoans is dependent on the development of highly
2 
 
efficient energy recovery system, oxidative phosphorylation. The recovery of energy 
contained in the chemical bonds of glucose through oxidative phosphorylation in 
metazoans is much more efficient than glycolysis.  
Oxygen is therefore vital for the survival of all metazoan organisms, as it is 
utilized as a substrate for the generation of energy through oxidative phosphorylation in 
the mitochondrial respiratory chain, where it is completely reduced to water. Oxygen 
serves as a terminal electron acceptor. The electrons transferred from NADH in 
mitochondrial respiratory chain ultimately react with oxygen through complete reduction 
to form water. (Figure 1.1).  
 
 
 
 
 
 
Figure 1.1 Oxidative Phosphorylation 
1.1.2. Reactive Oxygen Species 
Cells often produce partially reduced oxygen, termed reactive oxygen species 
(ROS), as products of normal cellular metabolism3. Reactive oxygen species are often 
referred as free radicals and other non-reactive species derived from oxygen. Precisely, 
reactive oxygen species can be defined as molecules or molecular fragments containing 
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one or more unpaired electrons in the outer atomic or molecular orbitals involving 
oxygen molecules. Reactive oxygen species represent the most important class of radical 
species generated in biological systems and is characterized by their short half-life, 
instability and the tendency to react with other molecules in order to achieve stability4.  
1.1.3. Sources of Reactive Oxygen Species  
A vast majority of reactive oxygen species are generated through electron transfer 
reactions in biological milieu. In an aerobic environment, reactive oxygen species are 
constantly generated in the power plants of the cell, mitochondria, as oxygen is reduced 
along the electron transport chain during normal cellular respiration. Addition of an 
electron to the molecular oxygen in the mitochondrial respiratory chain results in the 
formation of superoxide anion radical (O2•−) and subsequent addition of another electron 
in a controlled manner reduces superoxide anion to form water. The process of 
conversion of molecular oxygen to water is extremely efficient in providing the energy 
required for the existence of higher organisms. However, a significant portion of 
electrons escape the mitochondrial respiratory chain and reacts with oxygen prematurely 
resulting in the production of oxygen free radical, superoxide anion (O2•−)5. Superoxide 
anion is considered as the primary reactive oxygen species because of its propensity to 
react with the other molecules to generate secondary reactive oxygen species including 
neutral forms such as hydroxyl (•OH), hydroperoxy (HO2•) and peroxyl (RO2•) radicals. 
Certain nonradical oxidizing agents such as hydrogen peroxide (H2O2) contribute to the 
generation of reactive oxygen species when the peroxisomes that produced them are 
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damaged. Therefore, reactive oxygen species are formed as indispensable byproducts of 
cellular respiration6 (Figure 1.2).   
 
Figure 1.2 Generation of Reactive Oxygen Species 
In addition, reactive oxygen species are also generated endogenously as necessary 
intermediates in a variety of oxidative enzyme catalyzed reactions6. Uncoupling of the 
oxygen reduction from the substrate oxidation during the catalytic cycle of certain 
monooxygenase reactions results in the leakage of reactive oxygen species. For example, 
the drug metabolizing cytochrome P450 enzymes (CYPs) and enzymes dedicated for 
phagocytosis such as NADPH oxidase and myeloperoxidase in phagocytic cells, 
neutrophils and macrophages can generate reactive oxygen species through this 
uncoupling pathway7, 8. Virtually all the activities that involve oxygen consumption have 
the potential to produce reactive oxygen species during enzymatic catalysis. 
Other sources of reactive oxygen species include the interaction of ionizing 
radiation or smoke and other environmental pollutants such as herbicides and pesticides 
with biological molecules. Certain therapeutic drugs with oxidizing effects also 
contribute toward the generation of reactive oxygen species.  
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1.1.4. Functions of Reactive Oxygen Species 
Reactive oxygen species are critical for normal cell functions and cell signaling 
when the concentration is maintained within strict physiological limits9, 10. Reactive 
oxygen species are indispensable intermediates essential for enzymatic reactions, signal 
transduction pathways, activation of nuclear transcription factors, gene expression and 
cellular defense mechanisms by macrophages and neutrophils against various pathogens, 
in addition to the mitochondrial electron transport chain critical for the cell survival. 
Historically, reactive oxygen species are regarded as purely harmful intermediates in 
physiological environment despite their utility in the normal function of the cell. This is 
largely, but loosely, based on the highly reactive nature of these species and overlooked 
is the fact that the deleterious effects are only precipitated by the exceedingly high 
concentrations of reactive species. Importantly, this mechanism is also employed as 
defense mechanism to fight against invading foreign organisms and even in the situations 
of clean-up of the damaged cells that appear to be irreparable.  
1.1.5. Redox Homeostasis 
Reactive oxygen species normally occur in the living cells at relatively low 
steady-state levels. Redox homeostasis refers to intracellular redox balance that can be 
defined as a delicate balance between the rates of production and clearance of reactive 
oxygen species. Intracellular redox homeostasis is being achieved by antioxidant defense 
systems comprising of low molecular weight antioxidants such as glutathione, in addition 
to the protein antioxidants such as enzymes that are capable of competing with substrates 
6 
 
susceptible to oxidation and thus delay the oxidation of these substrates. The complex 
web of antioxidant defense systems checks and maintains the concentration of reactive 
oxygen species at a steady level. Low molecular weight antioxidants such as ascorbate 
(vitamin C), α-tocopherol (vitamin E), β-carotene and glutathione are also present in 
millimolar concentrations within the cells. An array of antioxidant enzymes such as 
superoxide dismutase (SOD), glutathione peroxidase (GPx) and catalase have specific 
subcellular localizations and chemical reactivities. Enzymatic antioxidants are also a 
component of the cellular system involved in phase II drug metabolism; for example, 
glutathione transferases and sulfotransferases facilitate the removal of foreign chemicals 
after activation by phase I or cytochrome P450 enzymes.  
1.1.6. Redox Regulation 
Redox regulation is required to maintain oxidant-antioxidant balance. Cells 
essentially remain in a stable condition when the rates of production and elimination of 
reactive oxygen species are in equilibrium. A summary of events contributing to the 
generation and elimination of reactive species is depicted in figure 1.3. The basis of redox 
regulation is dependent on a regulatory process called redox signaling in which a 
controlled increase in the production of reactive oxygen species leads to a temporary 
imbalance. Redox regulation requires the steady state to be disturbed from either an 
increase in reactive oxygen species concentrations or a decrease in the activities of one or 
more antioxidant systems. Such an oxidative event is induced in a regulated manner in 
higher organisms. Cells have several mechanisms to re-establish the original redox state 
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after a transient exposure to the reactive oxygen species. A transient increase in reactive 
oxygen species at relatively small concentrations stimulates antioxidant response to 
produce an adaptive cellular response sufficient to compensate for the increase and reset 
original redox balance. At low concentrations, it helps the cell to activate signal 
transduction pathways capable of instituting an adaptive cellular response. Reactive 
oxygen species thus help the cell to take a preemptive action against the impending 
toxicities and ailments by serving itself as a stimulus for the induction of the enzymes 
responsible for their own elimination. 
  
Figure 1.3 Redox Regulation of Reactive Oxygen Species 
One main mechanism for this adaptation response is the induction of redox 
sensitive signal cascades leading to an increased expression of antioxidant enzymes or an 
increase in cysteine transport system facilitating an increase in intracellular glutathione10, 
11. Many of the enzymes that are a part of this cascade have common characteristics such 
as coordinated induction by a broad range of chemical agents, including certain reactive 
oxygen species. Therefore, these enzymes are inducible and are redox regulated. In other 
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words, reactive oxygen species are capable of inducing the enzymes responsible for their 
own elimination.  
1.1.7. Dysregulation of Redox Homeostasis and Oxidative Stress 
A strong and persistent increase in reactive oxygen species production may often 
fail to elicit antioxidant response sufficient enough to reset redox homeostasis to basal 
level. It stems again from the highly unstable nature of reactive oxygen species that 
provides oxygen a two-faced character (Figure 1.4). Excessive levels of reactive oxygen 
species, if left uncontrolled damage the cellular structures associated with its production 
including lipids, membranes, proteins and nucleic acids. The magnitude and the duration 
of the dysregulation of reactive oxygen species can produce a chronic shift in redox 
homeostasis. However, dysregulation of reactive oxygen species may not be overt in 
appearance before it manifests into several pathological conditions. In fact, the normal 
process of aging is one such condition shown to be associated with oxidative state. 
Dysregulation of the redox balance towards the accumulation of reactive oxygen species 
refers to a condition called oxidative stress12. The resultant manifestations of various 
physiological processes during oxidative stress conditions thereafter lead to several 
pathological conditions as a consequence. Disease conditions such as inflammation, 
carcinogenesis, degenerative neurologic diseases, reperfusion injury, atherosclerosis, 
drug toxicities are some of the conditions resulting from oxidative stress. Therefore, 
redox homeostasis is highly desirable for the salutary effects to be predominant and 
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therefore, survival of the cell.  The irony is that the oxygen utilization critical for the 
survival of an organism is not without risk.  
  
Figure 1.4 Role of Reactive Oxygen Species in Regulation and Dysregulation of Cellular 
Homeostasis 
1.1.8. Oxidative Stress Paradigm and its Relevance to Health and Disease 
Oxidative stress paradigm premises a plausible concept that there exists a subtle 
balance between oxidants such as reactive oxygen species and antioxidants in normal 
physiology. Perturbation of this delicate balance between oxidants and antioxidants 
causes oxidative damage in the cellular milieu resulting in a condition called oxidative 
stress. Oxidative stress awaits several possible undesirable outcomes as pathologies ensue 
when oxidants are produced in excess of the endogenous antioxidants. Reactive oxygen 
species produce deleterious effects on the cell through indiscriminate damage to the 
macromolecules such as carbohydrates, lipids, proteins and nucleic acids leading to 
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cellular dysfunction or death. Therefore, strategies to counteract this biological damage to 
macromolecules by the reactive oxygen species have emerged with a promise to 
minimize associated pathological conditions. These strategies are historically based on 
the presupposition that all reactive oxygen species share a very common feature of 
damaging biological systems and that all antioxidants will prevent or reverse the 
pathological conditions associated with oxidative stress without any regard to the 
mechanism. Furthermore, to a large extent they have relied on identification of direct 
acting antioxidants that react in a 1:1 stoichiometry with the reactive oxygen species. 
For example, oxidative modifications of proteins by the products of lipid 
peroxidation by reactive oxygen species in disease conditions has been studied 
extensively with a focus on the development of therapeutic antioxidant compounds such 
as α-tocopherol (vitamin E), ascorbate (vitamin C), β-carotene and dietary polyphenolic 
compounds in an attempt to terminate lipid peroxidation. However, supplementation of 
antioxidants in many chronic diseases produced diffuse and nonspecific results in 
controlled clinical trials despite the evidences from basic research. Animal studies and 
epidemiological data collectively demonstrated oxidative damage of biomolecules by 
reactive oxygen species.  
These results also indicate that these traditional antioxidants such as α-tocopherol 
and glutathione essentially act as insulators of redox signaling moieties and prevent the 
cross-talk inside the cell. Further, the extent of modifications of biomolecules by reactive 
oxygen species in vivo in oxidant-dependent pathologies is extremely low with an 
abundance of antioxidants present in the cells and tissues. Therefore, the endogenous 
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antioxidants act as redox insulators. For example, the concentrations of exogenous 
oxidants required to offset the redox balance in vitro or in vivo are in the orders of 
magnitude much greater than the levels that can be achieved in healthy or disease 
conditions. Such exogenous oxidants must break down the redox insulation to produce an 
effect and therefore requires high nonphysiological concentrations. These findings 
demonstrate that effective antioxidants must have a greater role of modulating much 
more complex networks controlling cell signaling pathways related to redox balance. It 
also requires a precise definition of the molecular targets and mechanisms.  
Contrary to the corollary that all the reactive oxygen species are bad and 
antioxidants are good, reactive oxygen species such as hydrogen peroxide and nitric 
oxide are now established as important cell signaling molecules. This signals that reactive 
oxygen species plays an important role in biology and that antioxidants assume a 
regulatory function. For example, low levels of products from lipid peroxidation by 
enzymatic and nonenzymatic reactions accumulate over time and modify certain proteins 
in a specific manner to modulate protective cell signaling pathways. However, high levels 
result in the modifications of susceptible nucleophilic residues in a less specific manner 
leading to deleterious consequences if the subsequent repair or removal mechanisms fail 
to rescue the damage.  
Therefore, redox homeostasis is incessantly critical for the survival of organisms 
and consequently organisms have developed intricate mechanisms that modulate complex 
networks controlling cell signaling and metabolism.  
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1.1.9. Cellular Signaling and Adaptation 
Cell signaling can be thought of as a means of communication among the cells 
through biological mechanisms in response to extracellular stimuli. Transmission of the 
information from the outside of a cell to various functional elements inside the cell is 
referred to as signal transduction. Several stress responsive signaling pathways to the 
reactive oxygen species of endogenous or environmental origin have been identified10. 
The reactive oxygen species activate specific pathways in a controlled manner through 
the modifications of redox sensitive signaling proteins, thus eliciting downstream signal 
transduction pathways. This holds true with other reactive species including electrophiles 
resulting from oxidative reactions in cellular milieu. Further, the involvement of specific 
pathways and genes in response to reactive oxygen species demonstrates that the reactive 
oxygen species act as sub-cellular messengers in redox sensitive signal transduction. The 
signals are ultimately being transmitted to the transcriptional machinery in the nucleus 
responsible for gene regulation through a class of proteins called transcription factors. 
Binding of the transcription factors to the specific DNA sequences elicit transcription of 
target genes. Most of these pathways are characterized by response through localized 
receptors to specific stimulus modulating its function and therefore downstream effectors.  
These pathways are reversible, allowing the control and responsiveness to multiple 
stimuli. One of the most widely characterized signaling pathways that orchestrates with 
the dysregulation of redox homeostasis is Nrf2/ARE signaling pathway. 
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1.1.10. Oxidative Stress and Toxicology 
The toxicities arising from the exposure to a toxicant may result from a cascade of 
events at the cellular and molecular level that may eventually culminate in a toxic 
endpoint. A toxicant may be a chemical with intrinsic toxicity or a chemical derived 
through a process called bioactivation or metabolic activation, which can be defined as a 
process of metabolic conversion of an innocuous chemical into a toxicant. Initiation of 
toxicity usually begins with the covalent interactions of toxicants with the cellular 
macromolecules.  
Metabolic conversion of most of the xenobiotic is carried out by the cytochrome 
P450 enzymes transforming them into inactive and polar metabolites suitable for 
excretion. However, certain cytochrome P450 enzymes such as CYP1A1, CYP1A2, 
CYP2A6 and CYP2E1 have toxicological importance for their involvement in the 
bioactivation of xenobiotics, including drugs converting relatively inert chemical species 
into toxic products. In addition to bioactivation, the isoforms CYP2A6 and CYP2E1 with 
its leaky catalytic cycle also contributes to the generation of reactive oxygen species in 
the form of hydrogen peroxide or superoxide.  
1.1.11. Natural Products as Therapeutic Agents  
Natural products have been used for their medicinal properties over the millennia 
and are the single most productive source for the discovery of novel therapeutic agents. 
The inherent chemical diversity and chemical variations associated with natural products 
presumably makes them a very rich and viable source for the discovery and development 
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of new therapeutic and preventative agents for a variety of pathological conditions. This 
complexity presents itself as a limiting factor in the evaluation of the overall health 
benefits. Huge diversity among the natural products and low accessibility of the 
potentially bioactive constituents presents a major challenge that requires to be resolved 
to prove the concept that the bioactive constituents interact with their targets. Unraveling 
the complex composition of natural products through mechanistic studies and bioactivity 
guided fractionation has a huge potential to provide insights into target-ligand 
relationships. In addition, the pharmacokinetic and pharmacodynamic characteristics of 
natural products add even more complexity to these agents presenting several challenges 
in the understanding of mechanisms of action in vitro and in vivo. Despite the structural 
and functional complexity of the natural products, their screening for biological activity 
has proven to be an effective method for identifying potential therapeutic agents. 
Molecules with such exquisite complexities cannot be constructed easily by other means. 
Examples of plant-based molecules used in medicine dates back to more than 200 years 
where morphine stands as the first pharmacologically active pure compound isolated 
from Papaver somniferum. Examples of natural product based therapeutic agents 
includes antibiotics such as penicillin and tetracycline, antimalarials such as quinine and 
artemisinin, antiparasitics such as avermectin, antihyperlipidemics such as lovastatin, 
anticancer agents such as taxol, doxorubicin and immunosuppresants such as 
cyclosporine and rapamycin. In fact, natural products occupy a major share in the classes 
of antibacterial and anticancer agents. However, the repertoire of natural products has not 
been completely explored and only a small fraction of the chemical diversity present in 
15 
 
nature has been uncovered. It is therefore highly likely that nature will provide an 
abundant supply of the pharmaceutical agents in the years to come. 
Several classes of compounds of natural product origin have been shown to 
inhibit the enzymes involved in the generation of reactive oxygen species and stimulate 
cellular pathways that function to minimize the toxic effects of reactive oxygen species 13, 
14. Limiting the formation of reactive oxygen species inside a cell, as well as eliminating 
reactive oxygen species produced, using natural products represents a viable strategy to 
maintain a healthy redox balance. Thus, the use of natural products to maintain normal 
homeostasis of a cell presents a novel prophylactic strategy in preventing illnesses 
associated with oxidative stress.  
1.1.12. The Açaí Berry 
The Brazilian palm tree Euterpe oleracea, commonly known as açaí, belonging to 
the family Arecaceae, has been traditionally used as a medicinal plant in Brazil (Figure 
1.5). Açaí has been widely acclaimed in recent years for it health-promoting effects and 
emerged as a novel nutraceutical in the United States. The high nutritive values of açaí 
surely places it to be a part of the healthy diet but açaí is yet to be qualified to have any 
significant health benefits. Açaí is found to be richer in antioxidants than similar fruits 
such as cranberries, strawberries, raspberries, blackberries or blueberries. Numerous 
studies have demonstrated the dietary intake of fruits and vegetables as a rich source of 
nutrients or phytochemicals in relation to health benefits. Açaí has been touted as a 
superfruit by its manufacturers claiming to have a lot of health benefits. A lot of 
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enthusiasm has been exercised by its manufacturers in the rising of açaí as a 
commercially successful and viable product on market.   
 
Figure 1.5 Açaí Berry Fruit 
Currently, there is inadequate scientific evidence on both the chemical 
composition of açaí and its biological targets, both of which are decisive in our 
understanding of the purported health benefits of açaí. There is also a clear lack of 
definitive scientific evidence from studies involving basic research, animal and human 
studies concerning molecular mechanisms associated with the use of this product. 
Therefore, açaí is currently not qualified to be listed on the United States Food and Drug 
Administration (USFDA) Generally Regarded As Safe (GRAS) list for its intended use15.  
The benefits of açaí have been linked to high levels of antioxidants including 
anthocyanins, proanthocyanidins, flavonoids and other polyphenolic compounds present 
in it. The reported benefits, for the most part, are based on its in vitro antioxidant capacity 
and radical scavenging ability in biological samples, however; the biological significance 
has not been established. In fact, the United States Department of Agriculture (USDA) 
invalidated the physiological significance of a once widely accepted antioxidant assay, 
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oxygen radical absorbance capacity (ORAC) due to lack of scientific evidence that the 
ORAC values have no relevance to the effects of specific bioactive compounds, including 
polyphenols on human health (http://www.ars.usda.gov/services/docs.htm?docid=15866). 
Furthermore, the scientific refutation of ORAC resulted in USDA`s Nutrient Data 
Laboratory (NDL) removal of more than a decade-long web publication of ORAC 
database. Thus, the basis for the positive health effects of the açaí berry attributed to the 
presence of radical scavenging antioxidants is of debate and remains currently 
unresolved. Therefore, the purported health benefits of açaí are most likely the result of 
more complex interactions with biological targets, rather than direct radical scavenging 
effects. This clearly demonstrates the necessity to provide scientific evidence about the 
possible health benefits of açaí relating specific bioactive constituents to specific targets 
and associated molecular mechanisms.  
1.1.13. Target-based Identification of Bioactive Constituents of Açaí 
As with several other natural products, the diverse make-up of the açaí berries and 
the added complexity of antioxidant defense system limited identification of bioactive 
constituents and their biological targets. Therefore, the promising antioxidant potential of 
the açaí berry extracts needs to be deciphered down to individual bioactive constituents 
and their cellular targets to understand the associated mechanism of action conferring 
health benefits. Identifying açaí berry constituents as inhibitors of enzymes contributing 
to ROS generation and as signaling molecules of various pathways resulting in ROS 
elimination through induction of phase II antioxidant enzymes would provide a basis for 
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explaining its antioxidant potential, and may lead to effective approaches to 
chemoprevention of ROS-linked diseases. The identification and isolation of the 
bioactive chemical species is as complicated as identifying a biochemical target.  The 
current study aims at addressing both the challenges through better utilization of various 
chromatographic techniques.  
1.2. Hypothesis and Aims  
The primary focus of the current research is to understand the antioxidant 
properties of açaí berries by identifying potential biological targets and to delineate the 
biochemical basis of action for better insights into observed effects. Restoring the 
homeostasis of the cell using natural products and dietary supplements has become an 
active area of research owing to the increasingly common use of these products in 
modern world. Recently, açaí emerged as a superfruit and has been widely acknowledged 
to have high antioxidant potential. Although açaí has been shown to exhibit many 
physiological effects, its active constituents, cellular targets and the precise molecular 
mechanisms conferring specific biological activity are yet to be defined. Therefore, it is 
worthwhile to pursue the antioxidant properties of açaí as oxidative stress is the key 
determinant in the pathogenesis of a variety of human ailments.  
The central hypothesis for this dissertation is that several classes of compounds 
present in açaí may favorably interact with natural antioxidant defense system and 
cytochrome P450 enzymes to maintain and/or restore proper redox balance, thus 
preparing the cell to combat against oxidative stress. This leads to the broad objectives of 
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identifying the antioxidant constituents of açaí modulating oxidative stress, and their 
biological targets. The rationale for carrying out the present work is that a detailed 
understanding of the underlying mechanisms by which the açaí constituents restore or 
maintain proper redox balance within the cell is essential for its effective prophylactic 
use. Moreover, it may form basis for development of strategies utilizing açaí as a 
potential therapeutic agent in treating or preventing oxidative stress-related diseases. 
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CHAPTER II 
INHIBITION OF HUMAN CYTOCHROME P450 2E1 AND 2A6 BY 
ALDEHYDES: STRUCTURE AND ACTIVITY RELATIONSHIPS 
 
2.1. Introduction 
The function of microsomal cytochrome P450 enzymes is generally a protective one, 
where foreign chemicals entering the body can be oxidized in a way that makes them more 
readily excreted.  However, the human microsomal cytochrome P450 isoforms 2E1 and 
2A6 have been implicated in the deleterious effects of a variety of drugs and 
environmental agents, including acetaminophen, nitrosamines, and carbon tetrachloride, 
to name a few16-19.  There is also evidence to suggest that the inhibition of these isoforms 
during times of exposure to these agents can provide a level of protection against the 
harmful effects20-22. Consequently, identification of selective inhibitors of these isoforms 
and understanding the basis for selectivity has been the focus of a number of recent 
studies.  It has been established through crystallographic analysis and binding studies that 
the active sites of these two isoforms are relatively small compared with other 
microsomal P450s, with the 2A6 isoform being the more sterically restricted23-25. 
Comparisons between the two enzymes suggest that 2A6 is more structurally rigid, 
whereas the 2E1 active site may have more flexibility, and can change in response to 
different substrates26-28. Indeed, active site volumes ranging from 190 Å3 to 470 Å3 have
21 
 
been measured for 2E1 with different substrates bound27. This is consistent with 
spectroscopic studies indicating that the active site of this isoform displays a significant 
level of compressibility under high pressure, whereas the 2A6 active site is considerably 
more unyielding29, 30. Crystallographic and computational studies suggest that π-stacking 
interactions in the active site may facilitate the binding of planar low molecular weight 
molecules to both isoforms, and in 2E1, these interactions may be the basis for active site 
reorganization associated with observed substrate inhibition31, 32. 
The goal of the current study was to explore structure–activity relationships 
mediating the binding of a series of related aldehydes to human Cytochrome P4502E1 and 
P4502A6 in order to gain additional insight into the structural features contributing to 
selectivity of substrates and inhibitors toward these two isoforms, along with features that 
facilitate active site reorganization and expansion. In particular, factors such as chain 
length, branching in the 3-position and unsaturation in the 2-position were evaluated for 
their influence on KI. Aldehydes were selected on the basis of prior studies involving 
rabbit liver cytochrome P450s identifying aldehydes as a class of P450 inhibitors, and the 
availability of a wide range of structurally related compounds belonging to this class33. In 
addition, aldehydes of the type described in this study can be generated physiologically 
via lipid peroxidation, thus insight gained through this study may guide future studies 
related to toxicology and cellular oxidative stress. 
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2.2. Materials and Methods 
2.2.1. Chemicals 
The aldehyde compounds used in this study were purchased from Acros Organics. 
Coumarin, 7-hydroxycoumarin (umbelliferone), NADPH, p-nitrophenol and 4-
nitrocatechol were from Sigma Chemical Co. Human liver S9 fractions were purchased 
from Moltox Inc., Asheville, NC. 
2.2.2. Enzymatic Assays: P4502E1 
All assays for 2E1 (p-nitrophenol) were carried out according to published 
protocols with slight modifications34. S9 fractions (0.5 mg) were incubated in 100 mM 
phosphate buffer (pH 7.4) in the presence of 20–100 μM p-nitrophenol and 1.0 mM 
NADPH for a total of 30 min at 37 °C in a 0.5 mL total reaction volume. Reactions were 
terminated by addition of ice-cold 6% perchloric acid and incubation on ice for an 
additional 10 min, followed by centrifugation to remove precipitated protein. Cleared 
supernatant (50 μL) was then analyzed by RP-HPLC on a 150 × 4.6 C18 column with a 
mobile phase consisting of 35% acetonitrile, 64.5% H2O, 0.5% acetic acid at a flow rate 
of 1.0 mL/min. Absorbance detection at 340 nm was used to quantify the 4-nitrocatechol 
product. A Shimadzu LC 20A Series HPLC system consisting of an SPD-20A UV/Vis 
detector, LC 20AT solvent delivery, and a Sil 20A autosampler was used for analysis of 
samples. 
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2.2.3. Inhibition of P4502E1 
All inhibitors, including the aldehydes and acids, were prepared as aqueous stocks 
by diluting 4.0 μg inhibitor into 100 mL DI H2O immediately prior to their use. Initially, 
a dose–response curve was generated for each of the aldehydes with regard to their 
relative inhibitory effects on P4502E1. Reactions contained 0.5 mg S9 fractions, 50 μM p-
nitrophenol, 1.0 mM NADPH and aldehyde concentrations ranging from 5 μM to 370 μM 
in a 0.50 mL volume of 0.1 M phosphate buffer (pH 7.4). Samples were quenched and 
processed for HPLC analysis as described earlier. To obtain more detailed kinetic 
parameters, Michaelis–Menten kinetic experiments were then performed to probe the 
mode and potency of inhibition using inhibitor concentrations of either 30 μM or 60 μM. 
These concentrations were chosen based on the results of the screening experiments in 
which it was determined that this was the lowest concentration to produce measurable 
inhibition for all of the compounds being examined except for dodecyl aldehyde. The 
substrate concentrations were varied from 20.0 μM to 100 μM in a total reaction volume 
of 0.50 mL for 30 min, and reactions were processed as described above. A minimum of 
4 independent trials were carried out for each experiment and the standard deviations are 
reported. 
2.2.4. Enzymatic Assays: P4502A6 
The assay that was used to measure inhibition of 2A6 is one that utilizes the 
conversion of coumarin into 7-hydroxycoumarin. The procedure is modified from that of 
Waxman and Chang 35. Liver S9 fractions (0.50 mg) were incubated in a reaction mixture 
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containing 3.0 μM coumarin, 100 mM potassium phosphate buffer (pH 7.4) and 1.0 mM 
NADPH in a total volume of 0.50 mL. Following a 30 min incubation at 37 °C the 
protein was precipitated with 100 μL of 6% perchloric acid and placed on ice for 10 min. 
Samples were centrifuged at 13,500 rpm for 10 min and 40 μL of the cleared supernatant 
was injected onto a RP-C18 HPLC column with a mobile phase consisting of 59% DI 
water, 40% methanol, and 1% acetic acid, at a flow rate of 1.0 mL/min. 
2.2.5. Inhibition of P4502A6 
Inhibitors were prepared as aqueous stock solutions by diluting 4.0 μg inhibitor 
into 100 mL DI H2O immediately prior to their use. Dose–response curve was generated 
for each of the aldehydes with regard to their relative inhibitory effects on P4502A6. 
Reactions contained 0.5 mg S9 protein, 3.0 μM coumarin, 1.0 mM NADPH and aldehyde 
concentrations ranging from 5 μM to 370 μM in a 0.50 mL volume of 0.1 M phosphate 
buffer (pH 7.4). Samples were quenched and processed for HPLC analysis as described 
in the previous sections. Michaelis–Menton kinetic experiments were then performed 
using inhibitor concentrations of either 30 μM or 60 μM. Again, these inhibitor 
concentrations were selected based on the results of the screening experiments, as with 
the 2E1 reactions. The substrate concentrations were varied from 0.5 μM to 6.0 μM in a 
total reaction volume of 0.50 mL for 30 min, and reactions were processed as described 
above. A minimum of 4 independent trials were carried out for each experiment and the 
standard deviations are reported. 
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2.2.6. Reversibility Studies 
To determine whether the inhibition of each P450 isoform by the individual 
aldehydes was reversible or irreversible, microsomal samples were pre-incubated with (1) 
Buffer alone, (2) Buffer + Aldehyde and (3) Buffer + Aldehyde + NADPH, as described 
in previously by Raner et al.33. 
2.2.7. Aldehyde Oxidation by Human P450 Enzymes  
Oxidation of trans-2-octenal was carried out in a total reaction volume of 200 μL, 
and contained expressed human P450 (2E1 or 2A6 supersomes, Gentest, 50 nM final), 
100 mM potassium phosphate buffer (pH 7.4), 100 μM trans-2-octenal, and 1 mM 
NADPH. The reaction was quenched with 6% perchloric acid as described previously. A 
C18 RP HPLC column (4.6 × 250 mm) from Phenomenex was used with a mobile phase 
consisting of 55% acetonitrile and 45% water, both containing 0.1% TFA at a flow rate 
of 1.4 mL/min and detection was at 230 nm. A sample of trans-2-octenoic acid was 
acquired from Sigma–Aldrich and used to generate a standard curve for quantification of 
product. The reactions with human 2E1 supersomes were linear for 45 min at 37 °C, so 
all additional reactions were carried out under these conditions. The 2A6 supersomes 
failed to produce NADPH-dependent acid product. The oxidation of trans-2-
decenal, trans-2-nonenal, trans-2-octenal and trans-2-heptenal by the expressed 
cytochrome P4502E1 in supersomes was also carried out with each of the aldehydes 
present at the following concentrations: trans-2-decenal (110 μM), trans-2-nonenal 
(120 μM), trans-2-octenal (100 μM) and trans-2-heptenal (110 μM), along with 1.0 mM 
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NADPH in a 100 mM phosphate buffer at pH 7.4. Reactions were carried out for 45 min 
at 37 °C and quenched as described above. Control reactions without NADPH were 
carried out in parallel, and the reaction mixtures were analyzed using HPLC under the 
same conditions as described for trans-2-octenoic acid alone. The effects of ethanol 
(0.001%, 0.01%, 0.10% and 1.0%) on the activity in 2E1 supersomes was also monitored 
under identical conditions. 
2.2.8. Analysis of Kinetic Data 
Michaelis–Menten plots were prepared for each of the various activity data sets in 
the presence and absence of inhibitor. All data was fit using SlideWrite version 4.1 
(Advanced Graphics Software Inc.) and the non-linear regression analysis function using 
the Michaelis–Menten equation. Based on Michaelis–Menten plots for each aldehyde, the 
inhibition could be described using the competitive model, so values for KI were 
calculated using this model, where Vmax remains constant, α is defined as Kmapp/Km and 
KI = [I]/(α−1). 
2.2.9. Graphical Images of P450 Active Sites 
The active site images of the 2E1 and P4502A6 enzymes were generated using 
crystal structure coordinates deposited in the protein databank. The file PDB: 1Z10 was 
used for the image of P4502A6 with coumarin bound; PDB: 3T3Z was used for 
P4502E1 with pilocarpine bound; PDB: 3E6I was used to generate the P4502E1 image with 
indazole bound; and the PDB: 3LC4 coordinates were used for P4502E1 image with 
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imidazolyl-dodecanoic acid bound. RasWin 2.7.5.2 Molecular Graphics software was 
used to generate each of these images based on the respective PDB files. 
2.3. Results 
2.3.1. Inhibition of P4502E1 by Alkanals and Alkenals 
Dose–response inhibition studies using p-nitrophenol oxidation as a measure for 
2E1 activity were initially carried out using saturated straight-chain aldehydes ranging 
from 8 to 12 carbon atoms and 2-unsaturated aldehydes with 8-, 9- and 12-carbon atoms 
( Figure 2.1) at fixed inhibitor concentrations of 30 μM and 230 μM. Inhibition was 
observed for each aldehyde as a dose-dependent reduction in activity, relative to a control 
in which no aldehyde was present. The selection of these concentrations was based 
empirically on their ability to highlight the differences in potency among this group of 
aldehydes. Maximum inhibition was observed for the nonyl and decyl aldehydes, and 
unsaturation significantly increased the level of inhibition, suggesting the extended π-
system of the unsaturated aldehydes leads to more favorable binding in the active site. 
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Figure 2.1. Effects of Saturated and 2-Unsaturated Aldehydes on P4502E1 Activity. (A) 
Effect of Chain Length on P450 Inhibition by Saturated Aldehydes at 30 And 230 mM 
Aldehyde Concentration. (B) Comparison of the Effects of Saturated vs 2-Unsaturated 
Aldehydes on P4502E1 Inhibition at 30 and 230 mM Aldehyde Concentration. (C) 
Structures of Aldehydes used for These Comparative Studies. 
The reversibility of inhibition was examined for each of the aldehydes represented 
in figure 2.1 by pre-incubating the aldehydes with S9 fractions in the presence and 
absence of NADPH for 15 min at 37 °C. Dilution of the pre-incubation mixture resulted 
in complete restoration of the p-nitrophenol oxidation activity of the samples, thus all of 
these saturated and unsaturated aldehydes (data not shown) appeared to be reversible 
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inhibitors of 2E1 under the conditions used. As a positive control, the experiment was 
carried out using 11-undecylenic aldehyde at a concentration of 25 μM. Following a 
15 min pre-incubation at 37 °C in the presence of 1 mM NADPH, a loss of ∼50% of the 
activity of 2E1 was observed (data not shown). This compound possesses a terminal 
olefin group, which is known to cause irreversible damage to the heme36-38. 
Detailed inhibition studies were subsequently carried out in which the inhibition 
constants (KI) were calculated for the aldehydes, both saturated and unsaturated, with 
carbon chain lengths, between 5 and 12, using the standard Michaelis–Menten approach 
(Table 2.1). For all the aldehydes tested, Vmax was unaltered, once again indicating 
competitive-reversible type inhibition, thus the competitive model of inhibition was 
applied for KI determination. Consistent with the preliminary screening data, 
the KI values indicate that the 9- and 10-carbon aldehydes, possessing a 2-double bond 
(nonenal and decenal) were the most potent inhibitors of the human 2E1 isoform. It is 
also worth noting that a strong dependence on chain length was observed for the saturated 
compounds, whereas less dependence on chain length was observed with unsaturated 
aldehydes. Furthermore, the unsaturated compounds were all much more potent than the 
respective saturated compounds, with KI values as much as 30-fold lower in the case of 
the 11- and 12-carbon aldehydes. 
2.3.2. Effects of Branching on Inhibition of 2E1 
Additional aldehydes (citral and citronellal) with branching at the 3-position were 
evaluated for inhibitory potency against 2E1. Citral (3,7-dimethyl 2,6-octadienal) as 
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shown in figure 2.2, is a naturally occurring mixture of 2,3-unsaturated aldehyde isomers 
with branching methyl groups at carbon 3 and 7. Citronellal (3,7-dimethyl 6-octenal), 
shown in figure 2.3, also has a 3-methyl branch but does not have a double bond in the 2-
position. Both aldehydes showed reversible competitive inhibition profiles when 
evaluated using the Michaelis–Menten model. KI values were measured for both of these 
compounds and were compared with those of the linear 10-carbon saturated and 
unsaturated aldehydes. By comparing citral to citronellal it is clear that the double bond 
at the 2-position dramatically impacts inhibition; KI values of 18.8 μM vs 57.8 μM, 
respectively. As for the effects of branching, both decanal and citronellal are saturated at 
the 2-position and possess 10 carbon atoms, like decanal. The KI for Decanal, however, is 
about 8-fold lower than the branched citronellal (7.0 μM vs 57.8 μM). Likewise, a 
comparison between decenal and citral showed a 5-fold increase in KI (3.3–15.7 μM) 
with the inclusion of a branching methyl at the 3-position of the aldehyde. 
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Figure 2.2. Structure and Measured Inhibition Constants for Branched Saturated and 
Unsaturated Aldehydes, Citral, Citronellal, and the Corresponding Linear, Saturated and 
Unsaturated 10 Carbon Aldehydes, Decanal and Trans-2-Decenal. 
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Figure 2.3. Key Residues in the Active Site Structure of Human Cytochrome P450 2A6 
with the Substrate Coumarin Bound. Hydrogen Bond Interactions between the Carbonyl 
Oxygen on the Substrate and the Amide Group from Asn-297 and π–π Interactions 
between Phe-107 and the Aromatic Ring of Coumarin are shown (Generated using 
RasWin 2.7.5.2 and Coordinates from PDB: 1Z10). 
2.3.3. Effects of Aldehyde Function  
The importance of the aldehyde group for inhibition was probed by monitoring 
2E1 inhibition using the corresponding 8- to 12-carbon saturated carboxylic acids. Over a 
range of 1.0–100 μM, only lauric acid inhibited 2E1 significantly (data not shown). At a 
concentration of 50 μM, lauric acid reduced the activity of 2E1 by 50%, which is still 
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modest inhibition relative to the aldehydes. Due to the lack of observed inhibition at high 
concentrations of carboxylic acid, KI values were not determined. 
2.3.4. Inhibition of P4502A6 by Alkanals and Alkenals 
As with the 2E1 isoform, all of the aldehydes tested, both saturated and 
unsaturated, inhibited coumarin hydroxylation via a reversible competitive mode. Values 
for KI were determined for each of the saturated and unsaturated aldehydes used with 
2E1, and these values are presented in table 2.1. A trend similar to that observed with 
2E1 was also observed for 2A6. However, the optimal chain length appeared to be 
slightly shorter for 2A6, with a carbon chain length of 7–8 being most potent. 
Comparison of the saturated vs unsaturated aldehydes again suggested that the double 
bond in the 2-position improved the interaction with the active site, as indicated by a 2- to 
3-fold decrease in KI for the unsaturated aldehydes over nearly the entire range. It is 
worth pointing out that with 2A6 inhibition, dodecanal and undecanal appeared to be 
outliers in the general trends observed, as both of these saturated aldehydes inhibited 
more potently than the smaller decanal, and more potently than the corresponding 
unsaturated counterparts. Another clear distinction between the 2E1 and 2A6 data can be 
seen in the behavior of the unsaturated aldehydes. Where the 2E1 isoform appeared to be 
almost insensitive to chain length, the inhibitors of the 2A6 isoform had an optimal chain 
length of 7 or 8, and above or below this value the potency of inhibition decreased in a 
continuous manner, with the 2 notable exceptions previously pointed out. 
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Table 2.1. Experimentally Determined Inhibition Constants (KI) for the Inhibition of 
Human Cytochrome P4502A6 by Straight Chain Saturated and Unsaturated Aldehydes 
Ranging in Size from 5 to 12 Carbons. KI values were calculated using a competitive 
model for inhibition and a minimum of 3 trials were carried out for each aldehyde. 
 
 
Aldehyde P4502A6 P4502E1 
 
KI  (μM) 
Saturated 
KI  (μM) 
Unsaturated 
KI  (μM) 
Saturated 
KI  (μM) 
Unsaturated 
Pentyl 126 ± 16 1270 ± 150 155 ± 13 13 ± 1 
Hexyl 57 ± 7 33 ± 3 26 ± 2 6.7 ± 0.2 
Heptyl 16 ± 1 9 ± 1 32 ± 1 5.6 ± 0.1 
Octyl 25 ± 2 7 ± 1 13 ± 1 4.1 ± 0.1 
Nonyl 55 ± 6 34 ± 3 8.0 ± 1 2.9 ± 0.2 
Decyl 106 ± 29 59 ± 6 17 ± 1 3.3 ± 0.1 
Undecyl 68 ± 7 103 ± 22 117 ± 15 3.4 ± 0.1 
Dodecyl 48 ± 9 128 ± 35 85 ± 8 2.6 ± 0.1 
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2.3.5. Other Structural Determinants for P4502A6 Inhibition by Aldehydes 
As with P4502E1, saturated carboxylic acids were ineffective at inhibiting the 2A6 
isoform at concentrations as high as 100 μM, thus KI values were not determined. 
Interestingly, branching in the aldehyde also resulted in a dramatic loss in potency as 
demonstrated by the use of citral and citronellal as inhibitors of 2A6. Only citral inhibited 
2A6, and here the KI was still >100 μM (data not shown). 
2.3.6. Oxidation of Aldehydes by Human S9 Fractions and Expressed Cytochrome 
P4502E1 and P4502A6 
To determine that the aldehyde function of each inhibitor was inside the active 
site, reactions involving 4 of the unsaturated aldehydes, trans-2-heptenal, trans-2-
octenal, trans-2-nonenal and trans-2-decenal were evaluated for the formation of the 
corresponding carboxylic acid. The substrate trans-2-octenal was examined initially to 
establish linearity over time, and the effects of ascorbate and glutathione on the reaction. 
This aldehyde was selected on the basis of its ability to inhibit both 2A6 and 2E1 
isoforms effectively. The reaction with 2E1 supersomes was linear for 45 min at 37 °C, 
and beyond 45 min a marked decrease in activity was observed. In addition, inclusion of 
either 1.0 mM ascorbate or 1.0 mM glutathione had no effect on the rate of acid 
formation. Furthermore, for the 2E1-dependent reaction, increasing concentrations of 
ethanol (a P4502E1 inhibitor), between 0.001% and 1.0% caused a dose-dependent 
decrease in acid formation, with >80% inhibition at 1% and 40% inhibition at 0.1%  
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ethanol. In contrast, 2A6 supersomes did not catalyze oxidation of trans-2-octenal. An 
additional experiment was carried out in which the four aldehydes; trans-2-
heptenal, trans-2-octenal, trans-2-nonenal and trans-2-decenal were incubated with either 
expressed 2E1 or expressed 2A6, and the NADPH-dependent oxidation of each aldehyde 
was monitored. Supersomes containing expressed 2E1 were effective in the oxidation of 
all 4 aldehydes, while 2A6 supersomes again yielded no acid products. 
2.4. Discussion 
Prior studies involving rabbit cytochrome P4502B4 indicated that mammalian 
cytochrome P450s were susceptible to aldehyde-mediated irreversible mechanism-based 
inhibition33 Mechanistically, the inactivation was the result of heme destruction and was 
correlated to the aldehyde deformylation reaction mechanism39, 40. No prior studies have 
been reported involving interactions between aldehydes and the human isoforms, 
including 2E1 and 2A6, both of which are of considerable toxicological importance. In 
the current study, no evidence for irreversible inhibition was observed with any of the 
aldehydes or either cytochrome P450, rather, reversible competitive inhibition was 
observed. However, oxidation of the aldehyde function by the expressed 2E1 enzyme was 
observed indicating an “aldehyde in” binding orientation in the active site for these 
compounds. With 2A6, a different binding orientation must be envisioned based on the 
inability to oxidize the aldehyde function. It should be noted that in the rabbit liver study, 
aldehyde concentrations used to calculate inactivation rates were in the mM range, 
whereas in the current study, the highest aldehyde concentrations used were mostly 
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below 100 μM. It is conceivable that inactivation of the human P450s could occur at 
higher aldehyde concentrations. 
All of the saturated aldehydes inhibited both P450 isoforms, with varying 
potency, as determined by measured KI values. Several interesting trends were observed 
in this data. For both 2E1 and 2A6, there appeared to be an optimal carbon chain length 
as it related to inhibition potency. For 2E1, the nonyl and decyl aldehyde had the lowest 
measured KI, whereas heptyl and octyl aldehydes were most effective against 2A6, and 
neither isoform was inhibited by corresponding carboxylic acids. Several recent 
comparative studies have been carried out concerning structural and activity relationships 
between the 2E1 and the 2A6 human P450 isoforms that support these experimental 
observations26, 27, 29. Both enzymes have relatively small active sites, and therefore 
binding of larger molecules may be disfavored via steric interactions, consistent with the 
observed pattern of inhibition. The 2A6 active site has a slightly smaller volume than 2E1 
based on crystal structures with the small molecule pilocarpine bound (280 Å3 vs 
337 Å3), which is consistent with the smaller optimum chain length for inhibition of 2A6 
(7–8 carbons for 2A6 vs 9–10 for 2E1)28. In addition, DeVore et al., using both 
experimental and computational approaches showed that the 2E1 active site was slightly 
less polar than 2A6, however both contained a cluster of phenylalanine groups that 
appeared to define the active site boundaries28. The reduced interaction of both isoforms 
with carboxylic acids relative to aldehydes is most easily justified by the less polar 
character of the aldehyde group. The crystal structure of 2A6 reveals an Asn side chain 
(Asn 297) that may help to stabilize the carbonyl group of the aldehydes via hydrogen 
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bonding. Indeed, the substrates pilocarpine and coumarin both have carbonyl oxygens 
that form H-bond interactions with Asn 297 (Figure 2.3 shows the structure of the 2A6 
active site with coumarin bound). 
The 2-unsaturated aldehydes were generally more potent inhibitors of both 2E1 
and 2A6, with some KI values nearly 10-fold lower than the corresponding saturated 
compounds. Computational studies by Xu et al.  highlight the importance of π−π 
interactions in the binding of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in 
the active site of 2A6, thus similar interactions with the planar π-system of the 2-
unsaturated aldehydes could be envisioned as a basis for more efficient binding41. 
Furthermore, based on the crystal structure of the human 2A6 isoform with coumarin 
bound, the nature of this π–π interaction involves the perpendicular arrangement of the π-
orbitals on the aromatic ring systems of coumarin with those on Phe107 ring. , it is 
reasonable to suggest that the π-system of the 2-unsaturated aldehyde interacts favorably 
with Phe-107 of 2A6 in an analogous fashion, which serves to orient the substrate and 
restrict its mobility42. Thus, increasing size would create steric interference in the rigid 
2A6 active site, if these binding interactions were to be maintained27. This binding mode 
can also be used to rationalize the lack of aldehyde oxidation, as the carbonyl group of 
the aldehyde would be hydrogen bonded to Asn-297, which is removed from the 
activated oxygen in the catalytic site. The increase in potency toward 2A6 for the 
undecanal and dodecanal, relative to the corresponding unsaturated compounds was 
noted, however, it is not clear what the molecular basis for this observation is. It is 
tempting to rationalize this based on the greater flexibility of the large saturated 
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aldehydes in the rigid active site. This does not account for the increased potency of these 
larger aldehydes relative to the smaller decanal, which should have less steric restrictions 
on binding. A more likely explanation is that given the hydrophobic nature of these 
compounds, disruption of the P4502A6/P450-reductase complex may result in the more 
potent observed inhibitory action. 
Interestingly, for the unsaturated aldehydes, the dependence on chain length was 
almost completely abolished in 2E1, with the aldehydes containing 7–12 carbon atoms all 
inhibiting with KI in the 3–5 μM range. This is in stark contrast to the behavior of the un-
saturated aldehydes with 2A6. Although the π-interactions appear to be strongly driving 
the binding of these aldehydes to both enzymes, the 2E1 active site appears to have the 
ability to accommodate larger molecules in response to the presence of the π-system of 
the unsaturated aldehydes. First, 2E1 lacks the H-bond donor to the carbonyl that is 
present in 2A6, as Asn-297 is replaced in 2E1 with Asp-295, which is excluded from the 
active site. According to DeVore et al. the substrate pilocarpine appears to adapt to the 
2A6 active site upon binding, whereas the 2E1 active site may change topology in 
response to substrate binding28. In support of this flexibility model, the 2E1 active site 
volume can expand to 420–470 Å3 in response to the binding of the large substrate 
imidazolyl-dodecanoic acid25. 
Figure 2.4 shows a comparison of the active site structure of P4502E1 with (A) 
pilocarpine (B) imidazolyl-dodecanoic acid and (C) indazole bound (substrate molecules 
are omitted from the structure). Although each of these substrates is structurally distinct  
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from the aldehydes used in the current study, what is apparent is that there are residues in 
the active site that can rearrange in response to substrate and/or inhibitor binding. Four 
Phe side chains (Phe 116, Phe 207, Phe 298 and Phe 478) that form the upper surface of 
the active site are shown in this figure. The most significant differences on substrate 
binding occur in the position of Phe 298 and Phe 478 with respect to the heme. For 
example, in panel A, Phe 298 and Phe 478 have moved up relative to the heme, creating a 
larger volume directly above the heme when the bulky pilocarpine molecule binds. With 
indazole bound (panel C) Phe 478 is angled down toward the heme, reducing the overall 
volume of this cavity. Panel B shows the additional movement of Phe 298 in response to 
binding imidazolyl-decanoic acid. This motion allows the acyl chain of the substrate to 
access a binding channel running parallel to the I-helix just above Phe 298, which 
presumably accounts for the larger active site volume in the presence of this substrate. It 
is conceivable that π-interactions between unsaturated aldehydes and the 2E1 active site 
may have an analogous effect on Phe 298, essentially holding this door open so that 
longer chain aldehydes can gain access to the more remote areas of the active site. 
Alternatively, computational studies by Li et al. suggest that the phenyl ring of Phe 478 
can rotate to become almost perpendicular to the heme as a substrate binds to an 
“effector” site, which lies along the substrate access channel, directly above the γ-meso 
position on the heme32. This motion repositions both the active substrate and a key 
catalytic residue T303, resulting in negative cooperativity. Li et al. indicate the 
orientation of Phe 478 is significantly altered via π–π stacking interactions when an 
aromatic ligand occupies the effector site32. As the saturated aldehydes would not be 
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expected to bind to this effector site, it is also reasonable to suggest that the π-system of 
the 2-unsaturated aldehyde allows it to gain access to the effector site, thus increasing the 
available active site volume for unsaturated aldehydes. The lack of a hydrogen bonding 
group analogous to Asn-297 in 2A6 appears to allow the carbonyl group of the substrate 
more freedom to explore the active site, resulting in its oxidation by 2E1, but not 2A6. 
 
Figure 2.4 Active Site Structure of P450 2E1 Showing the Position of Key Phe Residues 
in the Presence of the Substrates (A) Pilocarpine (PDB: 3T3Z), (B) Indazole (PDB: 3E6I) 
and (C) Imidazolyl-dodecanoic Acid (PDB: 3LC4). Images were prepared using RasWin 
2.7.5.2 Molecular Graphics software. 
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2.5. Conclusions 
In summary, the current work demonstrates that a series of saturated and 
unsaturated aliphatic aldehydes are effective competitive inhibitors of both human P450 
2E1 and 2A6. The relatively small size of the 2E1 and 2A6 active sites result in a 
preference for binding the 7–10 carbon saturated aldehydes. In addition, 2-unsaturated 
aldehydes display 5 to 30-fold higher affinity for both human enzymes than their 
corresponding unsaturated counterparts, which is likely due to the potential for π-stacking 
interactions in Phenylalanine-rich active site of these enzymes. This study also provides 
direct experimental support for the flexibility model of substrate binding to 2E1, and 
suggests that an extended π-system may be a key determinant in active site expansion.
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CHAPTER III 
IDENTIFICATION OF INHIBITORS OF HUMAN CYTOCHROME P450 
ENZYMES INVOLVED IN DRUG METABOLISM AND TOXICOLOGY BY 
AÇAÍ EXTRACTS 
 
3.1. Introduction 
Cytochrome P450 enzymes belong to a superfamily of enzymes that are 
evolutionarily conserved across all the life forms. In mammals, cytochrome P450 
enzymes are heme-containing microsomal monooxygenases found membrane bound to 
the endoplasmic reticulum of the cells. The enzymes are distributed across all the tissues 
with specialized functions but a substantial proportion is found in liver, the primary 
detoxifying organ. Cytochrome P450s catalyze a wide variety of metabolic and 
biosynthetic processes through oxidative metabolism of various endogenous and 
exogenous compounds including drugs, carcinogens and xenobiotics. It usually results in 
the addition of a hydroxyl moiety resulting in more polar metabolites that in some 
instances are predisposed to further metabolism by phase II enzymes. This process of 
conversion of foreign compounds into polar metabolites that can be readily excreted out 
of the body is called biotransformation. This is usually achieved by attaching a polar 
hydroxyl moiety to the xenobiotic (Figure 3.1). Cytochrome P450-dependent metabolism 
usually results in the formation of less toxic compounds.  Cytochrome P450 enzymes
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metabolize a wide range of structurally diverse compounds and are responsible for the 
elimination of a vast majority of exogenous compounds and xenobiotics 43.  
 
Figure 3.1 Schematic of Cytochrome P450 Mediated Xenobiotic Metabolism 
In humans, a total of 57 genes coding Cytochrome P450 enzymes have been 
identified and conveniently categorized based on their sequence homology into 18 
families and 44 subfamilies44, 45. Enzymes that share more than 40% amino acid sequence 
identity are grouped into one family designated by an Arabic numeral. The members of a 
family sharing more than 55% sequence identity are assigned a letter. Members 
belonging to 1, 2 and 3 families metabolize a majority of xenobiotics. These enzymes are 
evolutionarily less conserved and exhibit polymorphism among individuals. They also 
have less affinity and therefore broader selectivity towards a wide range of foreign 
compounds. Among these CYP isoforms, CYP1A1, CYP1A2, CYP2A6, CYP2B6, 
CYP2C8, CYP2C9, CYP2D6, CYP2E1and CYP3A4 share the metabolism of 
xenobiotics to a great extent.  
Enzymes belonging to the family 4 participate in metabolism of fatty acids and 
related substrates and also some xenobiotics.  The other isoforms belonging to the 
families 5 through 51 are highly conserved with a high affinity for endogenous substrates 
and therefore have specific endogenous functions such as biosynthesis of steroid 
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hormones, prostaglandins and bile acids. Despite the broader selectivity and the 
overlapping sensitivity of these enzymes towards various substrates, metabolism of two-
thirds of foreign compounds that enter the human body including drugs, is carried out by 
one of these few enzymes as illustrated in figure 3.2 46.   
 
Figure 3.2. Distribution of the Metabolism of the Xenobiotics by Various Metabolizing 
Enzymes 
An important feature of these enzymes is that their expression and function can be 
altered by a variety of intrinsic and extrinsic factors, including the presence of multiple 
drugs or xenobiotics (Figure 3.3)47.  Factors such as age, sex, polymorphism and 
concomitant disease conditions and several drugs alter the expression of these enzymes 
with possible consequences of increased or decreased clearance of drugs administered 
concurrently. An increasing use of natural products for treating various ailments also 
adds complexity to metabolism of various concurrently used medications. These factors 
are implicated in many off-target undesirable effects through their influence on the 
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biotransformation and bioactivation of xenobiotics when the metabolites formed are 
reactive oxygen metabolites, radicals and reactive electrophiles. Therefore, a thorough 
knowledge of the interactions between each of the CYP isoforms and all forms of 
xenobiotics, including natural products, is essential towards a better understanding of 
overall effects on human health. It is also vital for a careful assessment of safety and 
efficacy, and prediction of interactions among xenobiotics including natural products. 
 
Figure 3.3. Distribution of the Metabolism of the Xenobiotics across Various CYP 
Isoforms and Factors Affecting their Expression  
3.1.1. Cytochrome P450 Catalytic Cycle 
Cytochrome P450 enzymes are metalloenzymes containing a heme iron center at 
the active site and are therefore termed as hemeproteins. The heme iron in its native ferric 
state (Fe3+) is stable and is bound by a protoporphyrin IX, along with a thiolate group 
arising from cysteine and water. Binding of the substrate to the low spin ferric state 
displaces the water molecule from the center and reduces iron to the ferrous state (Fe2+). 
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Cytochrome P450 enzymes require activation of molecular oxygen for their catalytic 
activity. Binding of molecular oxygen to the heme center followed by subsequent 
reduction, protonation and heterolysis of heme bound oxygen results in the formation of 
iron-oxo state (Fe5+) that oxidizes the substrate to the oxygenated product (Figure 3.4).   
The derivation of the name, P450 originates from the absorption maximum for the 
enzyme at 450nm, characteristic of the complex formed through the binding of carbon 
monoxide to the ferrous (Fe2+) state48.  
 
Figure 3.4 Schematic Representation of Cytochrome P450 Catalytic Cycle  
3.1.2. Cytochrome P450 Mediated Reactive Oxygen Species Generation 
Cytochrome P450 enzymes are also a major producer of the endogenous reactive 
oxygen species inside the cell. Inefficient coupling of the substrates to the cytochrome 
48 
 
P450 enzymes during the electron transfer from NADPH results in leakage of reactive 
oxygen species resulting from the association of these electrons with molecular oxygen. 
Certain xenobiotics such as alcohol, drugs and environmental pollutants have the 
tendency to increase the uncoupling reaction and subsequent production of reactive 
oxygen species 49. The release of activated oxygen in the form of superoxide or hydrogen 
peroxide as a by-product results from mechanisms that regulate production of reactive 
oxygen species by cytochrome P450. The formation of the superoxide anion radical 
results from the decay of the one electron reduced ternary complex while the formation of 
hydrogen peroxide results from the protonation of the peroxycytochrome P450 (Figure 
3.5).  
 
Figure 3.5. Schematic Representation of P450 Mediated Production of Reactive Oxygen 
Species. 
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Persistent production of reactive oxygen species by cytochrome P450 through 
NADPH consumption is an inevitable event in both the presence and absence of the 
substrates. Factors such as the type of substrate, pH, ionic strength and oxygen 
concentration also affect the production of reactive oxygen species by cytochrome P450 
enzymes 49. In addition, certain CYPs catalyze some less favorable reactions including 
activation of xenobiotic substrates leading to the generation of highly reactive 
electrophilic species called reactive metabolites such as epoxides, carbonium and 
nitrenium ions that may result in toxicity 50, 51. This process of transformation of 
innocuous chemicals to a potentially deleterious metabolite is referred to as bioactivation 
or metabolic activation. The resultant products of bioactivation are not efficiently 
detoxified particularly when the balance between their production and elimination is 
disrupted. Therefore, bioactivation forms the basis for the toxicities associated with 
several innocuous xenobiotics. Furthermore, cytochrome P450 enzymes contribute 
towards the generation of approximately two-third of carcinogen activation. Therefore, 
the mechanisms of toxicity associated with the cytochrome P450 mediated generation of 
reactive oxygen species have significant toxicological consequences. The enzyme 
isoforms, particularly CYP1A1/2, CYP2A6 and CYP2E1, are noteworthy for their roles 
in this process 52 (Figure 3.6).  
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Figure 3.6 Contributions towards the Generation of Reactive Species by Various Human 
Enzymes (A). Distribution of P450 Mediated Activation Reactions among Human P450 
Enzymes (B). 
Tightly controlled production of reactive oxygen species is an important 
constitutive process with critical roles ranging from cellular development to cellular 
toxicity. At low concentrations, reactive oxygen species are very well recognized to serve 
the role of secondary messenger in signal transduction pathways. Contrary to this, 
reactive oxygen species also serve as one of the central elements of cellular toxicity 
leading to the pathogenesis of many diseases. Another complication arising from 
cytochrome P450 enzymes is bioactivation or metabolic activation results from the 
conversion of physiologically inert substrates or xenobiotics to potentially deleterious 
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metabolically reactive and toxic compounds. Certain xenobiotics capable of undergoing 
redox cycling during the course of metabolism produce reactive oxygen metabolites. The 
mechanisms of toxicities precipitated from metabolites formed through bioactivation are 
very similar to the toxicities associated with reactive oxygen species. The reactive 
intermediates can also interact with molecular oxygen to produce reactive oxygen 
species. In addition, cytochrome P450 enzymes are highly sensitive to the chemical 
exposure resulting in the induction or inhibition of their expression.  
3.1.3. Cytochrome P450 2A6 
CYP2A6 is a human cytochrome P450 from family 2, sub-family A and 
polypeptide 6. It is predominantly found in liver but is also expressed in extrahepatic 
tissues such as lung, trachea and nasal mucosa. CYP2A6 comprises only about 4% of the 
total hepatic cytochrome P450 and metabolizes 3% of drugs. It metabolizes low 
molecular weight nonplanar compounds and is widely recognized as the major enzyme 
responsible for the metabolism of psychoactive tobacco ingredient, nicotine to inactive 
cotinine and subsequently to trans-3’-hydroxycotinine. In fact, CYP2A6 has been 
proposed a novel therapeutic target for smoking cessation owing to its major contribution 
to nicotine metabolism.  It is, however, involved in the bioactivation of tobacco-related 
N-nitrosamines and other carcinogens, which leads to the induction of oxidative stress 
resulting in cancer, cardiovascular and respiratory diseases 53. The metabolic activation of 
alkylnitrosamines with bulky chains is predominantly carried out by CYP2A6. It is also 
involved in the metabolic activation of environmental toxicants such as aflatoxin B1, 
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naphthalene, hexamethylphosphoramide, methyl-t-butyl ether 54, 55.  Thus, CYP2A6 
inhibition presents a potential strategy for protecting the cell from unwanted exposure to 
reactive metabolites thereby reducing the related cellular stress. Nonetheless, the 
conversion of anticancer prodrug tegafur to 5-florouracil is a clinically significant result 
of metabolic activation, thus unwanted inhibition of CYP2A6 may have pharmacological 
implications. 
3.1.4. Cytochrome P450 2E1 
CYP2E1 is expressed in both hepatic and extrahepatic tissues and is responsible 
for the metabolism of 3% of drugs. Low molecular weight compounds that are generally 
neutral and hydrophilic with planar configuration represent common substrates for this 
isoform. It usually metabolizes compounds such as aliphatic alcohols, ethers, halogenated 
alkanes, endogenous acetone and other ketone bodies 51. Elimination of endogenous 
acetone is largely carried out by CYP2E1. In fact, increased CYP2E1 activity has been 
observed in hyperketonemia as a cellular adaptive response for ketone bodies elimination. 
Substrates of CYP2E1 also include many industrial chemicals, occupational toxicants and 
environmental pollutants in addition to procarcinogens.   
CYP2E1 can directly form free radicals through disruption of its catalytic cycle 
leading to the leakage of activated oxygen as reactive species or by generating reactive 
metabolites through the activation of the xenobiotics. It is a potent generator of 
superoxide in aerobic environment and its tendency to generate reactive oxygen species 
through the leaky catalytic cycle makes it toxicologically important 49, 56. CYP2E1 is also 
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responsive to a variety of factors such as exposure to xenobiotics, metabolic and 
endocrine disorders, and several other pathophysiological conditions. Alcohol induces 
CYP2E1 and its abuse results is largely responsible for hepatocellular damage causing 
inflammation, steatosis and cirrhosis. For example, reversible induction of the enzyme 
through moderate alcohol consumption and its subsequent involvement in ethanol 
oxidation generates reactive oxygen species. Another important feature arises from the 
significant localization of CYP2E1 within the mitochondria, which further precipitates its 
deleterious effects. CYP2E1 also generates toxic and carcinogenic compounds from 
environmental pollutants such as nitrosamines in cigarette smoke, and has been 
implicated in drug-induced cytotoxicity 53. The reactive metabolites produced by this 
enzyme cause drug-induced hepatotoxicity as observed with paracetamol and halothane57, 
58.   
Moreover, CYP2E1 regulation is complex including inhibition, induction, 
transcriptional activation and post-translational modifications. The highly inducible 
nature of this enzyme by small molecular xenobiotics such as acetone, alcohol and 
isoniazid results in increased vulnerability toward drug-induced cytotoxicity 51. For 
example, increased toxicity of paracetamol in chronic alcoholics results from CYP2E1 
induction by alcohol 59. Furthermore, environmental pollutants such as azoxymethane, 
acrylonitrile, benzene, nitrosamines and halogenated hydrocarbons are metabolically 
activated by CYP2E1 to carcinogenic compounds 53, 60, 61.    
Inhibition of CYP2E1 by various compounds including natural products has been 
studied extensively as a measure to reduce the alcohol-induced and acetaminophen-
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induced CYP2E1 mediated toxicity and thereby protect the cells in vitro and in vivo.  
Organosulfur compounds from cruciferous vegetables such as diallylsulfide, 
diallyldisulfide sulforaphane, phenylethylisothiocyantates and S-allylmercaptocysteine 
have been shown to inhibit CYP2E1 enzymatic activity and also protein 62-65.  Lycopene 
from tomatoes, curcumin from ginger rhizomes, rhein from aloe, and fennel and 
raspberry leaf extracts has been shown to oppose the adverse effects of CYP2E1 
mediated toxicities 66-69. Therefore, inhibition of CYP2E1 with concurrent use of natural 
products that are safe appears to be viable strategy to mitigate hepatic damage.  
Further, in comparison with other CYP enzymes involved in drug metabolism, 
CYP2A6 and CYP2E1 mediated generation of reactive species is greater relative to its 
role in drug metabolism. Therefore, inhibition of this enzyme may prove beneficial in 
certain conditions. The potential benefits of selective inhibition of CYP2A6 and CYP2E1 
underscore the need for identification of specific inhibitors of these isoforms. Despite 
this, very few inhibitors specific to each of these isoforms have been identified. 
Extending this search to natural products may ultimately lead to alternative strategies for 
reducing the deleterious effects of exposure to environmental toxicants and lead to 
effective natural approaches to maintaining good health. 
3.1.5. The Açaí Berry 
Açaí berries have received tremendous attention in the recent years from general 
population that it emerged as a novel nutraceutical. The health benefits of açaí are often 
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obscure with little scientific evidence derived from in vitro antioxidant assays where 
quenching of reactive chemical species by the constituents of açaí was the main criteria.  
Açaí extracts have been shown to ameliorate oxidative stress in various in vitro 
assays 70, 71. Low molecular weight compounds belonging to several molecular classes 
have been found to inhibit CYP2A6 and CYP2E1. Açaí is so far found to have 
compounds belonging to several molecular classes including anthocyanins, 
proanthocyanidins and flavonoids 72, 73. These compounds or other compounds awaiting 
identification in the açaí may have the potential to inhibit CYP2A6 and CYP2E1. The 
underlying mechanisms responsible for reduced generation of reactive oxygen species, 
particularly in relation to the involvement of CYPs have never been studied. Therefore, 
identification of chemical constituents in açaí berry extract that inhibit CYP2A6 and 
CYP2E1 and the mechanism by which the identified inhibitors exert their action is 
particularly important in evaluating one aspect of the antioxidant potential of the açaí 
berry.  
Recently, there has been a growing interest in understanding the effects of 
phytochemicals on normal drug metabolism. Currently, there is a wide spread use of 
herbal preparations for various disease conditions as complementary and alternative 
therapeutic alternative. Therefore, the therapeutic outcomes of the phytochemicals 
present in the herbal supplements in addition to the adverse effects and also their 
potential for interactions upon co-administration with various drugs are of increasing 
interest. Certain phytochemicals are capable of inducing or inhibiting the drug 
metabolizing cytochrome P450 enzymes. Detoxification is the principal biological 
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function of cytochrome P450 enzymes and is achieved through the oxidative metabolism 
of various foreign compounds. There are a lot of variations observed in the 
pharmacokinetics of various drugs in relation to the consumption of phytochemicals as 
herbal supplements for health benefits. For example, the furanocoumarins such as 
bergamontin and 6’,7’-dihydroxybergamontin present in grapefruit juice are potent 
inhibitors of CYP3A4 enzyme. CYP3A4 is involved in the metabolism of approximately 
one-third of the drugs on market. Inhibition of CYP3A4 can lead to clinically relevant 
adverse effects that sometimes could lead to life-threatening conditions 74. An additional 
goal of this study was to probe the potential for acai products to interfere with normal 
drug metabolism, and thus it’s potential to bring about unwanted drug interactions.        
Currently, there is no evidence of the interactions between the constituents of açaí 
berry extracts and various drug metabolizing cytochrome P450 enzymes. The availability 
of this information is required for assisting the medical community for a better and 
effective use of açaí as herbal supplement. Furthermore, certain CYP isoforms are also 
involved in oxidative biotransformation of various procarcinogens including polycyclic 
aromatic hydrocarbons and tobacco-related nitrosamines to highly reactive species that 
are toxic to cells. In some instances, oxidative stress is biochemically connected to drug 
metabolism leading to several pathologies as a consequence.  
In vitro models using S9 fractions of human liver microsomes and cDNA 
expressed enzymes are commonly used in the identification of inhibitors of cytochrome 
P450 enzymes. The data obtained from in vitro experiments may prove to be 
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complementary in identifying probable adverse interactions including drug-herbal 
interactions.  
The goals of the current study were to understand the inhibition of cytochrome 
P450 enzymes by various crude extracts of açaí berry using cDNA expressed enzymes in 
order to gain new insights into the susceptibility of inhibition of various cytochrome 
P450 enzymes by açaí berry extracts. This forms the basis for the understanding of any 
potential interactions of açaí berry extracts with cytochrome P450 enzymes and possibly 
the interactions between açaí berry extracts with any co-administered drugs. Therefore, a 
panel of cytochrome P450 enzymes were screened for inhibition by açaí berry extracts. In 
addition, inhibition of two of the toxicologically important CYP isoforms, namely 
CYP2A6 and CYP2E1 was extensively studied using bioassay-guided fractionation 
approach in an attempt to establish the basis for use of açaí berry constituents for possible 
health benefits arising from inhibition of these toxicologically important enzymes. 
3.2. Materials and Methods 
3.2.1. Chemicals and Reagents  
All the chemicals for CYP assays and solvents for bioassay-guided fractionations 
and chromatography were HPLC grade reagents were purchased from Fisher Scientific 
and reagents were prepared using reagent grade chemicals or highest purity available. 
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3.2.2. Human Liver Microsomes and cDNA Expressed Supersomes 
Pooled human liver microsomes obtained from Molecular Toxicology Inc., 
(Asheville, NC) and cDNA expressed enzymes obtained from Xenotech LLC., (Lenexa, 
KS) were made into 100 µl aliquots and stored at -80˚C until used. The total protein 
concentration reported were 23.3 and 10 µg/µl for human liver microsomes and cDNA 
expressed supersomes, respectively. 
3.2.3. Açaí Berry Extracts 
Freeze-dried açaí berry powder was obtained from Optimally Organic Inc., 
(Westlake Village, CA) and stored at -80˚C until used. All the material used in the study 
arrived from a single lot and a corresponding voucher specimen was deposited on file at 
the Herbarium of the University of North Carolina at Chapel Hill, NC. The authenticity 
of the sample was verified by DNA identification testing by Authen Technologies, LLC. 
(Richmond. CA) that confirmed that the genomic DNA of freeze-dried açaí berry powder 
used in the study is consistent with Euterpe oleracea and is divergent form other closely 
related species as well. All the fractions generated from the bioassay-guided 
fractionations were carried out by Dr. Nicholas Oberlies research group at University of 
North Carolina at Greensboro. The fractions generated were conveniently distributed into 
aliquots and stored at 4˚C until used. 
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3.2.4. Bioassay-guided Fractionation of Açaí 
Bioassay-guided fractionation offers the opportunity to isolate bioactive 
constituents from complex natural products and was achieved by practicing standard 
extraction procedures and chromatographic separation techniques. The general approach 
towards bioassay-guided fractionation for in vitro CYP inhibition is depicted in figure 
3.7. Initially, crude extracts were generated and subsequently fractionated based on their 
potency towards the CYP isoforms and the process was repeated to a series of 
fractionations until the pure compounds were isolated. The identity of isolated 
constituents was determined by MS and NMR techniques, which were all carried out in 
the research laboratory of Dr. Nicholas Oberlies at the University of North Carolina at 
Greensboro.    
 
Figure 3.7 Schematic Representation of Bioassay-Guided Fractionation Approach 
Briefly, the freeze-dried açaí berry powder was extracted with methanol and 
subsequently partitioned between hexane, chloroform, butanol and aqueous phases, 
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respectively. The crude extracts were initially tested for CYP inhibition using cDNA 
expressed enzymes including  CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, 
CYP2C9, CYP2D6, CYP2E1and CYP3A4. The selection of these enzymes was based on 
their relevance to the metabolism of a vast majority of xenobiotics including drugs and 
natural product based supplements.  
3.2.5. Preparation of Crude Açaí Berry Extracts 
Bioassay-guided fractionation of freeze dried açaí berry powder was initiated by 
employing solvent partitioning techniques. The freeze dried açaí berry powder was 
initially extracted with methanol. The methanol extract was then subjected to series of 
partitioning events across the solvents beginning with hexanes, followed by chloroform, 
butanol and finally water to produce the initial four crude açaí berry extracts as illustrated 
in Scheme 1. These solvents allowed a very good separation of the chemical constituents 
of açaí based on their affinity to the partitioning solvents. For example, partitioning of 
methanol extract with hexanes allows for the extraction of fats and lipids as hexane 
extract. The hexane extract was then dried under inert atmosphere such as nitrogen to 
produce the initial crude hexane extract denoted by Açaí-31-1. The aqueous methanol 
extract was then partitioned with chloroform to produce the crude chloroform extract and 
dried to produce crude chloroform extract denoted by Açaí-31-2. The remaining aqueous 
methanol extract was subsequently partitioned between n-butanol and water to produce 
the crude butanol and aqueous extracts and are represented by Açaí-31-3 and Açaí-31-4, 
respectively.  
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Scheme 1. Bioassay-guided Fractionation of Freeze-dried Açaí Berry Powder. 
  The crude extracts that were found to be active in the in vitro inhibition of 
Cytochrome P450 enzymes using human liver microsomes were selected and subjected to 
a series of fractionations in an attempt to characterize the chemical constituents that were 
responsible for the observed inhibition. In the current study, two CYP isoforms, namely 
CYP2A6 and CYP2E1, with established roles in toxicology over metabolism were 
extensively studied.  
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3.2.6. Sample Preparation of Açaí for CYP Inhibition 
All the fractions generated through the bioassay-guided fractionation were 
partitioned into aliquots for future use. Methanol was used as a co-solvent in the 
preparation of açaí samples for cytochrome P450 inhibition, however as methanol itself 
can affect cytochrome P450 activity, its concentration in the final reaction mixture was 
maintained at a low level. For example, each aliquot initially received methanol in an 
amount that would produce 0.25% final concentration in the incubation mixture.  
3.2.7. Cytochrome P450 Assays 
 Açaí constituents, like most other drugs might act as substrates or inhibitors of 
enzymes including cytochrome P450 enzymes. The interactions between the drugs and 
the açaí constituents upon co-administration are better understood using Michaelis-
Menten equation. All the enzyme activity assays were developed using substrates that are 
specific as well as selective to the isoform under test. An initial Michaelis-Menten plot 
for each of the isoforms tested was generated in order to understand the kinetics of the 
enzyme function using appropriate probe substrates. Screening of açaí berry extracts for 
the inhibition of CYP isoforms employed only a single substrate concentration. This 
single substrate concentration for screening experiments was chosen to be close to the 
observed Km from the respective Michaelis-Menten plots. The results of enzyme 
inhibition from screening studies was expressed as percent inhibition with respect to the 
control reactions. Measurement of inhibition constant, KI for the açaí berry extracts 
towards CYP isoforms was carried out using the concentrations of açaí berry extracts 
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observed to produce more than 50% inhibition in the initial screening experiments. All 
the experiments were done in triplicates.  
3.2.8. Michaelis-Menten Model of Enzyme Kinetics  
Initially, the kinetics of Cytochrome P450 activity was studied using Michaelis-
Menten model of enzyme kinetics using probe substrate. An enzyme following a typical 
Michaelis-Menten kinetics establishes the relationship between the reaction rate and 
substrate concentration (Figure 3.8). It is characterized by an initial linear increase in rate 
of reaction where the amount of product [P] formed is proportional to the substrate [S] 
concentration. Then, the rate of reaction slowly begins to level off and assumes an 
asymptotic maximum, Vmax, at saturating substrate concentration. At low substrate 
concentrations, the rate of reaction depends on substrate concentration but at high 
substrate concentrations, the rate of reaction is independent of substrate concentration. 
The Michaelis constant, Km, is the substrate concentration at which the active site of the 
enzyme is half-filled and rate of reaction is half of Vmax. It is essentially the concentration 
at which the reaction rate is half of the predicted Vmax. Therefore, Km is the measure of 
substrate affinity for the enzyme where low Km indicates high affinity and vice-versa. 
 
By measuring the rates of catalysis over a range of substrate concentrations, the 
Michaelis constant, Km, and maximum rate, Vmax, can be readily calculated.  
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Figure 3.8 A Typical Michaelis-Menten Plot illustrating the Relationship between the 
Substrate Concentration [S] and the Reaction Rate V and Predicted Km and Vmax 
3.2.9. Screening of Açaí Extracts 
Screening of açaí berry extracts for CYP inhibition involved a single probe 
substrate concentration that was close to the observed Km as measured from Michaelis-
Menten kinetics for each isoform. A concentration close to the Km is appropriate for 
inhibition studies as Km implies that there can be significant competition for the enzyme 
molecules (Figure 3.9). Use of single probe concentration around Km also allows for 
high-through put analysis of various fractions of açaí berry extracts generated using 
bioassay-guided fractionation. All the analyses following the enzymatic incubations were 
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carried out using appropriate methods for each enzyme isoform. The results of enzyme 
inhibition were expressed as percent inhibition in comparison to the control reactions.  
 
Figure 3.9 A Typical Michaelis-Menten Kinetics Plot illustrating the Concentrations 
suitable for Inhibition Studies 
3.2.10. Determination of Inhibition Constant (KI) 
Inhibition constant KI for the açaí berry extracts towards P450 isoforms was 
measured using the concentrations of açaí berry extracts observed to produce 50% 
inhibition in the initial screening experiments. The amount of inhibition produced by açaí 
berry extracts was plotted against a Michaelis-Menten plot from control reactions. The 
inhibition alters the kinetics of the enzyme resulting in a change in Km or Vmax or both. 
During competitive inhibition, the Km increases while the Vmax remains unchanged 
indicating that the substrate concentration required to reach Vmax in the presence of 
inhibitor is greater compared to that of the absence of the inhibitor. Competitive 
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inhibition can be superseded by an increase in substrate concentration. Any change 
observed with regard to Km is referred to as Kmapp.  
 
where KI is the inhibitor`s dissociation constant or inhibition constant, and [I] is the 
inhibitor concentration. By rearranging the equation, KI for the inhibitor can be 
calculated.  
 
In case of noncompetitive inhibition, Vmax decreases while the Km remains 
unchanged and any change in Vmax is referred to as Vmaxapp.  
 
 
3.2.11. Isoform Specific Assay Conditions and Modes of Analyses 
All the kinetic studies were conducted using specific probe substrates selective for 
each of the enzyme isoforms in both S9 fractions of human liver microsomes and cDNA 
expressed supersomes as needed. Enzymatic incubations were performed in a total 
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volume of 200 µl containing appropriate probe substrates and enzyme isoforms in 100 
mM phosphate buffer (pH 7.4). Enzymatic reactions were initiated by the addition of 
final concentration of 1 mM NADPH and incubated on water bath for 10-30 minutes. The 
reactions were quenched by the addition of ice-cold 7% perchloric acid and placed on ice 
for 10 min followed by centrifugation at 16,000 rpm. The clear supernatant was then 
transferred to a clean vial for analysis using HPLC using UV detector or liquid 
chromatography tandem mass spectrometry for measurement of enzymatic activities.  
The probe substrates and the products formed in various CYP assays together 
with the substrate concentrations used for Michaelis-Menten kinetics studies were 
illustrated in Table 3.1. The observed Km and the actual substrate concentrations used for 
screening of açaí berry extracts were shown in Table 3.1. The detection parameters for 
products of the enzymatic reactions of each isoform were summarized in Table 3.2. 
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Table 3.1 Activity Assay Parameters for CYP isoforms 
CYP 
Isoform 
Substrate  Metabolite 
Substrate 
concentration 
used for 
Michaelis-
Menten 
Kinetics 
(µM) 
Substrate 
concentration 
used for Km 
(µM) 
1A1 7-ethoxycoumarin 7-hydroxycoumarin 1-200 20 
1A2 Naphthalene 1-naphthol 25-300 80 
2A6 Coumarin 7-hydroxycoumarin 0.5-10 2 
2B6 Bupropion 3-hydroxybupropion 25-400 36 
2C8 Amodiaquine N-desethylamodiaquine  0.5-16  2 
2C9 Diclofenac 4’-hydroxydiclofenac 20-100 50 
2D6 Dextromethorphan Dextrorphan 2.5-120 2 
2E1 p-nitrophenol p-nitrocatechol 20-200 50 
3A4 Nifedipine Dehydronifedipine 20-500 30 
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Table 3.2 Chromatographic Separation Parameters of CYP Activity Assays 
 
 
 
 
 
CYP 
Isoform 
Mobile Phase 
A:Acetonitrile with 0.1% 
Trifloroacetic acid and 
B:Water with 0.1% 
Trifloroacetic acid 
(%A/minutes) 
Substrate 
(Retention Time in 
minutes) 
Metabolite 
(Retention Time in 
minutes) 
1A1 30/0:00; 30/10:00; 
100/10:05; 100/13:00; 
30/13:05; 30/16:00 
 
7-ethoxycoumarin 
 
7-hydroxycoumarin 
 
1A2 25/0:00; 25/5:00; 100/5:05; 
100/8:00; 25/8:05; 25/12:00 
Naphthalene 
 
1-naphthol 
 
2A6 35/0:00; 35/10:00; 
100/10:05; 100/13:00; 
35/13:05; 35/16:00 
 
Coumarin 
 
7-hydroxycoumarin 
 
2B6 15/0:00; 15/5:00; 100/5:05; 
100/10:00; 15/10:05; 
15/14:00 
 
Bupropion 
 
3-hydroxybupropion 
 
2C8 0/0:00; 20/2:00; 30/8:00; 
100/8:10; 100/10:10; 
0/10:20; 0/10:20 
 
Amodiaquine 
 
N-desethylamodiaquine 
  
2C9 25/0:00; 25/5:00; 100/5:05; 
100/8:00; 25/8:05, 25/12:00 
Diclofenac 
 
4’-hydroxydiclofenac 
 
2D6 10/0:00; 0/1:00; 100/8:00; 
100/8:50; 10/9:00; 10/10:00 
Dextromethorphan 
 
Dextrorphan 
 
2E1 25/0:00; 25/12:00; 
100/12:05; 100/15:00; 
25/15:05, 25/18:00 
 
p-nitrophenol 
 
p-nitrocatechol 
 
3A4 10/0:00; 0/1:00; 100/8:00; 
100/8:50; 10/9:00; 10/10:00 
Nifedipine 
 
Dehydronifedipine 
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Table 3.3. Detection Parameters of CYP Activity Assays  
CYP 
Isoform 
Substrate  Metabolite 
HPLC UV 
Detection 
(nm) 
LC-MS/MS 
Mode of 
Ionization, 
(m/z) 
1A1 7-ethoxycoumarin 7-hydroxycoumarin 320   
1A2 Naphthalene 1-naphthol 250   
2A6 Coumarin 7-hydroxycoumarin 320   
2B6 Bupropion 3-hydroxybupropion 250   
2C8 Amodiaquine N-desethylamodiaquine  345   
2C9 Diclofenac 4’-hydroxydiclofenac 280   
2D6 Dextromethorphan Dextrorphan   positive, 258 
2E1 p-nitrophenol p-nitrocatechol 340   
3A4 Nifedipine Dehydronifedipine   positive, 345 
 
Detection of products of enzymatic reactions using a high performance liquid 
chromatography, HPLC (Shimadzu) involved a C18 column for separation of the 
products of the enzymatic reactions. Mobile phase to achieve chromatographic separation 
of enzymatic reaction products to be measured comprised of water and acetonitrile 
containing 0.1% trifloroacetic acid at appropriate flow rates with ratios suitable for 
efficient separation. Detection of metabolites in HPLC analyses was achieved using a UV 
detector. The mass spectrometric analysis were performed using Ultra Performance 
Liquid Chromatography, UPLC (Waters) coupled with Q Exactive Hybrid Quadrpole-
Orbitrap Mass Spectrometer (Thermo) using appropriate modes of ionization suitable for 
quantification of metabolites formed in the incubations. 
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3.2.12. Data Analysis 
Results were obtained from three different incubations and were represented as a 
percent inhibition. The activities were calculated from the mean ± standard deviation for 
triplicate measurements. Percent activities were obtained by calculating the ratio of the 
average activities of the açaí fractions to that of the solvent control measurements and 
expressed in percentage. Percent inhibitions were calculated by deducing the percent  
 
 
3. 3. Results  
 Currently, the extensive use of herbal and dietary supplements as complementary 
and alternative medicine has increased the human exposure to a wide variety of 
phytochemicals. The adverse effects together with their potential to interact with drugs 
upon co-administration for most herbal preparations currently remains unexplored. The 
information relevant to use of herbal supplements is also beginning to be addressed in a 
systematic manner. However, investigation of the interactions of drugs with herbal and 
dietary supplements is a challenging task often requiring methodologies formulated and 
optimized discretely for the context of study. Since, these interactions results from an 
array of phytochemicals present in herbal supplements and unraveling the complexity of 
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phytochemical constituents is fundamental for a greater understanding of such 
interactions.   
The current study begins with identification of individual CYPs that are 
susceptible to inhibition by crude extracts of açaí. It begins with studying in vitro 
inhibition of açaí berry extracts at crude level using cDNA expressed enzymes or 
supersomes in an attempt to dissect the interactions of açaí with each of the CYP isoform. 
CYP inhibition by chemical constituents present in açaí berry may lead to the interactions 
when co-administered with drugs. In addition, the inhibition of cytochrome P450 
enzymes is one process by which phytochemicals may impair metabolic activation or 
bioactivation of certain chemical and procarcinogens. Therefore, inhibition of CYP2A6 
and CYP2E1 was studied in greater detail to identify the inhibitors for these enzymes as a 
useful strategy for decreasing bioactivation process using human liver microsomes by 
employing bioassay-guided fractionation of açaí. 
3.3.1. In vitro Inhibition of cDNA Expressed Cytochrome P450 Enzymes 
 As the cDNA expressed enzymes or supersomes contain individual CYP 
isoforms, its use is devoid of any non-specific interactions that might arise from using 
human liver microsomes. Understanding of the Michaelis-Menten kinetic models is 
important for studying inhibition and therefore Michaelis-Menten plots were generated 
for each of the enzyme isoform using substrates selective for enzymes prior to the 
inhibition studies. The Michaelis-Menten plots generated for various CYP isoforms using 
supersomes were as follows.  
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3.3.2. CYP1A1 Assay 
CYP1A1 catalyzes the O-demethylation of 7-ethoxycoumarin to 7-
hydroxycoumarin or umbelliferone (Figure 3.10). The assay procedure for all CYP assays 
was generalized in section 3.2.11 and the activity assay and analytical parameters for the 
measurement of enzymatic activities were summarized in Table 3.1 and Table 3.2, 
respectively.  
 
Figure 3.10 CYP1A1 Mediated Catalysis of 7-Ethoxycoumarin to 7-Hydroxycoumarin 
Michaelis-Menten plots for CYP1A1 supersomes were generated using 
SlideWrite software (Advanced Graphics Software Inc.) by plotting the substrate 7-
ethoxycoumarin concentrations against the amounts of metabolite 7-hydroxycoumarin 
formed in the incubation (Figure 3.11). The amount of metabolite, 7-hydroxycoumarin 
produced in the incubations were quantified relative to substrate concentrations using 
HPLC with UV detector at 320 nm and expressed as arbitrary area units (AU). The 
Michaelis-Menten kinetics plot indicated a Km of 20 µM for O-demethylation of 7-
ethoxycoumarin by CYP1A1 supersomes. Therefore, a substrate concentration of 20 µM 
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7-ethoxycoumarin was used in the subsequent experiments for screening of açaí extracts 
for CYP1A1 inhibition. In a manner similar to Michaelis-Menten kinetics model, a range 
of substrate concentrations from 1-200 µM 7-ethoxycoumarin were used for KI 
determinations of açaí berry extracts. 
 
 Figure 3.11 Michaelis-Menten Kinetics Plot for O-Demethylation of 7-Ethoxycoumarin 
by CYP1A1 Supersomes 
3.3.3. CYP1A2 Assay 
CYP1A2 assay using supersomes involved oxidation of naphthalene to 1-naphthol 
as shown in Figure 3.12.  
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Figure 3.12 CYP1A2 Mediated Hydroxylation of Naphthalene to 1-Naphthol  
Michaelis-Menten kinetics for hydroxylation of naphthalene to 1-nahthol by 
CYP1A2 supersomes were generated using SlideWrite software in a similar manner to 
that described under CYP1A1 assay (Figure 3.13). The Km for CYP1A2 supersomes was 
found to be 35 µM naphthalene based on Michaelis-Menten kinetic study. Therefore, 
screening of açaí extracts for CYP1A2 inhibition utilized a substrate concentration of 70 
µM naphthalene. 
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Figure 3.13 Michaelis-Menten Kinetics Plot for Hydroxylation of Naphthalene to 1-
Naphthol by CYP1A2 Supersomes 
3.3.4. CYP2A6 Assay 
CYP2A6 assay was carried by studying coumarin-7-hydroxylation of coumarin to 
form 7-hydroxycoumarin or umbelliferone as illustrated in Figure 3.14.  
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Figure 3.14 CYP2A6 Mediated Hydroxylation of Coumarin to 7-Hydroxycoumarin 
Michaelis-Menten kinetics plots were generated using SlideWrite for coumarin-7-
hydroxylation by CYP2A6 supersomes established the Km to be 2.1 µM coumarin 
(Figure 3.15). Therefore, further studies into screening of açaí extracts for CYP2A6 
inhibition used a substrate concentration of 3 µM coumarin. 
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Figure 3.15 Michaelis-Menten Kinetics Plot for Hydroxylation of Coumarin to 7-
Hydroxycoumarin by CYP2A6 Supersomes 
3.3.5. CYP2B6 Assay 
CYP2B6 catalyzes the hydroxylation of bupropion to (2S,3S)-hydroxybupropion, 
a major metabolite as depicted in figure 3.16. Bupropion is a drug used for treating 
depression and also smoking cessation and is metabolized by CYP2B6.  
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Figure 3.16 CYP2B6 Mediated Catalysis of Bupropion to (2S,3S)-Hydroxybupropion 
  The kinetic parameters were determined by developing a Michaelis-Menten 
kinetics plot for CYP2B6 mediated hydroxylation of bupropion to (2S,3S)-
hydroxybupropion indicated the Km of 36 µM bupropion and therefore 40 µM bupropion 
was utilized for screening of açaí extracts for CYP2B6 inhibition (Figure 3.17). A range 
of substrate concentrations from 25-300 µM were employed for calculating KI values for 
açaí berry extracts as described for Michaelis-Menten kinetic model. 
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Figure 3.17 Michaelis-Menten Kinetics Plot for Hydroxylation of Bupropion to (2S,3S)-
Hydroxybupropion by CYP2B6 Supersomes 
3.3.6. CYP2C8 Assay 
CYP2C8 mediated catalysis of N-deethylation of an antimalarial drug, 
amodiaquine to N-desethylamodiaquine was carried out for assessing the enzymatic 
activity of CYP2C8 as illustrated in figure 3.18.  
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Figure 3.18 CYP2C8 Mediated N-Deethylation of Amodiaquine to N-
Desethylamodiaquine 
The Km for CYP2C8 mediated N-deethylation of amodiaquine to N-
desethylamodiaquine was found to be 2 µM (Figure 3.19). Subsequent experiments for 
screening of açaí extracts for CYP2C8 inhibition were carried out at 2 µM amodiaquine 
whereas amodiaquine concentrations ranging from 0.5 to 16 µM were used for KI 
determinations. 
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Figure 3.19 Michaelis-Menten Kinetics Plot for N-Deethylation of Amodiaquine to N-
Desethylamodiaquine by CYP2C8 Supersomes 
3.3.7. CYP2C9 Assay 
CYP2C9 catalyzes the hydroxylation of a non-steroidal anti-inflammatory drug, 
diclofenac to 4’-hydroxydiclofenac as shown in figure 3.20. The Km observed for 
CYP2C9 supersomes was found to be 55 µM and this concentration was used for 
screening of açaí extracts for CYP2C9 inhibition (Figure 3.21).  
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Figure 3.20 CYP2C9 Mediated Catalysis of Diclofenac to 4’-Hydroxydiclofenac 
 
Figure 3.21 Michaelis-Menten Kinetics Plot for Hydroxylation of Diclofenac to 4’-
Hydroxydiclofenac by CYP2C9 Supersomes 
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3.3.8. CYP2D6 Assay 
CYP2D6 catalyzes O-demethylation of dextromethorphan to dextrorphan as 
depicted in figure 3.22.  
 
Figure 3.22 CYP2D6 Mediated O-Demethylation of Dextromethorphan to Dextrorphan  
The Km for CYP2D6 supersomes found to be 2 µM and a concentration of 5 µM 
was used for subsequent screening of açaí extracts for CYP2D6 (Figure 3.23). 
Dextromethorphan concentrations from 2-25 µM were used for KI determinations. 
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Figure 3.23 Michaelis-Menten Kinetics Plot for O-Demethylation of Dextromethorphan 
to Dextrorphan by CYP2D6 Supersomes 
3.3.9. CYP2E1 Assay 
CYP2E1 catalyzes the hydroxylation of p-nitrophenol to p-nitrocatechol as 
depicted in figure 3.24.  
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Figure 3.24 CYP2E1 Mediated Hydroxylation of p-Nitrophenol to p-Nitrocatechol  
Michaelis-Menten kinetics plot for the hydroxylation of p-nitrophenol to p-
nitrocatechol by CYP2E1 supersomes generated using SlideWrite indicated the Km for 
CYP2E1 supersomes as 50 µM (Figure 3.25). Therefore, further studies included a 
substrate concentration of 50 µM p-nitrophenol for screening of açaí extracts for 
CYP2E1 inhibition used. 
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Figure 3.25 Michaelis-Menten Kinetics Plot for Hydroxylation of p -Nitrophenol to p-
Nitrocatechol by CYP2E1 Supersomes 
3.3.10. CYP3A4 Assay 
CYP3A4 catalyzes the oxidation of nifedipine to dehydronifedipine as depicted in 
figure 3.26. CYP3A4 enzymatic activities were determined by achieving the separation 
and quantification of oxidized nifedipine using UPLC coupled to mass spectrometer. The 
detection and quantification of metabolite, dextrorphan was achieved for m/z of 345 
under positive ion mode. 
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Figure 3.26 CYP3A4 Mediated Oxidation of Nifedipine to Dehydronifedipine 
The Km for CYP3A4 mediated oxidation of nifedipine to dehydronifedipine was 
found to be 30 µM and the same concentration was used for screening of açaí extracts for 
CYP3A4 inhibition and for KI determinations, 20-500 µM nifedipine were used (Figure 
3.27). 
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Figure 3.27 Michaelis-Menten Kinetics Plot for Conversion of Nifedipine to 
Dehydronifedipine by CYP3A4 Supersomes. 
3.3.11. Screening of Crude Açaí Berry Extracts for In vitro Inhibition of cDNA 
Expressed Cytochrome P450 Enzymes 
 Michaelis-Menten models provided the kinetic parameters required for CYP 
inhibition studies. Inhibition studies involved a single concentration that is close to the 
observed Km for each CYP isoform. The initial four crude fraction obtained from the 
bioassay-guided fractionation of freeze-dried açaí berry powder as illustrated in the 
Scheme 1 were screened for their ability to inhibit individually cDNA expressed 
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cytochrome P450 enzymes at a concentration of 50 µg/ml concentration. The selection of 
supersomes used in the screening of crude açaí berry extracts was based on the 
involvement of these enzymes in xenobiotic metabolism. The crude extracts were tested 
across a panel of CYP enzymes that includes isoforms CYP1A1, CYP1A2, CYP2A6, 
CYP2B6, CYP2C8, CYP2C9, CYP2D6, CYP2E1 and CYP3A4. These isoforms account 
for the metabolism of approximately 80% of drugs. Among the initial crude extracts, 
chloroform extract was found to be the most potent inhibitor across the P450 panel tested. 
The chloroform extract at a concentration of 50 µg/ml showed inhibition of the isoforms 
CYP1A1, CYP2B6, CYP2C8 and CYP2D6 to a great extent by more than 90% 
inhibition. Other enzymes that showed significant inhibition included CYP1A2, 
CYP2A6, CYP2E1 and CYP3A4 (Figure 3.28).  
In addition, the crude hexane extract was also found to inhibit CYP1A1 and 
CYP2C8 to great extent showing more than 95% inhibition for both the isoforms. The 
isoforms CYP2A6 and CYP2E1 were found be inhibited moderately by approximately 
70% at 50 µg/ml concentration. Moderate levels of inhibition was observed with 
CYP2A6 and CYP2E1 at 50 µg/ml concentration .The crude butanol extract was found to 
have moderate to mild inhibition of CYP1A1, CYP2B6 and CYP2C8 isoforms while the 
other isoforms were found to be unaffected by the crude butanol extract. The aqueous 
extract appears to have very little effect on the CYP isoforms tested in our study. 
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Figure 3.28 Inhibition of Various cDNA Expressed Cytochrome P450 Enzymes by Açaí 
Crude Extracts. Concentration of the Extracts used for Screening was 50 µg/ml. Red, 
Green, Yellow and Blue Bars represent Crude Hexane, Chloroform, Butanol and 
Aqueous Extracts of Açaí, respectively. † indicates the values were not determined.  
In order to determine the extent of inhibition by crude chloroform on these 
enzyme isoforms, a dose response study was carried out ranging the concentrations from 
5 to 50 µg/ml (Figure 3.29).  
0
20
40
60
80
100
120
1A1 1A2 2A6 2B6 2C8 2C9 2D6 2E1 3A4
%
 I
n
h
ib
it
io
n
CYP Isoforms
Inhibition of various CYPs by açaí crude extracts
Hexane extract Chloroform extract Butanol extract Aqueous extract
92 
 
 
Figure 3.29 Dose Response Relationship for the Inhibition of Various cDNA Expressed 
Cytochrome P450 Enzymes by Açaí Crude Chloroform Extract. Green, Red and Yellow 
Bars represent Crude Hexane, Chloroform, Butanol and Aqueous Extracts of Açaí, 
respectively. † indicates the values were not determined. 
  The crude chloroform extract exhibited a clear dose response relationship across 
all the CYP isoforms. The isoforms CYP1A1, CYP2B6, CYP2C8 and CYP2D6 that were 
greatly inhibited at 200 µg/ml concentration were also found to be inhibited significantly 
at the lowest concentration tested. At 5 µg/ml concentration, CYP2B6 and CYP2C8 were 
found to be inhibited by nearly 50% while CYP2D6 was inhibited by ~30%. Other 
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isoforms, CYP1A2, CYP2A6, CYP2E1 and CYP3A4 were also found to be inhibited by 
approximately 50% at 25 µg/ml concentration.  CYP1A1, based on its nearly 100% 
inhibition at 25 g/mL is also likely to be very strongly inhibited at 5 µg/mL, although this 
dose was not examined for this isoform.  
Michaelis-Menten kinetics studies were carried out using substrate concentrations 
described earlier in Table 3.1 for the CYP isoforms namely CYP1A1, CYP2B6 and 
CYP2C8 that were shown to be inhibited by chloroform extract in a dose dependent 
manner. The Michaelis-Menten kinetics studies carried out at a concentration of 10 µg/ml 
chloroform extract indicated a mixed mode of inhibition for CYP1A1, CYP2B6 and 
CYP2C8 enzymes (Table 3.4). Furthermore, the KI and KI‘ values obtained for CYP1A1, 
CYP2B6 and CYP2C8 were found to be in the low µg/ml range, suggesting further 
studies are warranted to identify specific inhibitors via the activity guided fractionation 
approach.     
Table 3.4 Inhibition constants, KI and KI’ for inhibition of CYP1A1, CYP2B6 and 
CYP2C8 by crude chloroform extract of açaí at 10µg/ml concentration  
CYP Isoform KI (µg/ml) KI’  (µg/ml) Mode of Inhibition 
CYP1A1 4.2 47.4 Mixed 
CYP2B6 7.1 18.2 Mixed 
CYP2C8 1.0 4.6 Mixed  
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The results of in vitro inhibition of CYP enzymes using supersomes identified 
individual CYPS that are susceptible to inhibition by chloroform extract of açaí. It 
indicated the potential for interactions of the chemical constituents present in chloroform 
extracts of açaí with CYP enzymes. As a consequence, these interactions may alter the 
rates of metabolism of several xenobiotics including drugs leading to pharmacokinetic 
interactions with the drugs in addition to altered endobiotic biotransformation. However, 
it is also possible that the chemical constituents from chloroform extract of açaí might 
elicit even more complex effects on CYP enzymes through other mechanisms such as 
induction of CYP enzymes following regulatory effects on CYP gene expression further 
complicating therapeutic applications.  
3.3.12. In vitro Inhibition of CYP2A6 and CYP2E1 using Human Liver Microsomes 
Metabolism and detoxification processes are the primary roles of CYP enzymes 
but generation of toxic metabolites during the course of metabolism is also often 
mediated by CYP enzymes. Interestingly, CYP enzymes also play an important role in 
the generation of biologically reactive intermediates though the process of bioactivation 
or metabolic activation. The chemical toxicity arising from CYP enzymes includes toxic 
metabolites that are electrophilic compounds, free radicals and activated oxygen species.  
More specifically, certain CYP isoforms are involved in the bioactivation of 
procarcinogens to ultimate carcinogens. Both CYP2A6 and CYP2E1 were shown to 
metabolize a greater number of compounds bearing toxicological relevance and are only 
minor contributors towards drug metabolism. In contrast to other major metabolizing 
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CYP enzymes such as CYP2C8/9, CYP2D6 and CYP3A4, CYP2A6 has never been 
implicated for any significant role in clinically significant drug interactions. CYP2A6 
with a clearer role in nicotine metabolism linked to decreased risk of tobacco-related 
cancers and nicotine addiction. The pursuit of finding chemical inhibitors for CYP2A6 is 
intriguing with a potential for use as adjuvant drugs in nicotine replacement therapy. 
Similarly, CYP2E1 has been studied extensively for its role in metabolism as well as 
metabolic activation of wide of variety of drugs, environmental toxicants, carcinogens 
and procarcinogens. Ethanol oxidation was originally believed to be the primary function 
of CYP2E1 but is now shown to be involved in metabolism of a wide variety of 
xenobiotics, with a majority of them having relatively low molecular compounds. A 
majority of these xenobiotics constitute protoxicants such benzene, carbon tetrachloride, 
pyridine, nitrosamine and acetaminophen that following the metabolism by CYP2E1 
deplete cellular levels of glutathione thus resulting in increased oxidative stress or 
damage through covalent binding to the proteins to the cells expressing CYP2E1. 
Inhibition of CYP2E1 by diallylsulfide was shown to decrease the toxicity associated 
with protoxicants. Similarly, over expression of CYP2E1 increased toxicity and oxidative 
stress with toxicants such as carbon tetrachloride. Consequently, inhibition of CYP2A6 
and CYP2E1 presents one useful strategy to decrease bioactivation processes and 
subsequent production of toxic metabolites. In the current research, inhibition of 
CYP2A6 and CYP2E1 using human liver microsomes by the constituents of açaí berry 
extracts was studied extensively using bioassay-guided fractionation. The goal is to 
identify specific inhibitors for CYP2A6 and CYP2E1 in açaí berry extracts. A major 
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change from the previous section is the choice of human liver microsomes over 
supersomes for the study and is justified for following reasons. First, the study is more 
comprehensive and was expected to consume huge amounts of CYP enzymes, human 
liver microsomes serves as relatively inexpensive option. Second, the availability of 
specific probe substrates, for example, coumarin and p-nitrophenol for CYP2A6 and 
CYP2E1 enzymes, respectively.  
3.3.13. Bioassay-guided Fractionation of Açaí Berry Extracts for CYP2A6 Inhibition 
In vitro using Human Liver Microsomes 
Coumarin is a very selective substrate for CYP2A6 enzyme and the enzyme does 
the hydroxylation of coumarin specifically at the 7-position resulting in the production of 
7-hydroxycoumarin as illustrated in Figure 3.14. An initial Michaelis-Menten kinetics 
plot was developed using coumarin as a substrate for CYP2A6 enzymes in human liver 
S9 fractions in a similar described for CYP2A6 supersomes and plotted using SlideWrite 
(Figure 3.30). The Michaelis-Menten kinetics plot indicated a Km of 1.0 µM for human 
liver microsomes and was found to be smaller compared to the Km of 1.0 µM observed 
for CYP2A6 supersomes (figure 3.15). The assay conditions and the detection parameters 
for CYP2A6 assay were described earlier. 
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Figure 3.30 Michaelis-Menten Kinetics Plot for Hydroxylation of Coumarin to 7-
Hydroxycoumarin by CYP2A6 Enzymes in Human Liver S9 Fraction 
Initially, crude açaí berry extracts were generated through the process of bioassay-
guided fractionation as previously described earlier in scheme 1 were depicted in scheme 
2.  A preliminary dose response using human liver S9 fractions was carried out for 
CYP2A6 inhibition by crude açaí berry extracts over a range of concentrations at 25, 50, 
100 and 200 µg/ml concentrations. All the initial crude extracts inhibited CYP2A6 in a 
dose dependent manner except for the aqueous extract (Açaí-31-4) with which no 
significant inhibition was observed at concentrations ≤100 µg/ml (Figure 3.31). The dose 
response plot revealed that the crude chloroform extract (Açaí-31-2) was the most potent 
of all the extracts followed by the crude hexane extract (Açaí-31-1) and crude butanol 
extract (Açaí-31-3), respectively. Both crude chloroform extract (Açaí-31-2) and crude 
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hexane extract (Açaí-31-1) have shown significant inhibition of approximately 50% at 50 
µg/ml concentration while the crude butanol extract (Açaí-31-3) showed significant 
inhibition only at concentrations above 100 µg/ml concentration.  
 
Scheme 2. Initial Crude Extracts of Açaí Berry. 
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Figure 3.31 Inhibition of Human CYP2A6 by Açaí Crude Extracts 
 The most potent chloroform extract (Açaí-31-2) among all the crude extracts was 
fractionated using column chromatography to produce 10 fractions, Açaí-34-1 through 
Açaí-34-10 (Scheme 3).        
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Scheme 3. Fractionation of Crude Chloroform Extract of Açaí (Açaí-31-2). 
The extent of inhibition observed with chloroform extract, Açaí-31-2 provided the 
rationale for testing the fractions at a reduced concentration. So, a reduced concentration 
of 50 µg/ml was used for studying CYP2A6 inhibition.  Among the 10 fractions, Açaí-
34-7, Açaí-34-8 and Açaí-34-9 showed inhibition of 81%, 80% and 61%, respectively 
(Figure 3.32).   
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Figure 3.32 Inhibition of Human CYP2A6 by Açaí-34-series 
Although Açaí-34-7 and Açaí-34-8 showed similar levels of inhibition, low 
sample size of Açaí-34-7 limited its fractionation and therefore, the largest fraction Açaí-
34-8 was chosen for further fractionation. Sub-fractionation of Açaí-34-8 by gel 
permeation chromatography resulted in 8 fractions, Açaí-38-1 through Açaí-38-8 
(Scheme 4).  
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Scheme 4. Fractionation of Açaí-34-8. 
Among these fractions, Açaí-38-1 and Açaí-38-2 showed greatest inhibition 
towards CYP2A6 by 76% and 86% at 50μg/ml concentration, respectively (Figure 3.33). 
While fraction, Açaí-38-3 inhibited CYP2A6 by 61%, Açaí-38-4 did not affect the 
activity of the enzyme significantly. The remaining fractions, Açaí-38-5 through Açaí-38-
8 showed moderate inhibition that appeared to be similar in extent in these fractions.  
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Figure 3.33 Inhibition of Human CYP2A6 by Açaí-38-series 
 Further fractionation was carried out on the active fractions, Açaí-38-1 and Açaí-
38-2 along with two other fractions, a moderately active fraction, Açaí-38-3 and an 
inactive fraction, Açaí-38-4. The criterion for proceeding into fractionations for Açaí-38-
4 was based on the abundance of the fraction obtained. This resulted in the generation of 
fractions, Açaí-61-1 through Açaí-61-7 from Açaí-38-1, Açaí-62-1 through Açaí-62-5 
from Açaí-38-2, Açaí-63-1 through Açaí-63-6 from Açaí-38-3 and Açaí-64-1 through 
Açaí-64-5 from Açaí-38-4 fractions (Scheme 5).  
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Scheme 5. Fractionation of Açaí-38-1, Açaí-38-2, Açaí-38-3 and Açaí-38-4. 
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As the fractionations proceeded, significant drop in the amounts generated for 
some of the fractions was observed. The diminishing amounts of the fractions generated 
over the course of fractionations, along with the expectation that as constituents were 
refined, their potency should increase, prompted a reduction in concentration of the 
inhibitor used. Therefore, the resultant fractions from this stage were tested at a reduced 
concentration of 25 µg/ml.  
Among the 7 fractions generated from Açaí-38-1, Açaí-61-4 and Açaí- 61-5 
inhibited CYP2A6 by about 53% and 70%, respectively at half-the-concentration of its 
parent fraction (Figure 3.34). The fraction Açaí- 61-5 showed 70% inhibition at 25 µg/ml 
and is comparable to the 76% inhibition observed with its parent fraction Açaí- 38-1 at 50 
µg/ml concentration. Among the other fractions, Açaí-61-3 and Açaí-61-6 showed mild 
inhibition and all the other fractions showed no or minimal inhibition properties. 
 
Figure 3.34 Inhibition of Human CYP2A6 by Açaí-61-series 
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A very similar pattern was observed with Açaí-38-2 sub-fractions; the fractions 
Açaí-62-2 and Açaí-62-3 showed moderate inhibition of about 64% and 53%, 
respectively at half the concentration of its parent fraction (Figure 3.35). The fractions 
Açaí-62-1 and Açaí-62-4 showed mild inhibition while the fraction Açaí-62-5 showed 
minimal inhibition. 
 
Figure 3.35 Inhibition of Human CYP2A6 by Açaí-62-series 
The moderately potent fraction Açaí-38-3 yielded six fractions among which 
Açaí-63-4 showed 72% inhibition of CYP2A6 at half the concentration of its parent 
fraction while the other fractions of açaí-63-series showed only minimal to no inhibition 
(Figure 3.36). 
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Figure 3.36 Inhibition of Human CYP2A6 by Açaí-63-series  
As expected, the inactive fraction Açaí-34-4 produced five fractions with 
inhibition ranging from minimal to no inhibition (Figure 3.37).  
 
Figure 3.37 Inhibition of Human CYP2A6 by Açaí-64-series 
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The potent fractions belonging to Açaí-62-series, namely, Açaí-62-2 and Açaí-62-
3 were further fractionated to produce Açaí-78-series and Açaí-82-series, respectively 
(Scheme 6). 
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Scheme 6. Fractionation of Açaí-62-2, Açaí-62-3, Açaí-63-4 and Açaí-64-3. 
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The process of bioassay-guided fractionation using chromatographic separation 
techniques is expected to increase the potency of the fractions as the procedure continues. 
It showed promise in narrowing the activity presumably by concentrating the inhibitory 
constituents into fewer extracts. However, the bioassay-guided fractionation approach 
appeared to have lost the pattern of generating potent fractions at this stage. For example, 
none of the fractions belonging to Açaí-78-series that were generated from a moderately 
potent fraction Açaí-62-2 at 25 µg/ml concentration showed any increase in potency 
(Figure 3.38). On the contrary, the potency was lost across all the fractions generated.  
 
 
Figure 3.38 Inhibition of Human CYP2A6 by Açaí-78-series 
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 Another moderately potent fraction Açaí-62-3 produced seven fractions belonging 
to Açaí-82-series (Scheme 6). These fractions also failed to attain further increase in 
potency instead more than half of the fractions showed potency similar or slightly higher 
than their parent fraction Açaí-62-3 (Figure 3.39). Four of the seven fractions namely, 
Açaí-82-B, Açaí-82-C, Açaí-82-D and Açaí-82-F showed CYP2A6 inhibition 
comparable to their parent fraction.  
 
Figure 3.39 Inhibition of Human CYP2A6 by Açaí-82-series 
A moderately potent fraction Açaí-63-4 produced 9 fractions belonging to Açaí-
94-series (Scheme 6). All of these fractions were found to have lost the potency 
compared to its parent fraction Açaí-63-4 (Figure 3.40). In fact, none of the fractions 
retained the ability to inhibit CYP2A6 enzyme.   
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Figure 3.40 Inhibition of Human CYP2A6 by Açaí-94-series 
Açaí-76-series fractions were obtained from a moderately potent fraction Açaí-
64-3 for CYP2A6 inhibition. However, two fractions namely Açaí-76-A and Açaí-76-B 
were found to greatly inhibit CYP2A6 enzyme while two other fractions Açaí-76-C and 
Açaí-76-D showed mild inhibition of CYP2A6 and the remaining three fractions had no 
effect on CYP2A6 enzyme (Figure 3.41). 
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Figure 3.41 Inhibition of Human CYP2A6 by Açaí-76-series 
Although Açaí-78-H was found to be an inactive fraction towards CYP2A6 
inhibition, it was fractionated for other purposes described in subsequent chapters. Nine 
fractions belonging to Açaí-97-series were produced from Açaí-78-H and the fractions 
Açaí-97-B and Açaí-97-D were found to be pure compounds belonging to the chemical 
class of compounds called pheophorbides (Scheme 6). Açaí-97-B and Açaí-97-D were 
characterized by mass spectrometry and NMR spectroscopy to be Pheophorbide-a methyl 
ester (C36H38N4O5) and Pheophorbide-a ethyl ester (C37H40N4O5), respectively (Figure 
4.20 and Table 4.1).  
The two potent fractions Açaí-76-A and Açaí-76-B belonging to the Açaí-76-
series were further fractionated to produce Açaí-98-series and Açaí-92-series, 
respectively (Scheme 7).   
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Scheme 7. Fractionation of Açaí-78-H, Açaí-76-A and Açaí-76-B. 
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 The fractions belonging to Açaí-97-series yielded a relatively potent fraction 
Açaí-97-I while all other fractions belonging to the series were found to be inactive or 
demonstrated moderate inhibition potential towards CYP2A6 enzyme (Figure3.42). 
Although Açaí-97-I appears to be potent at 25µg/ml concentration, it must be noted that 
the concentration appears to be high and may not be achieved in physiological 
concentrations to be able to cause CYP2A6 inhibition.  
 
 
Figure 3.42 Inhibition of Human CYP2A6 by Açaí-97-series 
The potent fraction Açaí-76-A produced Açaí-98-series and all the fractions were 
found to have lost the activity even at 50 µg/ml except for Açaí-98-F that showed 
moderate inhibition of CYP2A6 (Figure 3.43). Similar trend was observed with Açaí-92-
***
*
**
***
**
***
0 20 40 60 80 100
Acai-97-A
Acai-97-B
Acai-97-C
Acai-97-D
Acai-97-E
Acai-97-F
Acai-97-G
Acai-97-H
Acai-97-I
% Inhibition
Inhibition of CYP2A6 by Acai-97-Series
116 
 
series that was generated from yet another potent fraction Açaí-76-B. None of the 
fractions were found to have any inhibitory potential towards CYP2A6 (Data not shown).  
 
  
Figure 3.43 Inhibition of Human CYP2A6 by Açaí-98-series 
3.3.14 Summary of CYP2A6 Inhibition 
 Despite a minor functional role of CYP2A6 in xenobiotic metabolism, its role in 
the metabolism of nicotine and carcinogenic nitrosamines generated a lot of interest. The 
relation between CYP2A6 inhibition and decreased incidence of tobacco related cancers, 
the relation between CYP2A6 polymorphism and smoking habits contributed to an 
intriguing area of research. The current study aimed at identifying the inhibitors of 
CYP2A6 from açaí berry extracts as there were only a handful of inhibitors identified so 
far. Results from initial screening of crude extracts of açaí started on a promising note 
from bioassay-guided fractionation with the chloroform extract showing moderate 
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inhibition of CYP2A6 at 50 µg/ml concentration. The chloroform extract was then 
fractionated to yield 10 fractions that produced 2 fractions namely Açaí-34-7 and Açaí-
34-8. The most abundant Açaí-34-8 was fractionated to generate 8 fractions with 3 
fractions namely Açaí-38-1, Açaí-38-2 being potent followed by Açaí-38-3. However, 
contrary to what was expected, further fractionations beginning at this stage indicated a 
decrease in inhibitory potential towards CYP2A6. A couple of rounds of fractionations 
further utilizing active fractions indicated a common trend leading to a loss of activity. 
Altogether, 5 rounds of fractionations were carried out in the process of bioassay-guided 
fractionation. The result that no significant inhibition was observed can be explained as 
follows. The loss of activity over the course of fractionations may be the result that there 
were no specific inhibitors present in chloroform extract of açaí. It is also conceivable 
that the shelf-life, treatments during fractionations might have modified or adversely 
affected the chemical constituents leading to the loss of integrity contained in the crude 
extract. Further, CYP2A6 with restricted substrate specificities as demonstrated from its 
role in the metabolism of xenobiotics and endobiotics might have the demand for 
increased selectivity for its substrates. 
3.3.15. Bioassay-guided Fractionation of Açaí Berry Extracts for CYP2E1 Inhibition 
In vitro using Human Liver Microsomes 
The initial crude extracts obtained by fractionation of the freeze-dried açaí berry 
powder as described earlier were tested for CYP2E1 inhibition in a very similar manner 
using human liver microsomes. The assay employed for the study involved hydroxylation 
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of p-nitrophenol to p-nitrocatechol as described earlier and the overall design of the assay 
was summarized earlier in figure 3.23. An initial Michaelis-Menten kinetics plot 
generated using p-nitrophenol as a substrate for CYP2E1 enzymes in human liver S9 
fractions is illustrated in Figure 3.44. 
 
Figure 3.44 Michaelis-Menten Kinetics Plot for Hydroxylation of p-Nitrophenol to p- 
Nitrocatechol by CYP2E1 Enzymes in Human Liver S9 Fractions 
The process of bioassay-guided fractionation as described in scheme 1 initially 
produced crude açaí berry extracts as illustrated in scheme 2. A preliminary dose 
response for crude açaí berry extracts towards CYP2E1 inhibition was carried out using 
human liver S9 fractions over a range of concentrations at 25, 50, 100 and 200 µg/ml. 
Among all the crude extracts, chloroform extract (Açaí-31-2) showed significant 
inhibition of CYP2E1 enzyme in a dose dependent manner (Figure 3.45). Although 
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hexane extract (Açaí-31-1) showed a dose response, moderate inhibition of CYP2E1 was 
observed at only higher concentration such as 200 µg/ml. Both butanol extract (Açaí-31-
3) and aqueous extract (Açaí-31-4) were found have no effect on CYP2E1 inhibition. 
 
Figure 3.45 Inhibition of Human CYP2E1 by Açaí crude extracts 
The chloroform extract (Açaí-31-2) was the more potent extract for CYP2A6 
inhibition and therefore was already fractionated using column chromatography resulting 
in 10 fractions, Açaí-34-1 through Açaí-34-10 as described in scheme 3 were tested at 
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50μg/ml concentration.  Amongst 10 fractions, Açaí-34-7 and Açaí-34-8 showed 
moderate inhibition of 53% and 61%, respectively (Figure 3.46). The fractions Açaí-34-1 
and Açaí-34-4 showed mild inhibition of CYP2E1 and the remaining fractions showed no 
effect on CYP2E1.  
 
Figure 3.46 Inhibition of Human CYP2E1 by Açaí-34-series 
While the fraction Açaí-34-8 was proceeded for further fractionations, low sample 
size of Açaí-34-7 limited its fractionation (Scheme 4). Almost all the resultant 8 fractions 
of Açaí-34-08 were found to inhibit CYP2E1 as the inhibitory action was observed to be 
distributed among these fractions except for Açaí-38-04 (Figure 3.47). The 3 fractions 
preceding the inactive fraction Açaí-38-04 were slightly less active than the later 4 
fractions.   
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Figure 3.47 Inhibition of Human CYP2A6 by Açaí-38-series 
While most of the fractions belonging to Açaí-38-series showed similar levels of 
inhibition for CYP2E1, further fractionations of Açaí-38-series fractions was limited by 
the sample size generated. The first four fractions, Açaí-38-1 to Açaí-38-4 were the most 
abundant and were further fractionated. This resulted in the generation of fractions 
belonging to Açaí-61-series from Açaí-38-1, Açaí-62-series from Açaí-38-2, Açaí-63-
series from Açaí-38-3, and Açaí-64-series from Açaí-38-4 fractions as described earlier 
(Scheme 5). All the fractions here onwards were tested at 25 µg/ml concentration.  
Açaí-38-1 produced 7 fractions belonging to Açaí-61-series which were tested at 
25 µg/ml (Scheme 5). However, the inhibitory activity was observed to be spread out 
across most of the fractions except for Açaí-61-1 and Açaí-61-7 (Figure 3.48).  The 
extracts Açaí-61-4, Açaí-61-5 and Açaí-61-6 showed moderate inhibition of CYP2E1 at 
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25 µg/ml concentration. The fractions Açaí-61-2 and Açaí-61-3 showed mild inhibition 
of CYP2E1 at this concentration.  
 
Figure 3.48 Inhibition of Human CYP2E1 by Açaí-61-series 
 Similar results were obtained with the fractions generated from Açaí-38-2 that 
yielded 5 fractions belonging to Açaí-62-series (Scheme 5). These fractions were tested 
for CYP2E1 inhibition at 25 µg/ml concentration. Among these extracts, Açaí-62-2 and 
Açaí-62-3 showed inhibition greater than 50% and the rest of the fractions Açaí-62-1, 
Açaí-62-4 and Açaí-62-5 showed CYP2E1 inhibition that was slightly less potent (Figure 
3.49). 
**
**
**
***
***
***
***
0 20 40 60 80 100
Açaí-61-1
Açaí-61-2
Açaí-61-3
Açaí-61-4
Açaí-61-5
Açaí-61-6
Açaí-61-7
% Inhibition (25µg/ml)
Inhibition of CYP2E1 by Açaí-61-fractions
123 
 
  
Figure 3.49 Inhibition of Human CYP2E1 by Açaí-62-series 
 Similarly, Açaí-38-3 produced 6 fractions belonging to Açaí-63-series and these 
fractions too followed the same trend observed with Açaí-61-series and Açaí-62-series 
for CYP2E1 inhibition (Scheme 5). All six inhibited with Açaí-63-2 to Açaí-63-5 giving 
more than 50% reduction of CYP2E1 activity (Figure 3.50).  
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Figure 3.50 Inhibition of Human CYP2E1 by Açaí-63-series 
 The fraction Açaí-38-4 produced 5 fractions belonging to Açaí-64-series (Scheme 
5). These fractions also were found to be active towards CYP2E1 inhibition with the 
exception of Açaí-64-5 (Figure 3.51).  
 
***
***
***
***
***
***
0 20 40 60 80 100
Açaí-63-1
Açaí-63-2
Açaí-63-3
Açaí-63-4
Açaí-63-5
Açaí-63-6
% Inhibition (25µg/ml)
Inhibition of CYP2E1 by Açaí-63-fractions
125 
 
 
Figure 3.51 Inhibition of Human CYP2E1 by Açaí-64-series 
The process of bioassay-guided fractionation pursued so far by employing various 
chromatographic separation techniques was aimed to increase the inhibitory action by 
narrowing the activity towards fewer fractions as the procedure progresses. However, 
inhibitory action against CYP2E1 seemed to be spread-out over a very large proportion 
of all fractions collected. 
Further fractionations of two inhibitory fractions of Açaí-62-series, Açaí-62-2 and 
Açaí-62-3 produced Açaí-78-series and Açaí-82-series, respectively (Scheme 6). 
Unexpectedly, subsequent fractions at these late stages began to lose potency rather than 
increase in potency. For example, only one fraction belonging to Açaí-78-series namely 
Açaí-78-D generated from a moderately potent fraction Açaí-62-2 showed inhibition but 
at 50µg/ml concentration. It should be noted that this concentration is twice the 
concentration of its parent fraction indicating a clear loss of activity. A majority of 
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remaining fractions showed only mild inhibition with the exception of Açaí-78-E and 
Açaí-78-G, which did not show any increase in potency (Figure 3.52).  
 
Figure 3.52 Inhibition of Human CYP2E1 by Açaí-78-series 
Similarly, a moderately potent fraction Açaí-62-3 was fractionated to produce 
seven fractions belonging to Açaí-82-series (Scheme 6). All the fractions belonging to 
Açaí-82-series were found to be less potent than the parent fraction indicating loss of 
potency (Figure 3.53).   
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Figure 3.53 Inhibition of Human CYP2E1 by Açaí-82-series 
This trend was also observed with Açaí-94-series comprising of 9 fractions that 
were generated from a potent fraction Açaí-63-4 (Scheme 6). All the fractions belonging 
to Açaí-94-series were found to have lost the potency compared to its parent fraction 
Açaí-63-4 (Figure 3.54). For example, the parent fraction gave 70% inhibition at a 
concentration of 25 µg/ml, while the most potent fraction Açaí-94-H from Açaí-94-series 
only inhibited by 64% at the same dose. 
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Figure 3.54 Inhibition of Human CYP2E1 by Açaí-94-series 
Yet another moderately potent fraction Açaí-64-3 produced 7 fractions belonging 
to Açaí-76-series fractions (Scheme 6). Again, none of these fractions were found to 
show significant improvement potency. It produced two fractions, Açaí-76-C and Açaí-
76-D with potencies slightly higher than their parent fraction for CYP2E1 inhibition and 
all other fraction were found to have minimal inhibitory potential towards CYP2E1 
inhibition (Figure 3.55).  
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Figure 3.55 Inhibition of Human CYP2E1 by Açaí-76-series 
Açaí-78-H was also fractionated and 9 fractions were produced belonging to 
Açaí-97-series as described under scheme 7. Fractions Açaí-97-B and Açaí-97-D were 
found to be pure compounds belonging to the chemical class of compounds called 
pheophorbides. Açaí-97-B and Açaí-97-D were characterized by mass spectrometry and 
NMR spectroscopy to be Pheophorbide-a methyl ester (C36H38N4O5) and Pheophorbide-a 
ethyl ester (C37H40N4O5), respectively (Figure 4.20 and Table 4.1). Although Açaí-97-D 
was an inhibitor, its potency was very low, suggesting very little physiological 
significance (Figure 3.56).  
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Figure 3.56 Inhibition of Human CYP2E1 by Açaí-97-series 
Similarly, the two fractions Açaí-76-A and Açaí-76-B originally identified as 
promising candidates for further fractionations for CYP2A6 inhibition were further 
fractionated to produce Açaí-98-series and Açaí-92-series, respectively (Scheme 7). 
Neither the Açaí-92-series nor the 98 series contained fractions with inhibitory activity 
toward CYP2E1 (Data was not shown).  
3.3.16. Summary of CYP2E1 Inhibition 
 Inhibition of CYP2E1 by various crude extracts of açaí was studied using human 
liver microsomes. Among all the crude extracts, chloroform extract of açaí was found to 
inhibit CYP2E1 in a dose dependent manner while the hexane extract showed a weak 
inhibition of CYP2E1 only at high concentrations and the aqueous and butanol extract 
showed no inhibition. The chloroform extract when fractionated further produced two 
active fractions, Açaí-34-07 and Açaí-34-08 with the latter being more potent. Among the 
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eight fractions that were derived from Açaí-34-08, all the fractions except Açaí-38-04 
produced moderate inhibition of CYP2E1. This trend was most likely the result of a very 
broad substrate specificity. A very similar trend was observed with the fractions 
belonging to Açaí-61-series, Açaí-62-series, Açaí-63-series and Açaí-64-series that were 
generated from Açaí-38-1, Açaí-38-2, Açaí-38-3 and Açaí-38-4 fractions, respectively. 
This confirms our earlier finding with aldehydes that the active site of CYP2E1 is flexible 
with phenylalanine rich active site and extended π-system allowing for the expansion of 
its own active site. However, the trend failed to continue towards the generation of later 
fractions as most fractions appear to have lost the activity. The loss of activity can be 
attributed probably to the decreased stability of the constituents present in those fractions.  
3.4. Discussion 
The current research demonstrated the in vitro inhibition of several Cytochrome 
P450 enzymes involved in drug metabolism by crude açaí berry extracts in an attempt to 
understand potential drug-herbal interactions involving açaí berry and possible 
physiological significance. Among all the crude extracts, the chloroform extract inhibited 
most of the cDNA expressed CYP isoforms with variable potency. Additionally, a dose-
response relationship established the inhibition of isoforms such as CYP1A1, CYP2B6, 
CYP2C8 and CYP2D6 at low concentrations of 5 µg/ml. Finally, the KI values obtained 
for these enzymes indicates that crude chloroform extract of açaí berry might have 
clinical relevance with its possible role arising from drug-herbal interactions. The 
fractionation procedure initially isolated the fatty constituents into hexane fraction, then 
132 
 
isolated the water soluble constituents into aqueous fraction leaving the constituents with 
a good balance between the hydrophilic and lipophilic nature. This balance is critical for 
chemical constituents to bear any physiological relevance as these constituents are 
required to cross several biological membranes including gastrointestinal tract for oral 
absorption before they can even elicit any actions over its target receptors. The 
physiological significance of chloroform extract can further be rationalized by the 
apparent lack of inhibition of CYP enzymes by aqueous extract of açaí berry and also the 
lack of inhibition of most CYP enzymes by butanol and hexane extracts. Although, much 
of the recognition for açaí is touted to the presence of high levels of polyphenolic 
compounds such as anthocyanins and flavonoids, it is to be noted that the butanol and 
aqueous fractions rich in polyphenolic compounds showed least inhibition of various 
CYP isoforms tested. 
The study was extended towards the identification of inhibitors of the 
toxicologically important Cytochrome P450 enzymes. CYP2A6 and CYP2E1 were 
identified for the current study as the candidates of toxicological significance and 
inhibition of these enzymes may confer protection against their potential detrimental 
effects. There are several instances where the presence of small quantities of chemical 
constituents capable of inhibiting these enzymes resulted in protective effects. The 
bioassay-guided fractionation of freeze-dried açaí berry extracts started on a promising 
note of obtaining inhibitors of CYP2A6 and CYP2E1 enzymes. Overall bioassay-guided 
fractionation was pursued to produce six different stages of fractions. The promising 
potential was retained until the first four stages and then over the latter two stages this 
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potential lost its pattern. This result suggests that the açaí berry lacks specific chemical 
constituents capable of inhibiting CYP2A6 and CYP2E1 enzymes. The fact that earlier 
crude fractions possess inhibitory potential towards these enzymes can be partly 
explained by the nature of these enzymes. For example, the evolutionary role of 
cytochrome P450 enzymes in metabolism conferred these enzymes the key attribute of 
broad substrate selectivity. Multiple constituents present at crude level might have 
modulated the activities of CYP2A6 and CYP2E1 resulting in observed inhibition at 
crude levels better than the latter fractions that are presumed to have a less complexity. 
Simultaneous binding of several substrate molecules among the fractions at crude level 
results in the formation of different enzyme-substrate complexes with differing 
stoichiometry and differing functional properties. Understanding these complex kinetic 
behaviors however provide insights into the mechanisms worthwhile to predict 
interactions, the complexity however associated with crude extracts or certain fractions 
makes the process difficult to pursue. Additionally, the fractions might have lost the 
inhibitory chemical constituents because of stability issues arising from external factors 
such as time, temperature and light or through modifications of constituents itself through 
its exposure to fractionation procedures.  
The crude hexane extract of açaí produced response similar to the chloroform 
extract towards CYP2A6 and CYP2E1 inhibition. However, the presumption that the 
hexane extract is rich in fats and oils renders the extract to be poorly absorbed, 
metabolically less stable and kinetically short acting in nature in physiological 
environment. These factors together with chromatographic challenges for separation of 
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bioactive constituents limited further fractionation of hexane extract. Likewise, the high 
anthocyanin content that is presumed in butanol and aqueous extract did not affect the 
CYP enzymes as much at test concentrations and therefore the bioassay-guided 
fractionation of these was not pursued.  
All our findings from in vitro inhibition of cytochrome P450 enzymes collectively 
indicate the presence of chemical constituents in chloroform extract of açaí capable of 
modulating the enzymatic activities of certain CYP isoforms such as CYP1A1, CYP2B6, 
CYP2C8 and CYP2D6 as demonstrated by the low KI values. The potential for the 
pharmacokinetic interactions cannot be undermined and further studies are warranted for 
our understanding of the physiological, toxicological and clinical significance arising 
from drug- açaí interactions.
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CHAPTER IV 
INDUCTION OF ARE-DEPENDENT GENE EXPRESSION IN CULTURED 
HEPG2 CELLS BY CONSTITUENTS OF AÇAÍ  
 
4.1. Introduction 
Oxidative assaults are inevitable in the biological systems. Normal physiological 
processes ranging from mitochondrial metabolism to certain enzymatic reactions and 
various adverse environmental factors can produce reactive oxygen species as 
byproducts. Under normal physiological conditions, these reactive oxygen species are 
efficiently antagonized by various antioxidant defense components confined to particular 
compartments of the cell. However, a rapid increase in reactive oxygen species results in 
an oxidative burst that culminates into oxidative stress if it is not managed in a controlled 
manner. The burden of oxidative stress is largely counteracted by an intricate antioxidant 
defense system controlled, in part, by Nrf2/ARE signaling pathway. Activation of 
Nrf2/ARE signaling pathway deploys a battery of antioxidant enzymes that respond 
adequately to the oxidative stress, which is critical for the maintenance of life. Inadequate 
response elevates the risk for a variety of oxidative stress related diseases.  
The Nrf2/ARE signaling pathway mediates the induction of phase II antioxidant 
enzymes through the activation of nuclear transcription factors and protects the cells 
against the damaging effects of oxidants and electrophiles 13, 14. The damaging effects of 
reactive oxygen species are largely counteracted by cytoprotective antioxidant enzymes,
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many of which are part of the phase II drug metabolism system. These enzymes are 
generally under hormonal control but are also inducible by foreign chemicals. Induction 
of cytoprotective genes represents a highly effective strategy for protecting cells against 
oxidants and other reactive species. The activity of phase II enzymes is stimulated by a 
wide range of chemicals, bioactive agents and environmental conditions 13. This 
stimulation results in an increased expression of genes such as heme oxygenase (HO-1), 
NAD(P)H:quinone oxidoreductase (NQO1), glutathione-S-transferase (GST), glutamate 
cysteine ligase (GCL) and Thioredoxin (TXN), conferring protection against oxidative 
damage to the cell. The expressed enzymes catalyze a wide variety of reactions that 
neutralize reactive oxygen species and other reactive electrophiles. Numerous studies 
showed the induction of phase II enzymes such as HO-1 by synthetic and natural 
compounds, including polyphenolic compounds, is sufficient for the acquisition of 
antioxidant and cytoprotective activities in a variety of pathological models 75.  
4.1.1. The Nrf2/ARE Signaling Pathway  
Nrf2/ARE signaling pathway mediates expression of phase II antioxidant 
enzymes as depicted in figure 4.1. A cis-acting enhancer sequence in the promoter region 
of target genes known as the antioxidant response element (ARE). The consensus ARE 
sequence was initially identified and characterized to have 5’-rTGACnnnGC-3’, where 
“r” represents a purine 76, 77. The consensus ARE motif was subsequently revised and 
extended to 5’-TMAnnRTGAYnnnGCRwwww-3’, where “R” is adenosine or guanine 
and “Y” represents cytosine or thymine “w” is adenine of adenine or thymine 78. The 
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ARE sequence is recognized mainly by a key transcription factor called nuclear factor 
erythroid 2 related factor 2 (Nrf2) 79. Nrf2 is known to regulate basal and inducible 
expression of cytoprotective enzymes. Under basal homeostatic conditions, Nrf2 is 
repressed by a cysteine-rich protein, Kelch-like ECH associated protein1 (Keap1) in the 
cytosol 80. Keap1 bridges Nrf2 to Cullin3-based E3 ligase (Cul3), a ubiquitin ligase that 
ubiquitinates Nrf2, which marks it for degradation at the proteasome 81. Keap1 and Cul3 
collectively sequester Nrf2 and prevent the activation of Nrf2 target genes. The 
disruption of the interaction between Keap1 and Nrf2 results in the activation and 
subsequent nuclear localization of Nrf2. Nrf2 then forms heterodimers with other 
transcription factors such as small Maf proteins and binds to AREs, resulting in 
transactivation of ARE-driven genes. Therefore, the Nrf2/ARE pathway serves as a 
defense system in higher organisms to protect them against a wide range of chemical 
assaults. Nrf2 has a relatively short half-life as it is phosphorylated by the enzyme Fyn 
kinase. The phosphorylated Nrf2 then translocates back into the cytosol for further 
degradation (Figure 4.1).  
138 
 
 
Figure 4.1 Nrf2/ARE Signaling Pathway  
The general strategy used in the current study was to examine the effects of 
constituents of the açaí berry on Nrf2-mediateed antioxidant gene expression. To do this, 
an ARE of human thioredoxin (hTXN) was cloned into an experimental luciferase 
reporter vector, transiently transfected in human hepatocarcinoma (HepG2) cells, and 
then the cells were treated with açaí fractions. The increases in the transcriptional activity 
of the reporter luciferase that is under the control of thioredoxin ARE upon treatment 
with açaí extracts was studied to identify specific chemical constituents in the açaí that 
stimulate the Nrf2/ARE antioxidant pathway.  A bioassay-guided fractionation approach 
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was done on the freeze-dried açaí berry extracts to identify the activators of Nrf2/ARE 
signaling pathway. 
4.1.2. Açaí Berries in Relation to Nrf2 Antioxidant Pathway 
 The widely acclaimed health benefits of açaí are thought to be related to high 
levels of antioxidants including anthocyanins, flavonoids and polyphenolic compounds 70, 
71, 82, 83. The major anthocyanins identified in açaí are cyanidin-3-gluocoside, cyanidin-3-
rutinoside and cyanidin-3-diglycoside but only accounted for 10 % its overall antioxidant 
capacity of açaí 70, 73. Several of the physiological effects of açaí can be related to the 
modulation of Nrf2 antioxidant pathway. For example, pretreatment of açaí prior to 
hydrogen peroxide-induced oxidative stress greatly reduced ROS generation in freshly 
prepared neutrophils 71.  Açaí modulated ROS production by neutrophils and favored a 
healthy oxidant balance in rats by inducing antioxidant gene expression 84. Açaí 
supplementation in rats improved serum  biomarkers of protein oxidation and also 
reduced the need for protective responses by reducing stress 85. Also, a systemic 
evaluation of açaí in healthy human volunteers resulted in a significant increase in 
antioxidant activity of plasma, as demonstrated by ORAC assay 86. Proanthocyanidins of 
açaí ameliorated acute lung inflammation and emphysema induced by cigarette smoke in 
mice probably by reducing oxidative stress through modulation of antioxidant gene 
expression and inflammatory reactions87, 88. In addition, the compounds related to 
chemical classes found in açaí are shown to induce various phase II antioxidant enzymes 
through Nrf2 and various other signal transduction pathways. For example, anthocyanin 
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fractions of purple sweet potato reduced dimethylaminonitrosamine- induced oxidative 
stress in rats by inducing HO-1, NQ01 and also Nrf2, in addition to the enzymes involved 
in the glutathione system. Induction of HO-1, NQ01 and Nrf2, all of which possess an 
ARE sequence in their promoter region, demonstrates involvement of the Nrf2/ARE 
pathway 89. Also, induction of antioxidant enzymes such as HO-1  by flavonoid 
compounds was shown to involve activation of protein kinase and mitogen activated 
kinase pathways, which is linked to the Nrf2 signal transduction pathway in human 
umbilical vein epithelial cells 90.  
Several studies demonstrated a positive relationship between the antioxidant 
capacities of açaí with the observed physiological activities. Inhibition of lipid 
peroxidation as a result of inhibition of glutathione peroxidase and glutathione reductase, 
in addition to inhibition of NF-κB activation through the regulation of inflammatory 
mediators contributed to the athero-protective effect by flavonoids of açaí 83, 91. A strong 
correlation between the antioxidant status and anti-inflammatory activity through 
inhibition of cyclooxygenase was observed in purified human neutrophils 71, 92. 
Furthermore, dietary açaí reduced N-nitrosomethylbenzylamine-induced esophageal 
tumorigenesis in rats through the regulation of cytokines 93. Other studies demonstrated 
the relationship between antioxidant capacity of anthocyanins and oxidative stress-
induced apoptosis by correlating the induction of phase II antioxidant enzymes to the 
inhibition of caspase-3 in rat liver epithelial cell line 94.  
All the above studies collectively indicate the involvement of signaling pathways 
modulating the expression patterns of cytoprotective genes by the extracts of açaí. 
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Despite the evidence that açaí protects the cell in conditions of oxidative stress, the 
studies related to its antioxidant potential are limited with regard to generalized 
regulation of phase II enzymes and the related molecular mechanisms associated with the 
protective effects of açaí products are not clearly understood. The recent refutation of 
ORAC assay by USDA`s NDL further emphasizes the need to identify mechanisms 
associated with the antioxidant activity of açaí that could possibly involve transcriptional 
regulatory pathways, like the Nrf2 pathway, or any other mechanism unrelated to direct 
quenching of reactive species. This forms the long range goal of the current project 
whose short term aims are to identify the chemical constituents that may take part in the 
complex process of Nrf2-dependent gene induction.  
4.2. Materials and Methods 
4.2.1. Chemicals and Reagents  
All the chemicals and reagents were purchased as molecular biology grade from 
Fisher Scientific and Promega. 
4.2.2. Cell Culture 
The human hepatocellular carcinoma (HepG2) cells, were obtained from 
American Type Culture Collection (ATCC) were grown in cell culture treated plates. The 
growth medium for HepG2 cells comprised of high glucose Dulbecco Modified Eagle 
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/ml 
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penicillin, and 100 µg/ml streptomycin and incubated at 37C in a 5% carbon dioxide 
atmosphere.   
4.2.3. Oligonucleotides, Vectors and Enzymes 
Custom synthesized oligonucleotides used in the construction of plasmid vectors 
and in PCR were purchased from Integrated DNA Technologies, Inc. All the enzymes for 
cloning purposes such as restriction digestion, phosphorylation and ligations were from 
New England Biolabs. The luciferase reporter plasmids, pGL3 promoter vector 
containing firefly luciferase and pRL vector containing renilla luciferase, and the dual-
luciferase assay system were from Promega. Sequencing service for both the wt-ARE and 
mARE containing pGL3 plasmid vectors was verified by SeqWright Genomic Services.  
4.2.4. Construction of ARE Reporter Vectors 
A cis-acting DNA sequence called ARE is now widely recognized to be involved 
in the transcriptional activation of phase II antioxidant enzymes following Nrf2/ARE 
signaling pathway. The pGL3 promoter vector containing genetically engineered firefly 
luciferase from Photinus pyralis was used for monitoring of transcriptional activity in 
transfected eukaryotic cells. The pGL3-promoter vector is driven by a simian virus 40 
(SV40) minimum promoter with upstream restriction sites including KpnI and NheI. The 
sequences of sense and antisense strands of oligonucleotides corresponding to wild-type 
ARE of Thioredoxin and its mutant containing overhangs complementary to KpnI and 
NheI sticky ends were initially phosphorylated and subsequently annealed to form 
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double-stranded oligonucleotides as illustrated in figure 4.2. The double-stranded 
oligonucleotides were then subcloned between KpnI and NheI restriction sites of a pGL3 
promoter vector. A wild-type and a mutant version of ARE-luciferase plasmid vector 
were generated using pGL3 promoter vector (Figure 4.3). Amplification of the ligated 
recombinant DNA was then carried out separately for pGL3 plasmid and the two plasmid 
constructs, pGL3-wtARE and pGL3-mARE, in competent Escherichia coli cells. 
Verification of the sequences for the inserts in the plasmid constructs was confirmed by 
SeqWright Genomic Services. Successful constructs of both the wild-type and the mutant 
ARE-containing plasmid vectors were amplified in large scale and transfection-grade 
plasmid purification was achieved using QIAGEN plasmid Maxi Kit.  
 
Figure 4.2 Schematic Illustration of Promoter Region of pGL3 Plasmid Vector, Wild-
type and Mutant ARE Constructs 
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Figure 4.3 Construction of ARE-luciferase containing Plasmid Vectors 
4.2.5. Bioassay-guided Fractionation of Açaí 
All the bioassay-guided fractionations on freeze-dried açaí berry powder for 
identification of inducers of Nrf2/ARE signaling pathway were carried out by Dr. 
Oberlies research group as described earlier.  
4.2.6. Sample Preparation of Açaí 
Procurement of freeze-dried açaí berry powder, storage and its authentication 
were discussed earlier in Chapter 3.  All the fractions generated through the bioassay-
guided fractionation of freeze-dried açaí berry powder were partitioned into aliquots for 
future use. Dimethyl sulfoxide at 0.2% was used as a co-solvent in the preparation of açaí 
samples for all cell culture experiments. Each sample initially received dimethyl 
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sulfoxide required to produce 0.2% final concentration in the incubation mixture 
followed by slow addition of the medium while vortexing. 
4.2.7. Induction of ARE-luciferase 
The general experimental approach for the identification of inducers of Nrf2/ARE 
signaling pathway is illustrated in figure 4.4. Bioassays involved cultured HepG2 cells 
that were transfected with ARE-containing luciferase vector prior to the treatment with 
the fractions being tested. HepG2 cells were grown up to 50-60% confluence were 
transiently transfected with appropriate expression plasmid vectors and then treated with 
various extracts of açaí. 
 
Figure 4.4 Schematic Illustration of ARE-luciferase Induction by Açaí Berry in Cultured 
HepG2 Cells. 
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4.2.8. Transfection 
Reporter gene assays serve as an excellent tool for studying the transcriptional 
activation of mammalian gene expression. The quantitative analysis of synthesized pGL3 
plasmid constructs in transfected HepG2 cells was used to screen a series of fractions 
generated through bioassay-guided fractionation of freeze-dried açaí berry powder. 
Transient transfection of HepG2 cells grown up to 60% confluence in 96 well plates with 
the plasmid vectors was facilitated by FuGENE® HD transfection reagent (Promega). 
Briefly, the plasmid vectors were initially incubated with FuGENE® HD transfection 
reagent for 15 minutes in plasmid to transfection reagent ratio of 200 ng:0.6 µl per well to 
generate the transfection complex. Then serum-free DMEM devoid of antibiotics was 
prepared and incubated for another 15 minutes to generate transfection medium. To 
account for the variability in the transfection efficiency, a control plasmid vector pRL-
CMV encoding for renilla luciferase combined with transfection medium was prepared 
simultaneously and combined with pGL3 containing transfection medium. Transfection 
medium was added such that each well of a 96 well plate received 200ng of appropriate 
pGL3 plasmid luciferase vector and 20ng of renilla luciferase vector in a serum-free 
DMEM medium for a period of 24 hours.  
4.2.9. Treatment 
After 24 hours of transfection, the cells were treated for 24 hours with the 
appropriate controls and the fractions generated through bioassay-guided fractionation. 
After the treatments were completed, the cells were washed twice with phosphate 
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buffered saline (PBS). Each well then received 40 µl of passive lysis buffer and was 
sonicated with 5 pulses of 5 seconds each on a water bath sonicator.  
4.2.10. Measurement of ARE-luciferase Activity  
Transcriptional activity of the firefly luciferase was determined and normalized to 
the renilla luciferase expression using Dual-Glo luciferase reporter assay kit (Promega) 
on a PolarStar Optima Microtiter Plate Reader (BMG LabTech). All the measurements 
were carried out in triplicates and the results were expressed as fold induction with 
standard deviations compared to the 0.2% DMSO solvent control. In all the experiments, 
100 µM t-butylhydroquinone, which is a known inducer of Nrf2/ARE signaling pathway 
was used as a positive control. The concentration of the açaí fractions was maintained at 
50 µg/ml in all the experiments. A dose response study was carried out whenever a 
fraction warranted for it. Figure 4.5 illustrates the assay principle for measuring 
luminescence from the enzymatic activities of firefly and renilla luciferase enzymes 
expressed in HepG2 cells. 
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Figure 4.5 Bioluminescence Reactions Catalyzed by Firefly and Renilla Luciferases 
Firefly luciferase converts D-luciferin to oxyluciferin and renilla luciferase 
converts coelenterazine to coelenteramide. Both oxyluciferin and coelenteramide were 
luminescent products and the amounts produced as a result of enzymatic reaction were 
measured using a luminometer. The expression of firefly luciferase was normalized to the 
expression of renilla luciferase, an internal control vector used in transfection. The 
luminescence produced in the cell lysates were correlated to the luciferase expression that 
is dependent on the promoter activity. An increase in the expression of firefly luciferase 
in HepG2 cells receiving pGL3-wtARE reporter plasmid in response to positive control 
and açaí extracts was quantified as induction mediated by Nrf2/ARE signaling pathway. 
A strong transcriptional activation and therefore luciferase expression observed with 
wtARE-pGL3 luciferase vector was completely abolished in mARE-pGL3 vector.  
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4.3. Results 
An Antioxidant Response Element (ARE) sequence is an evolutionarily 
conserved consensus sequence present in the promoter region of the antioxidant genes. 
The ARE element modulates the expression of Nrf2/ARE signaling pathway and is 
responsive to various internal and external factors. Inducers of Nrf2/ARE signaling 
pathway act through the modulation of several factors called transcription factors 
involved in the process. However, the direct measurement of involvement of Nrf2/ARE 
signaling pathway is often cumbersome requiring experimental setups such as large 
amounts of cells, large volumes of reagents and tedious purification processes. Therefore, 
an indirect measurement for the involvement of the Nrf2/ARE signaling pathway was 
employed in the study in order to identify chemical constituents with potential ARE 
activating and therefore antioxidant properties. It involved the construction of luciferase 
containing promoter vectors and transfection of the promoter vector into cultured HepG2 
cells. The promoter containing plasmid vectors work in a manner similar to the 
expression of antioxidant genes. The plasmid vectors are luminogenic, so their activities 
were measured by the expression of luciferase enzyme. The detection of ARE-dependent 
luciferase enzyme is much more sensitive than the actual ARE-dependent antioxidant 
genes, thus enabling a convenient and sensitive high through put analysis that can be 
correlated to the involvement of Nrf2/ARE signaling pathway.   
In the current research, an ARE sequence corresponding to the human 
Thioredoxin (hTXN) was successfully cloned into the promoter region of luciferase 
containing pGL3 plasmid vector to produce pGL3-wtARE plasmid vector. An ARE 
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sequence present in pGL3-wtARE promoter plasmid vector when stimulated induces the 
expression of downstream luciferase whose activities were measured using luminometer. 
Similarly, a mutated ARE sequence containing plasmid was constructed to produce 
pGL3-mARE plasmid vector. The pGL3-mARE plasmid owing to the presence of non-
functional ARE is expected to return the expression of luciferase to the basal level and is 
expected to be similar to the luciferase expression by pGL3 vector. The success of 
plasmid construction was verified with SeqWright Genomic Services and the working of 
the plasmid constructs was verified by conducting a preliminary experiment using tert-
butylhydroquinone (tBHQ) at 100 µM as a positive control. The results from preliminary 
experiment corroborated the success of plasmid construction (Figure 4.6). The pGL3-
wtARE vector in controls showed basal expression of luciferase that was normalized to 
one and the expression of all other vectors and all other treatments were shown as fold 
induction compared to the expression pGL3-wtARE expression from controls. Both the 
pGL3 and pGL3-mARE vectors showed minimal expression of luciferase because pGL3 
lacked the promoter sequence and pGL3-mARE contained a non-functional ARE 
promoter. The presence of functional ARE in pGL3-wtARE induced the expression of 
luciferase enzyme by about 2.5 times upon treatment with 100 µM t-butylhydroquinone 
compared to that of 0.2% DMSO solvent control.    
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Figure 4.6 Induction of ARE-driven Luciferase Expression pGL3, pGL3-wtARE and 
pGL3-mARE containing Plasmids in Cultured HepG2 Cells by t-Butylhydroquinone 
 The generation of the initial four crude extracts through partitioning of methanol 
extract of freeze-dried açaí berry powder into various solvents is described earlier in 
Chapter 3. All the initial four extracts of açaí were tested for their ability to induce ARE-
driven luciferase expression in cultured HepG2 cells transfected pGL3, pGL3-wtARE 
and pGL3-mARE plasmid vectors (Figure 4.7). Any increase in the expression of 
luciferase in cells transfected with pGL3-wtARE vector in response to various treatments 
compared were compared to the 0.2% DMSO control and is considered as induction. The 
results from crude extracts indicated that the crude chloroform extract induced the 
expression of ARE-dependent luciferase in HepG2 cells transfected with pGL3-wtARE 
plasmid vector by more than 3.5 times at 200 µg/ml concentration. Both butanol and 
aqueous extracts showed only a slight induction of pGL3-wtARE luciferase at 200 µg/ml 
concentration while the hexane extract was found to be inactive. In all treatment groups, 
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the expression of luciferase in cells treated with pGL3 vector remained at the basal level 
and the expression of luciferase in cells treated with pGL3-mARE was at the basal level.  
 
Figure 4.7 Induction of ARE-driven Luciferase Expression in Cultured HepG2 Cells by 
Crude Açaí Berry Extracts 
 Further, transfection of pGL3-wtARE plasmid produced induction of ARE-driven 
luciferase expression with positive control in all experiments and the transfection of 
pGL3 and pGL3-mARE plasmids failed to produce luciferase expression. It indicates that 
the ARE sequence present in the promoter of pGL3-wtARE plasmid essentially mediates 
the increased expression of luciferase and is consistent with the involvement of 
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Nrf2/ARE signaling pathway. The results were reproduced on several occasions and 
therefore the transfection experiments from this stage onward were limited to the pGL3-
wtARE plasmid vectors. 
A dose response relationship was established for chloroform extract of açaí 
including 50, 100 and 200 µg/ml concentration and the results indicated the induction of 
luciferase in cells treated with pGL3-wtARE vector in a dose dependent manner (Figure 
4.8).  
 
Figure 4.8 Induction of ARE-driven Luciferase Expression in Cultured HepG2 cells by 
Crude Chloroform Extract Of Açaí 
Although the crude chloroform extract (Açaí-31-2) showed a mild induction of 
ARE-luciferase at 50 µg/ml concentration, this concentration was chosen for all the ARE-
luciferase assays as the bioassay-guided fractionation process was presumed to produce 
fractions with increased potency. Therefore, all the fractions from this stage were tested 
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for the induction of ARE-dependent luciferase expression at 50 µg/ml concentration. For 
qualitative and quantitative purposes, any induction of ARE-luciferase that was less than 
2 fold was considered to be no different from basal levels of expression of ARE-
luciferase and therefore considered as inactive fraction. Any induction of ARE-luciferase 
induction between 2 and 4 folds was considered as mild induction. Likewise, any level of 
induction between 4 and 6 folds was considered as moderate and induction beyond 6 
folds was considered as strong induction. The crude chloroform extract (Açaí-31-2) of 
açaí was fractionated using column chromatography to produce 10 fractions, Açaí-34-1 
through Açaí-34-10 as illustrated in Scheme 8.  
 
Scheme 8. Bioassay-guided Fractionation of Açaí-31-2 and Açaí-34-8. 
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Among these fractions, Açaí-34-8 was found to be a strong inducer of ARE-
luciferase expression showing a 6 fold induction while the remaining 9 fractions were 
considered to be inactive as these fractions showed less than a 2 fold induction of ARE-
luciferase (Figure 4.9). Incidentally, Açaí-34-8 happened to be the potent fraction 
towards CYP2A6 and CYP2E1 inhibition as well and was already fractionated to 8 
fractions belonging to Açaí-38-Series (Scheme 8). 
 
Figure 4.9 Induction of ARE-driven Luciferase Expression in Cultured HepG2 cells by 
Açaí-34-Series. 
 Among the fractions of Açaí-38-Series, induction of ARE-luciferase by Açaí-38-7 
and Açaí-38-8 presented difficulties with the measurement of luminescence resulting 
from the enzymatic activity of luciferase enzyme. Therefore, the activities of these 
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fractions were measured at a reduced concentration of 25 µg/ml and were represented in 
Figure 4.10. Overall, the fractions Açaí-38-7 and Açaí-38-8 appeared to have potencies 
greater than their preceding fractions Açaí-38-1 through Açaí-38-5. Açaí-38-1 showed a 
moderate induction of ARE-luciferase whereas the fractions Açaí-38-2, Açaí-38-3 and 
Açaí-38-4 fractions showed mild induction of ARE-luciferase (Figure 4.10).  
 
Figure 4.10 Induction of ARE-driven Luciferase Expression in Cultured HepG2 Cells by 
Açaí-38-Series. 
 Although the fractions Açaí-38-7 and Açaí-38-8 were found to be more potent 
fractions, their limited sample size hindered their further processing via bioassay-guided 
fractionation.  Consequently, Açaí-38-6, Açaí-38-7 and Açaí-38-8 were pooled together 
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and subsequently re-fractionated to produce 7 fractions belonging to Açaí-86-Series 
(Scheme 9).  
 
Scheme 9. Fractionation of Pooled Extracts Açaí-38-6, Açaí-38-7 and Açaí-38-8.  
No further increase in the induction of ARE-luciferase was observed with any of 
the fractions among Açaí-86-Series. In fact, none of the fractions were found to retain the 
ARE-luciferase expression showed by the individual fractions Açaí-38-6, Açaí-38-7 and 
Açaí-38-8 that contributed to the generation of the Açaí-86-Series (Figure 4.11). 
Moreover, the activities of Açaí-86-Series fractions was spread out across all the 
fractions and was within the range of minimal to mild induction of ARE-luciferase. 
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Figure 4.11 Induction of ARE-driven Luciferase Expression in Cultured HepG2 Cells by 
Açaí-86-Series. 
 The early 4 fractions Açaí-38-1, Açaí-38-2, Açaí-38-3 and Açaí-38-4 belonging to 
the Açaí-38-Series were also fractionated because these are the abundant fractions. The 
fractions namely Açaí-61-Series, Açaí-62-Series, Açaí-63-Series and Açaí-64-Series 
generated from Açaí-38-1, Açaí-38-2, Açaí-38-3 and Açaí-38-4 were readily available 
(Scheme 10). These fractions were also studied for induction of ARE-luciferase in 
HepG2 cells, given their observed mild induction, and abundance. 
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Scheme 10. Fractionation of Açaí-38-1, Açaí-38-2, Açaí-38-3 and Açaí-38-4.    
 The Açaí-61-Series was comprised of 7 fractions that were generated from a 
moderately potent fraction Açaí-38-1 (Scheme 10). Among these fractions, Açaí-61-6 
was found to be the fraction with a moderate induction of ARE-luciferase while the 
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fractions Açaí-61-1 and Açaí-61-2 were found to be inactive and remaining fractions 
showed mild induction of ARE-luciferase (Figure 4.12).  
 
Figure 4.12 Induction of ARE-driven Luciferase Expression in Cultured HepG2 Cells by 
Açaí-61-Series. 
 Açaí-38-2 showed only a mild induction of ARE-luciferase but was already 
fractionated for studying CYP inhibition to yield Açaí-62-Series consisting of 5 fractions 
(Scheme 10). These available fractions were tested for ARE-luciferase induction and 
again, all the fractions were found to be mild inducers of ARE-luciferase except one 
fraction Açaí-62-5 that was found to be an inactive fraction (Figure 4.13).   
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Figure 4.13 Induction of ARE-driven Luciferase Expression in Cultured HepG2 Cells by 
Açaí-62-Series. 
 Another fraction Açaí-38-3 that showed mild induction of ARE-luciferase 
produced 6 fractions of Açaí-63-Series and each of these fractions were tested at 50µg/ml 
(Scheme 10). Among these fractions Açaí-63-04 was found to be a strong inducer of 
ARE-luciferase, and the fractions Açaí-63-3 and Açaí-63-6 were found to be moderate 
inducers of ARE-luciferase. The remaining fractions were found to be mild inducers of 
ARE-luciferase (Figure 4.14). 
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 Figure 4.14 Induction of ARE-driven Luciferase Expression in Cultured HepG2 Cells by 
Açaí-63-Series. 
 The Açaí-64-Series comprised of 5 fractions and was generated from Açaí-38-4, 
which was also a mild inducer of ARE-luciferase activity. Among these fractions, Açaí-
64-1 was found to be a strong inducer of ARE-luciferase while the other 4 fractions were 
mild inducers of ARE-luciferase (Figure 4.15). 
*
***
**
**
**
**
***
0 2 4 6 8 10 12 14
0.2% DMSO Control
100μM tBHQ
Açaí-63-01
Açaí-63-02
Açaí-63-03
Açaí-63-04
Açaí-63-05
Açaí-63-06
Fold Induction (50µg/ml)
Induction of ARE-driven Luciferase by Açaí-63-Series
163 
 
 
Figure 4.15 Induction of ARE-driven Luciferase Expression in Cultured HepG2 Cells by 
Açaí-64-Series. 
 Açaí-63-4 and Açaí-64-1 were found to be the potent inducers of ARE-luciferase 
(Figure 4.14 and Figure 4.15). Açaí-63-4 was fractionated to generate Açaí-94-Series and 
the limited sample size halted the fractionation of Açaí-64-1 despite the results indicate 
that it is most potent fraction so far (Scheme 11). The potent fraction Açaí-63-4 that 
showed strong induction was fractionated to produce Açaí-94-Series comprising of 10 
fractions. Contrary to what was expected, the potencies across all the fractions of Açaí-
94-series was noticed to be lower their parent fraction Açaí-63-4 (Figure 4.16). Only 
Açaí-94-F and Açaí-94-G were found to be moderate inducers of ARE-luciferase and all 
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the other fractions showed mild induction except for Açaí-94-C that was found to be 
inactive fraction.   
 
Scheme 11. Fractionation of Açaí-63-4.    
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Figure 4.16 Induction of ARE-driven Luciferase Expression in Cultured HepG2 Cells by 
Açaí-94-Series. 
Although Açaí-64-1 was more potent it was not fractionated further because of 
limited sample size but another abundant fraction from the same series Açaí-64-3 was 
fractionated for studying ARE-luciferase activity to produce Açaí-76-series comprising 
of 7 fractions (Scheme 12). All the 7 fractions were found to be mild inducers of ARE-
luciferase, as expected (Figure 4.17). 
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Scheme 12. Fractionation of Açaí-64-3. 
 
Figure 4.17 Induction of ARE-driven Luciferase Expression in Cultured HepG2 Cells by 
Açaí-76-Series. 
The most abundant fractions from Açaí-76-series, Açaí-76-A and Açaí-76-B were 
fractionated to produce Açaí-98-Series and Açaí-92-Series, respectively (Scheme 13).  
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Scheme 13. Fractionation of Açaí-76-A and Açaí-76-B. 
Among the 6 fractions from Açaí-98-Series, all the fractions were found to be 
inactive except for Açaí-98-F that only showed mild induction of ARE-luciferase (Figure 
4.18). Other available fractions belonging to Açaí-98-Series produced from Açaí-76-A 
did not yield any increase in potency. In fact, all the fractions lost the activity except for 
Açaí-98-F that barely retained the potency similar to its parent fraction. 
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Figure 4.18 Induction of ARE-driven Luciferase Expression in Cultured HepG2 Cells by 
Açaí-98-Series. 
 Interestingly, Açaí-92-H that was produced from Açaí-76-B showed remarkable 
induction of ARE-luciferase activity (Figure 4.19). All the remaining fractions in the 
series showed mild to no effect on ARE-luciferase activity. Subsequent fractionation of 
Açaí-92-H produced 11 fractions and contrary to what was expected, all the 11 fractions 
produced from Açaí-92-H have lost the activity. This also includes Açaí-92-H that was 
recovered after sample preparation for fractionations indicating that the constituents of 
Açaí-92-H responsible for ARE-induction might be unstable in nature (Data not shown). 
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Figure 4.19 Induction of ARE-driven Luciferase Expression in Cultured HepG2 Cells by 
Açaí-92-Series. 
Although, the fractions Açaí-62-2 and Açaí-62-3 were shown to be mild inducers 
of ARE-luciferase, they were moved forward for studying ARE-luciferase activity since 
these two fractions were the most abundant and active fractions. Açaí-62-2 and Açaí-62-3 
produced Açaí-78-series and Açaí-82-series, respectively (Scheme 14). 
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Scheme 14. Fractionation of Açaí-62-2. 
 Açaí-78-Series comprising of 8 fractions were produced from Açaí-62-2 that was 
shown to be a mild inducer of ARE-luciferase. These results indicated the presence of a 
potent inducer in the form of Açaí-78-H in addition to two other moderate inducers Açaí-
78-B and Açaí-78-C. The remaining fractions were found be mild inducers except for one 
inactive fraction in form of Açaí-78-F (Figure 4.20). 
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Figure 4.20 Induction of ARE-driven Luciferase Expression in Cultured HepG2 Cells by 
Açaí-78-Series. 
The potent fraction Açaí-78-H that was shown to be a strong inducer of ARE-
luciferase was fractionated to generate 9 fractions belonging to Açaí-97-Series (Scheme 
15). Açaí-78-H was found to be a strong inducer and it convincingly produced three 
fractions namely Açaí-97-B, Açaí-97-C and Açaí-97-D (Figure 4.21). Both Açaí-97-B 
and Açaí-97-D together with Açaí-97-C which is a mixture of Açaí-97-B and Açaí-97-D 
showed similar potency. The remaining fractions were found to be mild inducers of ARE-
luciferase except for Açaí-97-F that showed minimal induction of ARE-luciferase.  
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Scheme 15. Fractionation of Açaí-78-H.  
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Figure 4.21 Induction of ARE-driven Luciferase Expression in Cultured HepG2 Cells by 
Açaí-97-Series. 
 Interestingly, Açaí-97-B and Açaí-97-D were determined to be pure compounds 
by chromatography, mass spectrometry and NMR techniques and were identified to be 
and grouped into a class of compounds called pheophorbides (Figure 4.22). Açaí-97-B 
was characterized as pheophorbide-a methyl ester and Açaí-97-D was characterized as 
pheophorbide-a ethyl ester (Table 4.1).  
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Figure 4.22 Chemical Structure of Pheophorbide-A Derivatives. The substituent R=H 
refers to Pheophorbide a.  
Table 4.1 Chemical Structure of Pheophorbide-a Derivatives. 
 R Molecular formula Molecular weight 
Pheophorbide a H C35H36N4O5 592.70gm 
Pheophorbide a methyl 
ester (Açaí-97-B) 
CH3 C36H38N4O5 606.72g 
Pheophorbide a ethyl 
ester (Açaí-97-D) 
C2H5 C37H40N4O5 618.74g 
 
 Further, availability of pure standards for Açaí-97-B which is Pheophorbide-a 
methyl ester together with the basic chemical entity Pheophorbide-a allowed for a dose 
response relationship on these compounds. Both Pheophorbide-a methyl ester and 
Pheophorbide-a showed a dose dependent induction of ARE-luciferase (Figure 4.23). A 
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two-fold induction of ARE-luciferase was observed with Pheophorbide-a methyl ester 
and Pheophorbide-a at lower concentrations of 5 and 10 µg/ml, respectively. Induction at 
this concentration would translate to 8.2 µM and 16.9 µM for Pheophorbide-a methyl 
ester and Pheophorbide a, respectively.  
 
Figure 4.23 Induction of ARE-driven Luciferase Expression in Cultured HepG2 cells by 
Pheophorbide-a Methyl Ester and Pheophorbide-a 
 Similarly, another mild inducer of ARE-luciferase Açaí-62-3 produced 7 fractions 
belonging to Açaí-82-Series (Scheme 16). Among the 7 fractions, Açaí-82-A was found 
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to be strong inducer while the remaining fractions were found to be mild inducers of 
ARE-luciferase (Figure 4.24).  
 
Scheme 16. Fractionation of Açaí-62-3. 
 
Figure 4.24 Induction of ARE-driven Luciferase Expression in Cultured HepG2 Cells by 
Açaí-82-Series. 
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4.4. Discussion 
The current research attempts to fill the gap about the notion among the general 
population regarding the purported health benefits of açaí. To address this, an ARE-
luciferase plasmid vector, as a synthetic model of Nrf2/ARE signaling in the cell, was 
employed in combination with activity guided fractionation of crude acai powder. In this 
study, crude chloroform extract of açaí berry showed a moderate induction of ARE-
luciferase in HepG2 cells and a series of fractionations were pursued further on the 
chloroform extract with convincing results. Interestingly, a class of compounds called 
pheophorbides were isolated in their pure form and were showed to be effective inducers 
of ARE-luciferase. A concentration of 8.2 µM and 16.9 µM for Pheophorbide-a methyl 
ester and Pheophorbide a, respectively showed a 2 fold induction of ARE-luciferase and 
is considered to be conceivable in human plasma and therefore has the potential to 
produce physiological effects. The pheophorbides that were tested in the study included 
pheophorbide a methyl ester and pheophorbide a ethyl ester along with the commercially 
available pheophorbide a. A dose response using pheophorbide a and pheophorbide a 
methyl ester indicated differences in potency probably resulting from structure activity 
relationship from within pheophorbide class of molecules.  
Pheophorbides are compounds that are closely related to chlorophyll-like 
compounds previously identified as a bioactive constituent in spinach, green seaweed and 
green algae95. Pheophorbide a was shown to have strong in vitro antioxidant activities as 
demonstrated by DPPH radical scavenging assay and hydroxyl radical scavenging 
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assay96. However, much of the recognition for pheophorbides come from their potential 
photosensitizing nature and was studied for photodynamic therapeutic effects in a variety 
of cancer models. Photodynamic therapy is a relatively new modality of treatment 
developed against cancer where the photosensitizing compounds trigger the generation of 
reactive oxygen species leading to toxic events including cell death. Reactive oxygen 
species was detected in photodynamic therapy with pheophorbides in cancer models.  
Photoactivation of pheophorbide a presented an oxidative challenge in HepG2 
cells, subsequently induced heme oxygenase-01 in a Nrf2-dependent manner and such 
induction was related to the inactivation of Bach1, a repressor protein of Nrf2/ARE 
signaling pathway97. Nrf2 is a key transcription factor and is highly responsive to 
oxidative stress. It is constitutively over expressed in cancer cells conferring resistance to 
anticancer drugs. Therefore, the silencing of Nrf2 increased cellular levels of singlet 
oxygen and other reactive oxygen species resulting in cell death in breast and colon 
cancer cell lines following pheophorbide a based photodynamic therapy98. Further, 
pheophorbides were also shown to have immunomodulatory activities through the ERK 
and MAP kinase pathways in a dose dependent manner99. Further, pheophorbides when 
illuminated even by the light from the microscope showed profound antiproliferative 
properties through induction of photocytotoxic properties leading to apoptosis and cell 
death100. Pheophorbide was shown to have antitumor properties and was shown to induce 
apoptosis in Hep3b cells, a viral induced hepatoma cell line101. The bioavailability of 
pheophorbides is likely to be low because of its highly hydrophobic nature and therefore 
several forms have been derived to improve the pharmacokinetic properties of 
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pheophorbides such as pegylation with polyethylene glycols such that these agents reach 
the target sites of action such as cancer cells102. Another study found that pheophorbide a 
protected from diabetic kidney failure as a consequence of streptozotocin induced 
oxidative stress in rat models by decreasing lipid peroxidation and increasing reactive 
oxygen species scavenging enzymes such as catalase103. However, it must be noted that 
precise molecular mechanisms underlying the observed effects were not clear and some 
studies also identified individual differences in some models97. 
In addition to pheophorbides, there were a couple of other fractions namely, Açaí-
82-A and Açaí-92-H capable of producing inducers of ARE-luciferase. Açaí-82-A 
appears to be a promising candidate to pursue upon further fractionation as it happens to 
be a fraction close to Açaí-78-H that produced pheophorbides. It is also possible that 
Açaí-82-A may contain molecules that are related to pheophorbides as it is the closest 
neighbor of Açaí-78-H. Another potent fraction Açaí-92-H upon further fractionation lost 
the activity and the quest to identify similarly looking constituents in a related fractions is 
targeted to identify possible inducers in ARE-luciferase in those fractions. 
In summary, the process of bioassay-guided fractionation of açaí was successfully 
carried out resulting in the identification of pheophorbides as putative inducers of 
Nrf2/ARE signaling pathway as demonstrated by the induction of ARE-luciferase.
180 
 
REFERENCES 
1. Semenza, G. L. (2007) Life with oxygen, Science 318, 62-64. 
2. Lindahl, S. G. (2008) Oxygen and life on earth: an anesthesiologist's views on oxygen 
evolution, discovery, sensing, and utilization, Anesthesiology 109, 7-13. 
3. Valentine, J. S., Wertz, D. L., Lyons, T. J., Liou, L. L., Goto, J. J., and Gralla, E. B. (1998) The 
dark side of dioxygen biochemistry, Curr Opin Chem Biol 2, 253-262. 
4. Bergendi, L., Benes, L., Duracková, Z., and Ferencik, M. (1999) Chemistry, physiology and 
pathology of free radicals, Life Sci 65, 1865-1874. 
5. Nohl, H., Kozlov, A. V., Gille, L., and Staniek, K. (2003) Cell respiration and formation of 
reactive oxygen species: facts and artefacts, Biochem Soc Trans 31, 1308-1311. 
6. Dickinson, B. C., and Chang, C. J. (2011) Chemistry and biology of reactive oxygen 
species in signaling or stress responses, Nat Chem Biol 7, 504-511. 
7. Slauch, J. M. (2011) How does the oxidative burst of macrophages kill bacteria? Still an 
open question, Mol Microbiol 80, 580-583. 
8. Kuhns, D. B., Alvord, W. G., Heller, T., Feld, J. J., Pike, K. M., Marciano, B. E., Uzel, G., 
DeRavin, S. S., Priel, D. A., Soule, B. P., Zarember, K. A., Malech, H. L., Holland, S. M., and 
Gallin, J. I. (2010) Residual NADPH oxidase and survival in chronic granulomatous 
disease, N Engl J Med 363, 2600-2610. 
9. Go, Y. M., and Jones, D. P. (2010) Redox control systems in the nucleus: mechanisms and 
functions, Antioxid Redox Signal 13, 489-509. 
10. Ray, P. D., Huang, B. W., and Tsuji, Y. (2012) Reactive oxygen species (ROS) homeostasis 
and redox regulation in cellular signaling, Cell Signal 24, 981-990. 
11. Jones, D. P., and Sies, H. (2015) The Redox Code, Antioxid Redox Signal. 
12. Sies, H. (1985) 1 - Oxidative Stress: Introductory Remarks, In Oxidative Stress (Sies, H., 
Ed.), pp 1-8, Academic Press, London. 
13. Magesh, S., Chen, Y., and Hu, L. (2012) Small molecule modulators of Keap1-Nrf2-ARE 
pathway as potential preventive and therapeutic agents, Med Res Rev 32, 687-726. 
14. Dinkova-Kostova, A. T., and Talalay, P. (2008) Direct and indirect antioxidant properties 
of inducers of cytoprotective proteins, Mol Nutr Food Res 52 Suppl 1, S128-138. 
15. Ulbricht, C. (2012) An Evidence-Based Systematic Review of Acai ( Euterpe oleracea) by 
the Natural Standard Research Collaboration, Journal of Dietary Supplements 9, 128-
147. 
16. Guengerich, F. P., Kim, D. H., and Iwasaki, M. (1991) Role of human cytochrome P-450 
IIE1 in the oxidation of many low molecular weight cancer suspects, Chem Res Toxicol 4, 
168-179. 
17. Chowdhury, G., Calcutt, M. W., and Guengerich, F. P. (2010) Oxidation of N-
Nitrosoalkylamines by human cytochrome P450 2A6: sequential oxidation to aldehydes 
and carboxylic acids and analysis of reaction steps, J Biol Chem 285, 8031-8044. 
18. Liu, Y., and Glatt, H. (2008) Mutagenicity of N-nitrosodiethanolamine in a V79-derived 
cell line expressing two human biotransformation enzymes, Mutat Res 643, 64-69. 
181 
 
19. Castillo, T., Koop, D. R., Kamimura, S., Triadafilopoulos, G., and Tsukamoto, H. (1992) 
Role of cytochrome P-450 2E1 in ethanol-, carbon tetrachloride- and iron-dependent 
microsomal lipid peroxidation, Hepatology 16, 992-996. 
20. Tung, Y. T., Wu, J. H., Huang, C. C., Peng, H. C., Chen, Y. L., Yang, S. C., and Chang, S. T. 
(2009) Protective effect of Acacia confusa bark extract and its active compound gallic 
acid against carbon tetrachloride-induced chronic liver injury in rats, Food Chem Toxicol 
47, 1385-1392. 
21. Karamanakos, P. N., Trafalis, D. T., Geromichalos, G. D., Pappas, P., Harkitis, P., 
Konstandi, M., and Marselos, M. (2009) Inhibition of rat hepatic CYP2E1 by quinacrine: 
molecular modeling investigation and effects on 4-(methyl nitrosamino)-1-(3-pyridyl)-1-
butanone (NNK)-induced mutagenicity, Arch Toxicol 83, 571-580. 
22. von Weymarn, L. B., Chun, J. A., and Hollenberg, P. F. (2006) Effects of benzyl and 
phenethyl isothiocyanate on P450s 2A6 and 2A13: potential for chemoprevention in 
smokers, Carcinogenesis 27, 782-790. 
23. Yano, J. K., Denton, T. T., Cerny, M. A., Zhang, X., Johnson, E. F., and Cashman, J. R. 
(2006) Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference 
spectra, mechanism of inhibition, and protein cocrystallization, J Med Chem 49, 6987-
7001. 
24. Porubsky, P. R., Meneely, K. M., and Scott, E. E. (2008) Structures of human cytochrome 
P-450 2E1. Insights into the binding of inhibitors and both small molecular weight and 
fatty acid substrates, J Biol Chem 283, 33698-33707. 
25. Wang, M. H., Wade, D., Chen, L., White, S., and Yang, C. S. (1995) Probing the active 
sites of rat and human cytochrome P450 2E1 with alcohols and carboxylic acids, Arch 
Biochem Biophys 317, 299-304. 
26. Anzenbacherova, E., Hudecek, J., Murgida, D., Hildebrandt, P., Marchal, S., Lange, R., 
and Anzenbacher, P. (2005) Active sites of two orthologous cytochromes P450 2E1: 
differences revealed by spectroscopic methods, Biochem Biophys Res Commun 338, 
477-482. 
27. Porubsky, P. R., Battaile, K. P., and Scott, E. E. (2010) Human cytochrome P450 2E1 
structures with fatty acid analogs reveal a previously unobserved binding mode, J Biol 
Chem 285, 22282-22290. 
28. DeVore, N. M., Meneely, K. M., Bart, A. G., Stephens, E. S., Battaile, K. P., and Scott, E. E. 
(2012) Structural comparison of cytochromes P450 2A6, 2A13, and 2E1 with pilocarpine, 
FEBS J 279, 1621-1631. 
29. Skopalík, J., Anzenbacher, P., and Otyepka, M. (2008) Flexibility of human cytochromes 
P450: molecular dynamics reveals differences between CYPs 3A4, 2C9, and 2A6, which 
correlate with their substrate preferences, J Phys Chem B 112, 8165-8173. 
30. Hendrychova, T., Berka, K., Navratilova, V., Anzenbacher, P., and Otyepka, M. (2012) 
Dynamics and hydration of the active sites of mammalian cytochromes P450 probed by 
molecular dynamics simulations, Curr Drug Metab 13, 177-189. 
31. Ping, J., Wang, Y. J., Wang, J. F., Li, X., Li, Y. X., and Hao, P. (2012) Negatively cooperative 
binding properties of human cytochrome P450 2E1 with monocyclic substrates, Curr 
Drug Metab 13, 1024-1031. 
182 
 
32. Li, J., Wei, D. Q., Wang, J. F., and Li, Y. X. (2011) A negative cooperativity mechanism of 
human CYP2E1 inferred from molecular dynamics simulations and free energy 
calculations, J Chem Inf Model 51, 3217-3225. 
33. Raner, G. M., Chiang, E. W., Vaz, A. D., and Coon, M. J. (1997) Mechanism-based 
inactivation of cytochrome P450 2B4 by aldehydes: relationship to aldehyde 
deformylation via a peroxyhemiacetal intermediate, Biochemistry 36, 4895-4902. 
34. Yang, S. P., Medling, T., and Raner, G. M. (2003) Cytochrome P450 expression and 
activities in rat, rabbit and bovine tongue, Comp Biochem Physiol C Toxicol Pharmacol 
136, 297-308. 
35. Waxman, D. J., and Chang, T. K. (2006) Spectrofluorometric analysis of CYP2A6-catalyzed 
coumarin 7-hydroxylation, Methods Mol Biol 320, 91-96. 
36. Ortiz de Montellano, P. R., Beilan, H. S., Kunze, K. L., and Mico, B. A. (1981) Destruction 
of cytochrome P-450 by ethylene. Structure of the resulting prosthetic heme adduct, J 
Biol Chem 256, 4395-4399. 
37. Ortiz de Montellano, P. R., Beilan, H. S., and Kunze, K. L. (1981) N-Alkylprotoporphyrin IX 
formation in 3,5-dicarbethoxy-1,4-dihydrocollidine-treated rats. Transfer of the alkyl 
group from the substrate to the porphyrin, J Biol Chem 256, 6708-6713. 
38. Ortiz de Montellano, P. R., Beilan, H. S., and Kunze, K. L. (1981) N-Methylprotoporphyrin 
IX: chemical synthesis and identification as the green pigment produced by 3,5-
diethoxycarbonyl-1,4-dihydrocollidine treatment, Proc Natl Acad Sci U S A 78, 1490-
1494. 
39. Kuo, C. L., Raner, G. M., Vaz, A. D., and Coon, M. J. (1999) Discrete species of activated 
oxygen yield different cytochrome P450 heme adducts from aldehydes, Biochemistry 38, 
10511-10518. 
40. Vaz, A. D., Pernecky, S. J., Raner, G. M., and Coon, M. J. (1996) Peroxo-iron and oxenoid-
iron species as alternative oxygenating agents in cytochrome P450-catalyzed reactions: 
switching by threonine-302 to alanine mutagenesis of cytochrome P450 2B4, Proc Natl 
Acad Sci U S A 93, 4644-4648. 
41. Xu, Y., Shen, Z., Shen, J., Liu, G., Li, W., and Tang, Y. (2011) Computational insights into 
the different catalytic activities of CYP2A13 and CYP2A6 on NNK, J Mol Graph Model 30, 
1-9. 
42. Yano, J. K., Hsu, M. H., Griffin, K. J., Stout, C. D., and Johnson, E. F. (2005) Structures of 
human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen, 
Nat Struct Mol Biol 12, 822-823. 
43. Rendic, S. (2002) Summary of information on human CYP enzymes: human P450 
metabolism data, Drug Metab Rev 34, 83-448. 
44. Ingelman-Sundberg, M. (2004) Human drug metabolising cytochrome P450 enzymes: 
properties and polymorphisms, Naunyn Schmiedebergs Arch Pharmacol 369, 89-104. 
45. Nebert, D. W., and Russell, D. W. (2002) Clinical importance of the cytochromes P450, 
Lancet 360, 1155-1162. 
46. Williams, J. A., Hyland, R., Jones, B. C., Smith, D. A., Hurst, S., Goosen, T. C., Peterkin, V., 
Koup, J. R., and Ball, S. E. (2004) Drug-drug interactions for UDP-glucuronosyltransferase 
substrates: a pharmacokinetic explanation for typically observed low exposure 
(AUCi/AUC) ratios, Drug Metab Dispos 32, 1201-1208. 
183 
 
47. Zanger, U. M., and Schwab, M. (2013) Cytochrome P450 enzymes in drug metabolism: 
regulation of gene expression, enzyme activities, and impact of genetic variation, 
Pharmacol Ther 138, 103-141. 
48. Omura, T., and Sato, R. (1964) The Carbon Monoxide-binding Pigment of Liver 
Microsomes. II. Solubilization, Purification, and Properties., J Biol Chem 239, 2379-2385. 
49. Zangar, R. C., Davydov, D. R., and Verma, S. (2004) Mechanisms that regulate production 
of reactive oxygen species by cytochrome P450, Toxicol Appl Pharmacol 199, 316-331. 
50. Guengerich, F. P. (2003) Cytochrome P450 oxidations in the generation of reactive 
electrophiles: epoxidation and related reactions, Arch Biochem Biophys 409, 59-71. 
51. Ioannides, C., and Lewis, D. F. (2004) Cytochromes P450 in the bioactivation of 
chemicals, Curr Top Med Chem 4, 1767-1788. 
52. Rendic, S., and Guengerich, F. P. (2012) Contributions of human enzymes in carcinogen 
metabolism, Chem Res Toxicol 25, 1316-1383. 
53. Kushida, H., Fujita, K.-i., Suzuki, A., Yamada, M., Endo, T., Nohmi, T., and Kamataki, T. 
(2000) Metabolic activation of N-alkylnitrosamines in genetically engineered Salmonella 
typhimurium expressing CYP2E1 or CYP2A6 together with human NADPH-cytochrome 
P450 reductase, Carcinogenesis 21, 1227-1232. 
54. Liu, C., Zhuo, X., Gonzalez, F. J., and Ding, X. (1996) Baculovirus-mediated expression and 
characterization of rat CYP2A3 and human CYP2a6: role in metabolic activation of nasal 
toxicants, Molecular Pharmacology 50, 781-788. 
55. Aoyama, T., Yamano, S., Guzelian, P. S., Gelboin, H. V., and Gonzalez, F. J. (1990) Five of 
12 forms of vaccinia virus-expressed human hepatic cytochrome P450 metabolically 
activate aflatoxin B1, Proceedings of the National Academy of Sciences 87, 4790-4793. 
56. Davydov, D. R., Petushkova, N. A., Bobrovnikova, E. V., Knyushko, T. V., and Dansette, P. 
(2001) Association of cytochromes P450 1A2 and 2B4: are the interactions between 
different P450 species involved in the control of the monooxygenase activity and 
coupling?, Adv Exp Med Biol 500, 335-338. 
57. Lee, S. S., Buters, J. T., Pineau, T., Fernandez-Salguero, P., and Gonzalez, F. J. (1996) Role 
of CYP2E1 in the hepatotoxicity of acetaminophen, J Biol Chem 271, 12063-12067. 
58. Spracklin, D. K., Hankins, D. C., Fisher, J. M., Thummel, K. E., and Kharasch, E. D. (1997) 
Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism 
in vitro, J Pharmacol Exp Ther 281, 400-411. 
59. Zimmerman, H. J., and Maddrey, W. C. (1995) Acetaminophen (paracetamol) 
hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic 
misadventure, Hepatology 22, 767-773. 
60. Sohn, O. S., Fiala, E. S., Requeijo, S. P., Weisburger, J. H., and Gonzalez, F. J. (2001) 
Differential effects of CYP2E1 status on the metabolic activation of the colon 
carcinogens azoxymethane and methylazoxymethanol, Cancer Res 61, 8435-8440. 
61. Wang, H., Chanas, B., and Ghanayem, B. I. (2002) Cytochrome P450 2E1 (CYP2E1) is 
Essential for Acrylonitrile Metabolism to Cyanide: Comparative Studies Using CYP2E1-
Null and Wild-Type Mice, Drug Metabolism and Disposition 30, 911-917. 
62. Matsumoto, H., Matsubayashi, K., and Fukui, Y. (1996) Evidence that cytochrome P-
4502E1 contributes to ethanol elimination at low doses: effects of diallyl sulfide and 4-
methyl pyrazole on ethanol elimination in the perfused rat liver, Alcohol Clin Exp Res 20, 
12A-16A. 
184 
 
63. Sumioka, I., Matsura, T., and Yamada, K. (2001) Therapeutic effect of S-
allylmercaptocysteine on acetaminophen-induced liver injury in mice, Eur J Pharmacol 
433, 177-185. 
64. Shimada, M., Liu, L., Nussler, N., Jonas, S., Langrehr, J. M., Ogawa, T., Kaminishi, M., 
Neuhaus, P., and Nussler, A. K. (2006) Human hepatocytes are protected from ethanol-
induced cytotoxicity by DADS via CYP2E1 inhibition, Toxicol Lett 163, 242-249. 
65. Morris, C. R., Chen, S. C., Zhou, L., Schopfer, L. M., Ding, X., and Mirvish, S. S. (2004) 
Inhibition by allyl sulfides and phenethyl isothiocyanate of methyl-n-pentylnitrosamine 
depentylation by rat esophageal microsomes, human and rat CYP2E1, and Rat CYP2A3, 
Nutr Cancer 48, 54-63. 
66. Gui, H. Y., Chen, R. N., Peng, Y., Hu, J. H., Mao, Z., Ning, R., Shang, W., Liu, W., Xiong, J., 
Hu, G., and Yang, J. (2013) Curcumin Protects against 1-Methyl-4-phenylpyridinium Ion- 
and Lipopolysaccharide-Induced Cytotoxicities in the Mouse Mesencephalic Astrocyte 
via Inhibiting the Cytochrome P450 2E1, Evid Based Complement Alternat Med 2013, 
523484. 
67. Xu, Y., Leo, M. A., and Lieber, C. S. (2003) Lycopene attenuates arachidonic acid toxicity 
in HepG2 cells overexpressing CYP2E1, Biochem Biophys Res Commun 303, 745-750. 
68. Tang, J. C., Yang, H., Song, X. Y., Song, X. H., Yan, S. L., Shao, J. Q., Zhang, T. L., and 
Zhang, J. N. (2009) Inhibition of cytochrome P450 enzymes by rhein in rat liver 
microsomes, Phytother Res 23, 159-164. 
69. Langhammer, A. J., and Nilsen, O. G. (2014) Fennel and raspberry leaf as possible 
inhibitors of acetaminophen oxidation, Phytother Res 28, 1573-1576. 
70. Rodrigues, R. B., Lichtenthäler, R., Zimmermann, B. F., Papagiannopoulos, M., Fabricius, 
H., Marx, F., Maia, J. G. S., and Almeida, O. (2006) Total oxidant scavenging capacity of 
Euterpe oleracea Mart. (açaí) seeds and identification of their polyphenolic compounds, 
Journal of Agricultural and Food Chemistry 54, 4162-4167. 
71. Schauss, A. G., Wu, X., Prior, R. L., Ou, B., Huang, D., Owens, J., Agarwal, A., Jensen, G. S., 
Hart, A. N., and Shanbrom, E. (2006) Antioxidant Capacity and Other Bioactivities of the 
Freeze-Dried Amazonian Palm Berry, Euterpe oleraceae Mart. (Acai), Journal of 
Agricultural and Food Chemistry 54, 8604-8610. 
72. Del Pozo-Insfran, D., Percival, S. S., and Talcott, S. T. (2006) Açai (Euterpe oleracea 
Mart.) Polyphenolics in Their Glycoside and Aglycone Forms Induce Apoptosis of HL-60 
Leukemia Cells, Journal of Agricultural and Food Chemistry 54, 1222-1229. 
73. Jensen, G. S., Wu, X., Patterson, K. M., Barnes, J., Carter, S. G., Scherwitz, L., Beaman, R., 
Endres, J. R., and Schauss, A. G. (2008) In vitro and in vivo antioxidant and anti-
inflammatory capacities of an antioxidant-rich fruit and berry juice blend. Results of a 
pilot and randomized, double-blinded, placebo-controlled, crossover study, J Agric Food 
Chem 56, 8326-8333. 
74. Dresser, G. K., Spence, J. D., and Bailey, D. G. (2000) Pharmacokinetic-pharmacodynamic 
consequences and clinical relevance of cytochrome P450 3A4 inhibition, Clin 
Pharmacokinet 38, 41-57. 
75. Surh, Y. J., Kundu, J. K., and Na, H. K. (2008) Nrf2 as a master redox switch in turning on 
the cellular signaling involved in the induction of cytoprotective genes by some 
chemopreventive phytochemicals, Planta Med 74, 1526-1539. 
185 
 
76. Rushmore, T. H., Morton, M. R., and Pickett, C. B. (1991) The antioxidant responsive 
element. Activation by oxidative stress and identification of the DNA consensus 
sequence required for functional activity, Journal of Biological Chemistry 266, 11632-
11639. 
77. Friling, R. S., Bensimon, A., Tichauer, Y., and Daniel, V. (1990) Xenobiotic-inducible 
expression of murine glutathione S-transferase Ya subunit gene is controlled by an 
electrophile-responsive element, Proceedings of the National Academy of Sciences 87, 
6258-6262. 
78. Wasserman, W. W., and Fahl, W. E. (1997) Functional antioxidant responsive elements, 
Proceedings of the National Academy of Sciences 94, 5361-5366. 
79. Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., 
Satoh, K., Hatayama, I., Yamamoto, M., and Nabeshima, Y.-i. (1997) An Nrf2/Small Maf 
Heterodimer Mediates the Induction of Phase II Detoxifying Enzyme Genes through 
Antioxidant Response Elements, Biochemical and Biophysical Research Communications 
236, 313-322. 
80. Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J. D., and Yamamoto, M. 
(1999) Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 
through binding to the amino-terminal Neh2 domain, Genes Dev 13, 76-86. 
81. Kobayashi, A., Kang, M. I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., and 
Yamamoto, M. (2004) Oxidative stress sensor Keap1 functions as an adaptor for Cul3-
based E3 ligase to regulate proteasomal degradation of Nrf2, Mol Cell Biol 24, 7130-
7139. 
82. Del Pozo-Insfran, D., Brenes, C. H., and Talcott, S. T. (2004) Phytochemical Composition 
and Pigment Stability of Açai (Euterpe oleracea Mart.), Journal of Agricultural and Food 
Chemistry 52, 1539-1545. 
83. Kang, J., Xie, C., Li, Z., Nagarajan, S., Schauss, A. G., Wu, T., and Wu, X. (2011) Flavonoids 
from acai (Euterpe oleracea Mart.) pulp and their antioxidant and anti-inflammatory 
activities, Food Chemistry 128, 152-157. 
84. Guerra, J. F. d. C., Magalh, atilde, es, C., iacute, ntia Lopes de, B., Costa, D. C., Silva, M. 
E., aacute, quio, Pedrosa, M. L., uacute, and cia. (2011) Dietary a&ccedil;ai modulates 
ROS production by neutrophils and gene expression of liver antioxidant enzymes in rats, 
Journal of Clinical Biochemistry and Nutrition 49, 188-194. 
85. Oliveira de Souza, M., Silva, M., Silva, M. E., de Paula Oliveira, R., and Pedrosa, M. L. 
(2010) Diet supplementation with acai (Euterpe oleracea Mart.) pulp improves 
biomarkers of oxidative stress and the serum lipid profile in rats, Nutrition 26, 804-810. 
86. Mertens-Talcott, S. U., Rios, J., Jilma-Stohlawetz, P., Pacheco-Palencia, L. A., Meibohm, 
B., Talcott, S. T., and Derendorf, H. (2008) Pharmacokinetics of anthocyanins and 
antioxidant effects after the consumption of anthocyanin-rich acai juice and pulp 
(Euterpe oleracea Mart.) in human healthy volunteers, J Agric Food Chem 56, 7796-
7802. 
87. de Moura, R. S., Ferreira, T. S., Lopes, A. A., Pires, K. M. P., Nesi, R. T., Resende, A. C., 
Souza, P. J. C., da Silva, A. J. R., Borges, R. M., Porto, L. C., and Valenca, S. S. (2012) 
Effects of Euterpe oleracea Mart. (AÇAÍ) extract in acute lung inflammation induced by 
cigarette smoke in the mouse, Phytomedicine 19, 262-269. 
186 
 
88. de Moura, R. S., Pires, K. M. P., Ferreira, T. S., Lopes, A. A., Nesi, R. T., Resende, A. C., 
Sousa, P. J. C., da Silva, A. J. R., Porto, L. C., and Valenca, S. S. (2011) Addition of açaí 
(Euterpe oleracea) to cigarettes has a protective effect against emphysema in mice, 
Food and Chemical Toxicology 49, 855-863. 
89. Hwang, Y. P., Choi, J. H., Yun, H. J., Han, E. H., Kim, H. G., Kim, J. Y., Park, B. H., Khanal, T., 
Choi, J. M., Chung, Y. C., and Jeong, H. G. (2011) Anthocyanins from purple sweet potato 
attenuate dimethylnitrosamine-induced liver injury in rats by inducing Nrf2-mediated 
antioxidant enzymes and reducing COX-2 and iNOS expression, Food and Chemical 
Toxicology 49, 93-99. 
90. Lee, S. E., Jeong, S. I., Yang, H., Park, C.-S., Jin, Y.-H., and Park, Y. S. (2011) Fisetin induces 
Nrf2-mediated HO-1 expression through PKC-δ and p38 in human umbilical vein 
endothelial cells, Journal of Cellular Biochemistry 112, 2352-2360. 
91. Xie, C., Kang, J., Burris, R., Ferguson, M. E., Schauss, A. G., Nagarajan, S., and Wu, X. 
(2011) Açaí juice attenuates atherosclerosis in ApoE deficient mice through antioxidant 
and anti-inflammatory activities, Atherosclerosis 216, 327-333. 
92. Jensen, G. S., Ager, D. M., Redman, K. A., Mitzner, M. A., Benson, K. F., and Schauss, A. 
G. (2011) Pain reduction and improvement in range of motion after daily consumption 
of an açai (Euterpe oleracea Mart.) pulp-fortified polyphenolic-rich fruit and berry juice 
blend, J Med Food 14, 702-711. 
93. Stoner, G. D., Wang, L. S., Seguin, C., Rocha, C., Stoner, K., Chiu, S., and Kinghorn, A. D. 
(2010) Multiple berry types prevent N-nitrosomethylbenzylamine-induced esophageal 
cancer in rats, Pharm Res 27, 1138-1145. 
94. Shih, P.-H., Yeh, C.-T., and Yen, G.-C. (2007) Anthocyanins Induce the Activation of Phase 
II Enzymes through the Antioxidant Response Element Pathway against Oxidative Stress-
Induced Apoptosis, Journal of Agricultural and Food Chemistry 55, 9427-9435. 
95. Jubert, C., and Bailey, G. (2007) Isolation of chlorophylls a and b from spinach by 
counter-current chromatography, J Chromatogr A 1140, 95-100. 
96. Cho, M., Lee, H. S., Kang, I. J., Won, M H., and You, S. (2011) Antioxidant properties of 
extract and fractions from Enteromorpha prolifera, a type of green seaweed, Food Chem 
127, 999-1006. 
97. Hagiya, Y., Adachi, T., Ogura, S., An, R., Tamura, A., Nakagawa, H., Okura, I., Mochizuki, 
T., and Ishikawa, T. (2008) Nrf2-dependent induction of human ABC transporter ABCG2 
and heme oxygenase-1 in HepG2 cells by photoactivation of porphyrins: biochemical 
implications for cancer cell response to photodynamic therapy, J Exp Ther Oncol 7, 153-
167. 
98. Choi, B. H., Ryoo, I. G., Kang, H. C., and Kwak, M. K. (2014) The sensitivity of cancer cells 
to pheophorbide a-based photodynamic therapy is enhanced by Nrf2 silencing, PLoS 
One 9, e107158. 
99. Bui-Xuan, N. H., Tang, P. M., Wong, C. K., Chan, J. Y., Cheung, K. K., Jiang, J. L., and Fung, 
K. P. (2011) Pheophorbide a: a photosensitizer with immunostimulating activities on 
mouse macrophage RAW 264.7 cells in the absence of irradiation, Cell Immunol 269, 60-
67. 
100. Lai, C. S., Mas, R. H., Nair, N. K., Mansor, S. M., and Navaratnam, V. (2010) Chemical 
constituents and in vitro anticancer activity of Typhonium flagelliforme (Araceae), J 
Ethnopharmacol 127, 486-494. 
187 
 
101. Chan, J. Y., Tang, P. M., Hon, P. M., Au, S. W., Tsui, S. K., Waye, M. M., Kong, S. K., Mak, 
T. C., and Fung, K. P. (2006) Pheophorbide a, a major antitumor component purified 
from Scutellaria barbata, induces apoptosis in human hepatocellular carcinoma cells, 
Planta Med 72, 28-33. 
102. Rapozzi, V., Zacchigna, M., Biffi, S., Garrovo, C., Cateni, F., Stebel, M., Zorzet, S., Bonora, 
G. M., Drioli, S., and Xodo, L. E. (2010) Conjugated PDT drug: photosensitizing activity 
and tissue distribution of PEGylated pheophorbide a, Cancer Biol Ther 10, 471-482. 
103. Nam, M. H. (2014) In vivo study of the renal protective effects of Capsosiphon 
fulvescens against streptozotocin-induced oxidative stress, Korean Journal of Food 
Science and Technology 46, 641-647. 
